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SUMMARY.
Small cell lung cancer (SCLC) accounts for approximately 25% of all 
lung cancers. It is distinguished from other lung cancers by the 
presence of neurosecretory granules, frequent peptide secretion, high 
levels of L-DOPA decarboxylase (DDC), creatine kinase BB isoenzyme 
(CKBB) ,neuronespecific enolase (NSE) and bombesin-like immunoreactivity 
(BLI). It is a particularly aggressive neoplasm which has the
potential for early metastatic dissemination, and by the time of 
diagnosis metastatic spread is often extensive. Consequently, 
surgical removal of the tumour is in most cases unlikely to result in 
a cure from the disease and chemotherapy is the most important 
treatment modality for SCLC. The eventual goal in the treatment of 
SCLC is to develop effective systemic therapy that will produce high 
response rates and a high percentage of long term disease-free 
survivors (cures).
The cell of origin for SCLC has not been identified. The expression 
of certain specific characteristics by SCLC cells has suggested that 
SCLC may have a separate cell of origin from the other forms of lung 
cancer, collectively called non-small cell lung cancer (nonSCLC). The 
presence of dense core granules and the production of amine and 
peptide hormones have suggested that SCLC may originate from the 
endocrine cell of the lung, the K cell. In contrast, the expression 
of certain cell surface antigens, thought to be restricted to cells of 
the haemopoietic cell lineage, by SCLC has implicated a haemopoietic 
origin. The probability of a separate histogenesis for SCLC has
become less secure with the recent data demonstrating that 
neuroendocrine features can be found in nonSCLC as well as SCLC.
Moreover, the findings that SCLC and nonSCLC can co-exist within the
same tumour deposit and that transitions between SCLC and nonSCLC may 
occur, in vivo and in vitro, has suggested that a closer link may 
exist between the different histological subtypes of lung cancer.
Mixed cell types of SCLC with large cell or other histological types 
of lung cancer are frequently recognised at autopsy in patients who 
initially presented with "pure" SCLC in their biopsy specimen. 
Moreover, in those patients in whom a mixture of SC and large cell 
carcinoma are detected at diagnosis the prognosis for these patients 
is significantly worse than for those patients with "pure" SCLC. It 
is unclear, however, whether this observation represents the evolution 
of two separate lung cancers or the transformation of the initial 
"pure" SCLC to another cell type. However, since nonSCLC tumours 
generally harbour a relative resistance to radiation and chemotherapy 
a change in SCLC morphology and/or neuroendocrine properties towards
the nonSCLC non-neuroendocrine types could be a factor in the
inevitable resistance to therapy that emerges with time in patients 
with SCLC. The aim of this study was to investigate whether the 
changes in pathological and biochemical characteristics of SCLC and 
the associated changes in sensitivity to radiotherapy and/or 
chemotherapy, could be due to an alteration in the SCLC phenotype. 
SCLC cells were treated with phenotypic inducer agents to see whether 
the SCLC phenotype could be altered. Following alteration of the SCLC 
phenotype the chemosensitivity of the cells was determined to see
whether SCLC phenotypic change had any effect on the sensitivity of
the cells to cytotoxic agents.
SCLC cell lines were treated with drugs known to induce phenotypic 
changes in other cell lines. Following treatment, selected SCLC 
phenotypic markers were measured; DDC, CKBB and BLI. Changes in the 
JL^ vels of these markers were taken as representing an alteration in 
the SCLC phenotype. The SCLC growth characteristics and cellular 
morphology were also examined following phenotypic inducer treatment. 
Three cell lines were included in this study, NCI-H187, NCI-H69 and 
NCI-H128d. These cell lines differed in a number of characteristics, 
namely cellular morphology, DDC and BLI expression.
When the SCLC cell lines were treated with various phenotypic inducer 
agents changes in the levels of the. selected SCLC phenotypic markers 
were found. Taking the SCLC cell lines as a whole, there was no 
consistent pattern of phenotypic change following drug treatment. 
However, within a cell line, the phenotypic shift induced by the 
various drugs always appeared to be in the same direction.
Changes in the levels of the selected SCLC phenotypic markers was 
taken as representing an alteration in the SCLC phenotype. In 
particular, HMBA induced a phenotypic shift in the H69 cells, 
represented by decreased expression of DDC and BLI and an increased 
expression of CKBB. Furthermore, HMBA induced a cytostatic effect and 
a change in the H69 cellular morphology. Also, a phenotypic 
alteration was noted when H187 cells were treated with dbcAMP. DbcAMP 
induced a significant increase in the expression of DDC, BLI and CKBB. 
It also induced a cytostatic effect and altered the H187 cellular 
morphology. These SCLC phenotypic changes induced by either HMBA or 
dbcAMP were found to require de novo protein synthesis, since 
incubation with cycloheximide inhibited the drug induced effects.
Having established that the SCLC phenotype could be altered by 
phenotypic inducer agents the effect of this change on the 
chemosensitivity to cytotoxic drugs was examined. It was found that 
in general the SCLC phenotypic change, as represented by changes in 
the expression of specific markers, did not alter the cells* 
chemosensitivity. However, dbcAMP treated H187 cells were found to be 
significantly more resistant to VP16 than the untreated controls.
1CHAPTER 1.
PRODUCTION.
Early in this century, lung cancer was regarded as a rarity but during 
the last 50 years there has been such an alarming increase in the 
incidence of the disease that it is now the leading form of cancer 
affecting man. There appears to be no single aetiological agent 
responsible for lung cancer. However, the increase in mortality that 
has been demonstrated in various parts of the world has been 
associated with the introduction of carcinogenic agents in the
respiratory environment. A careful study of the environment has 
revealed three major groups of factors in connection with the 
aetiology of lung cancer; in order of importance these are: cigarette 
smoking, atmospheric pollution and industrial hazards.
Most primary tumours of the lung arise from bronchial epithelium, and 
of these the overwhelming majority are bronchogenic carcinomas. 
Bronchogenic carcinoma can be classified into four main histological 
types: squamous lung cancer, adenocarcinoma, large cell carcinoma and 
small cell lung cancer (SCLC). SCLC is further classified into
lymphocyte-like (oat cell type) and intermediate cell type.
Snail Cell Lung Cancer.
SCLC has been viewed as a unique clinical and pathological entity 
from the other types of lung cancer, collectively referred to as non 
small cell lung cancer (nonSCLC). The distinction between SCLC and
the other types of lung cancer has been based upon: (1) a relatively
high growth fraction, (2) an extremely early potential for metastatic 
dissemination, (3) sensitivity to both radiation therapy and/or 
chemotherapy as opposed to most other types of lung cancer and (4) 
expression of neuroendocrine properties and frequent ectopic hormone 
secretion.
2SCLC accounts for approximately 25% of lung cancers. It is a 
particularly aggressive neoplasm. Metastatic spread to extrapulmonary 
organs usually starts at an early stage of the disease, and by the 
time pulmonary SCLC is diagnosed metastatic spread is often extensive. 
Consequently, surgical removal of the tumour is, in most cases, 
unlikely to result in a cure from the disease. Chemotherapy is the 
most important treatment modality for SCLC. A number of single agents 
or classes of drugs are active against this tumour including 
alkylating agents (especially cyclophosphamide), adriamycin,
periwinkle alkaloids (especially vincristine), VP16, cisplatinum,
methotrexate, nitrosoureas, procarbazine, hexamethylmelamine and 
bleomycin. Single agents alone were initially shown to impact 
slightly upon survival, but the major progress including potential 
cure was first appreciated when combination chemotherapy regimens, 
with or without radiotherapy, were employed. The most widely used 
drug combinations in the treatment of SCLC include, traditionally, 
three of the following drugs: vincristine, adriamycin,
cyclophosphamide or VP16 (Klastersky, - 1988). However, subsequent 
relapse is common with a 2 year survival of only 10%. The high rate 
of relapse and failure of chemotherapy is believed to be due to a 
large degree to drug resistant cells either existing prior to or 
arising during treatment.
Prior to any therapy a given tumour can be composed of a number of 
cell populations of variable size and heterogeneous in terms of drug 
sensitivity phenotype. Within a tumour, drug sensitive cells and drug 
resistant cells can co-exist. Tumour cells that are drug resistant 
may be resistant to one, or more than one, drug or class of drugs 
which can be structurally and biologically unrelated.
3Although drug resistance is unquestionably the single most important 
factor impairing the curative outcome of chemotherapy a number of 
other factors may also limit the overall success of this modality. 
Solid tumours often have a limiting blood supply that impairs direct 
exposure of some tumour cells to adequate cytotoxic drug 
concentrations. The use of radiotherapy and/or surgery has been 
employed as an additional approach to eradicate this type of disease. 
A major problem in the administration of anticancer agents is that 
they may not always be distributed throughout the body and sanctuary 
sites may exist which protect the tumour cells from the cytotoxic 
therapy. For SCLC sanctuary sites are often found in the CNS where 
the blood brain barrier prevents adequate diffusion of the most 
effective agents to the tumour. Chemotherapeutic agents demonstrate a 
dose response effect and so potentially a greater cell kill might be 
appreciated by utilising regimens in which one or more of the drugs 
are given in higher doses. However, the cost of higher cytotoxic drug 
concentrations is considerably greater toxicity including more 
treatment related deaths. Toxicity is therefore a primary limiting 
factor to the administered concentration of chemotherapeutic agents.
The eventual goal in the treatment of SCLC is to develop effective 
systemic therapy that will produce high response rates and a high 
percentage of long term disease-free survivors (cures). Currently, 
the results that can be obtained with maximally delivered combination 
chemotherapy (with or without additional radiotherapy) are limited by 
the available agents. In the past decade studies on SCLC have 
accumulated a vast amount of data although no therapeutic progress has 
been made during this time. Information derived from biological 
studies as well as the development of new active anticancer agents 
look to be the most promising avenues to a more effective control of 
SCLC.
4Biology of Small Cell Lung Cancer.
The development of in vitro systems for supporting the continual 
growth of cell lines of SCLC obtained from patients with this disease 
has greatly advanced our knowledge of the origin and biology of SCLC. 
Approaches that have been utilised to develop these cell lines include 
(1) direct culture in liquid medium (serum-supplemented medium or 
selective chemically defined medium) of specimens obtained directly 
from patients, and (2) establishment in culture of nude mouse SCLC 
heterotransplants developed by the inoculation of clinical material 
into these animals. The nude athymic mouse also serves as a useful 
means of evaluating the tunourigenicity of both fresh specimens and 
cell lines and for studying the effects of chemotherapeutic agents on 
tumours established in nude mice. Cell lines, as well as providing a 
tool to aid the further understanding of the biology and origin of 
SCLC, provide a tool for the development of monoclonal antibodies 
with specificity for this tumour and also provide an in vitro model 
for the screening of new cytotoxic agents with potential clinical 
activity in SCLC. Moreover, the use of SCLC cell lines have permitted 
the identification of a specific cytogenetic abnormality associated 
with SCLC. All of these have direct application to patient management.
Since the late 1970*s, several laboratories have been successful in 
the establishment of continuous cell lines from SCLC (Gazdar et al 
1980; Carney et al 1985; Baillie-Johnson et al 1985). While few have 
been cultured from primary tumours, cell lines have been cultured from 
a variety of metastatic sites. Although earlier attempts to establish 
cell lines of this tumour met with limited success, with improved 
techniques and better culture conditions cell lines can now be 
established from 50-70% of all adequate specimens. The use of 
conditioned media from established SCLC cell lines (Gazdar et al 1980) 
and the use of a chemically defined serum-free medium (Carney et. al 
1981) has greatly enhanced the ability to establish new cell lines.
5Once established the tumour cells grow either as floating cell 
aggregates or attached to the substrate. In the latter cases, as cell 
density increases large clumps of cells detach from the surface of the 
dish and float. Based on their appearance the lines can be
subgrouped into four major categories: types 1,2,3, & 4 (Carney et al 
1985). Type 1 grow as tightly packed spherical aggregates of floating 
cells, which frequently demonstrate areas of central necrosis in the
larger spheroids. Type 2 grow as relatively densely packed floating
aggregates, amorphous and irregular in outline, and lacking central 
necrosis. Type 3 lines grow as very loosely adherent floating 
aggregates growing in small clumps and intertwined cords. Central 
necrosis is absent in these lines. Type 4 grow attached to substrate. 
These cells consist of large overlapping polygonal cells lacking the 
epithelioid appearance of adherent nonSCLC cultures.
In continuous culture, cell lines of SCLC have a relatively prolonged 
doubling time, express human isoenzymes, form colonies in soft agarose 
(1-5%) and form tumours in athymic nude mice with the typical 
morphological characteristics of SCLC (Gazdar et al 1980). The cells 
in culture have the typical cytological characteristics of SCLC and 
also express many APUD properties associated with SCLC, including 
neurosecretory granules, which may be present either singly or in 
clusters, formaldehyde-induced fluorescence and the presence of the 
key APUD enzyme, L-DOPA decarboxylase (DDC) (Gazdar et al 1980). DDC 
activity has been demonstrated in clinical specimens, cell lines and 
nude mouse tumours of SCLC (Baylin et al 1980). At one time the 
presence of DDC activity was believed to distinguish SCLC from 
nonSCLC. However, DDC activity has been found in surgical and
autopsy tissues from both SCLC and nonSCLC, although the highest DDC
activity was found in SCLC. Therefore the presence of DDC in surgical 
and autopsy specimens does not necessarily distinguish SCLC from 
nonSCLC. The average SCLC DDC activity in tissue culture and in 
athymic nude mouse heterotransplants was found to be much higher than
6in the in vivo specimens (Baylin et al 1980). The presence of high 
levels of DDC activity in culture and in nude mouse heteroplants 
clearly distinguished SCLC from nonSCLC.
Recent studies in vitro have clearly demonstrated that certain markers 
are very useful in separating tumour cell lines of SCLC from cell 
lines of other histologic types of lung cancer. These markers include 
the BB isoenzyme of creatine kinase (CKBB), bombesin and neurone 
specific enolase (NSE). CKBB is normally found in large amounts only 
in striated muscle, brain, bladder and gastrointestinal tract (Shatton 
et al 1979). Clinical tumour specimens and cultures (classic and 
variant) of SCLC were found to produce 10- to 100- fold higher 
quantities of CKBB than the other types of lung cancer (Gazdar/ .et jal
1981). Therefore, CKBB expression clearly differentiates cell lines 
of SCLC origin from those of other forms of lung cancer. Moreover, 
serum CKBB levels correlated with extent of disease and sequential 
measurements of CKBB demonstrated an excellent correlation with 
observed clinical response to therapy. CKBB may be of value in 
estimating the extent of tumour dissemination, assigning prognosis and 
monitoring response to therapy in patients with SCLC.
NSE is a neuronal form of the glycolytic enzyme enolase which is most 
frequently found in brain tissue although it is also present in a 
variety of APUD cells and neurones of the diffuse neuroendocrine 
system,but not in other peripheral cells (Schmechel, Marangos & Brightman 
1978). It was also found to be produced in considerable quantities by 
neuroendocrine tumours including SCLC (Tapia et al 1981). Serum NSE 
was found to be raised in 69% of all patients diagnosed SCLC and the 
levels of NSE in continuous cultures of SCLC were much higher than 
those observed in nonSCLC cells (Carney et al 1982). Although NSE has 
been proposed as a specific marker of the SCLC phenotype it has been 
reported that a specific monoclonal antibody for NSE reacted
7extensively with all SCLC cell lines and biopsy specimens and also 
displayed considerable reactivity with nonSCLC cell lines and biopsy 
specimens (Reeve et al 1986). Therefore, the presence of NSE does not 
necessarily distinguish SCLC from nonSCLC.
Bombesin is a tetradecapeptide found in high amounts in brain, 
stomach, intestine and fetal lung (Moody et al 1981). It was first 
isolated from frog skin (Anastasi, Erspamer & Bucci 1971). A number 
of biological activities have been ascribed to the effects of bombesin 
including hyperglycaemia, anorexia, hypothermia and brain-site 
dependent analgesia. Human SCLC tumours and cell lines produce and 
secrete bombesin or its mammalian counterpart gastrin-releasing 
peptide (GRP) (Moody et al, 1981; Moody et al 1983) and can express 
high affinity receptors for bombesin/GRP (Moody et al 1985). 
Measurorient of intracellular bombesin in cell lines of lung cancer has 
revealed that only SCLC cell lines express high levels of bombesin, 
nonSCLC cell lines did not contain detectable levels of bombesin-like 
immunoreactivity (BLI) (Moody et al, 1981). Furthermore, exogenously 
added bombesin and GRP stimulated colony formation in SCLC in vitro 
but had no stimulatory effect on nonSCLC cell lines (Carney et al 
1987). These findings have led to the suggestion that bombesin may 
function as a growth promoting factor for SCLC (autocrine growth 
factor).
Recently, Carney et al (1985) and Gazdar et al (1985) proposed a new 
subclassification of SCLC cells based on extensive morphological and 
biochemical analysis of more than 50 cultured SCLC cell lines. In the 
new classification, SCLC cells were subdivided into two major classes, 
classic and variant SCLC cells. Classic SCLC cells express elevated 
levels of all four markers, DDC, BLI, NSE and CKBB, exhibit either 
type 1 or 2 morphology in culture and exhibit features typical of the 
intermediate cell type of SCLC in nude mice xenografts. Variant SCLC 
cells fail to express DDC and BLI but still continue to express
8elevated levels of CKBB and/or NSE. The majority of variant cell 
lines have either type 3 or 4 morphology. SCLC variant lines are 
further divided into (1) biochemical variant lines having variant 
biochemical profile but retaining typical SCLC morphology and growth 
characteristics and exhibiting intermediate cell type of SCLC in nude 
mice xenografts; and (2) morphological variant lines having variant 
biochemical profile, altered morphology, growth characteristics and 
have a histological appearance in nude mice xenografts of large cell 
undifferentiated carcinoma.
The use of established cell lines has allowed the identification of a 
specific cytogenetic abnormality associated with SCLC, a deletion of 
all or a portion of the short arm of chromosome 3 (Whang-Peng et al
1982). The abnormality was found in cell lines from males and females 
from treated and untreated patients and in lines established from a 
variety of metastatic sites. The 3p abnormality was identified in all 
fresh specimens examined confirming that its presence was not an 
artifact of culture but rather a specific defect associated with SCLC.
In the past several years a remarkable advance in cancer research has 
been achieved by the study of oncogenes. Amplification of three myc 
family oncogenes, c-myc, N-myc and L-myc, has been found in SCLC 
(Little et al 1983; Nau et al 1985; Nau et al 1986). SCLC 
morphological variant cell lines have a higher degree of amplification 
of the c-myc oncogene and express high amounts of c-myc m-RNA compared 
to the biochemical variant and classic cell lines (Little et al, 1983; 
Gazdar et al 1985). The high degree of c-myc oncogene amplification 
and expression in cell lines with a more aggressive phenotype suggests 
that this amplification may be associated with, or responsible for, 
the malignant behaviour of these variant tumours. This hypothesis was 
examined by transfecting a normal human C-myc gene into a cloned 
classic SCLC cell line not amplified for or expressing detectable c- 
myc iriRNA (Johnson et al 1986). It was found that c-myc expression in
9the transfected clones was associated with altered large cell 
morphology, a shorter doubling time, and increased cloning efficiency 
but no difference in DDC levels or BLI. Therefore, increased c-myc 
expression correlates with some of the phenotypic properties 
distinguishing c-myc amplified variants from unamplified classic SCLC 
lines. Amplifications of L-myc and N-myc oncogenes have no constant 
association with both cell types of SCLC. In all SCLC cell lines 
examined, if at all, only one gene out of the three myc-related 
oncogenes were amplified (Nau et al, 1985; Nau et al, 1986).
SCLC is frequently associated with the presence of paraneoplastic 
syndromes, thus many investigators have studied the expression of a 
wide range of biomarkers and hormones in these tumours. A wide 
variety of hormones have been recognised in SCLC, both in vivo and in 
vitro, these include calcitonin, ACIH, ADH and neurophysins (Sorenson, 
et al 1981). The presence of many peptide hormones in SCLC suggests 
that these peptides may have an important physiological role in this 
tumour.
Although there are four major histological types of lung cancer only 
SCLC remains curable with combination cytotoxic therapy. Considerable 
advances in the understanding of the biology of this tumour have 
occurred through the ability to establish continuous cell lines of 
SCLC. The, cell lines have allowed confirmation of ' the APUD properties of 
SCLC including the presence of neurosecretory granules' and high levels 
of the key APUD enzyme DDC. The characterisation of these lines has 
identified markers not previously associated with SCLC, including 
CKBB, NSE and bombesin. Although the functional role of these markers 
has not yet been determined data suggest that serum measurements of 
these markers may prove useful in both the staging and management of 
patients with SCLC.
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The Origin of SCLC.
The cell of origin for SCLC has not been identified. It has been 
suggested that different forms of lung cancer originate from 
specialised normal cells. In this concept, SCLC is thought to stem 
from the normal APUD cells of the lung, the K cells, which were 
originally supposed to be of ectodermal neural crest origin. In 
contrast, another theory of lung carcinoma histogenesis is that all 
lung cells arise from a "common stem cell" of endodermal origin and 
that the different histologically discernible tumour types represent 
different lines of differentiation. A haemopoietic stem cell origin 
has also been proposed for SCLC based on the expression of cell 
surface antigens thought to be restricted to cells of the haemopoietic 
cell lineage. It has been suggested that cancerous cells may arise 
from macrophage precursors in bone marrow and these precursors migrate 
to the lung to participate in the repair of damaged tissue a 
consequence of continual heavy smoking, often associated with SCLC.
The K Cell Hypothesis
The neuroendocrine properties of SCLC, which includes the presence of 
dense core granules in the cytoplasm and the production of amine and 
peptide hormones, have suggested that this neoplasm may have a 
separate histogenesis from the other major types of human lung 
tumours. This tendency of SCLC to produce amine and peptide hormones, 
such as vasopressin and adrenocorticotrophin, has led some workers to 
include SCLC among the group of peptide hormone and amine synthesising 
cells termed by Pearse as the amine precusor uptake and 
decarboxylation (APUD) system (Pearse 1969). According to this
hypothesis, the proposed SCLC cell of origin is the K cell in the 
lung.
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The role of the K cell is poorly understood, but even more basic 
aspects about this cell such as its prevalence, life span, physiologic 
factors affecting its turnover and response to various stimuli, 
including carcinogens are unknown. K cells are present in human 
bronchial and bronchiolar lining of adults as well as newborn infants 
and fetuses. In the mucosa of the adult human respiratory tract these 
cells are usually located singly close to the basement membrane. 
Interestingly, in contrast to the adult, such a cell, or sometimes 
even groups of them, appear to be present more frequently on the 
bronchial lumen in the lungs of human fetuses and neonates (Bonikos & 
Bensch, 1977). The precise function of these cells either singly or 
in groups, and the interplay between these two components, under 
physiological and pathological conditions is not entirely clear. It 
has been suggested that the groups of K cells may function mostly as 
intrapulmonary chemoreceptors, whereas, the solitary K cells may act 
locally in a regulatory, or paracrine manner. The comparative 
frequency of the groups of K cells in foetal lungs and their relative 
scarcity in adult lungs may also indicate a role related to pulmonary 
growth and development. The feature most characteristic of this cell 
is its large complement of spherical, electron dense cytoplasmic 
granules which closely resemble neurosecretory granules, the contents 
of which are yet to be identified. Immunohistochemical studies have 
shown that both solitary K cells and the groups of K cells possess 
immunoreactive serotonin, bombesin, neurone specific enolase and 
calcitonin whereas only solitary K cells display immunoreactive leu- 
enkephalin (Gould et al 1983).
The K cell groups and solitary K cells are regarded as the 
bronchopulmonary components of the dispersed neuroendocrine APUD 
system. The APUD system is based on the common property of some cells 
to accumulate and to store fluorogenic amines (dopamine and 
serotonin), which, however, may also be synthesised within these cells 
by decarboxylation of the appropriate amino acid precusors (L-DOPA and
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5-hydroxtryptophan). This system is supposed to consist of a variety 
of solitary or aggregates of polypeptide producing endocrine cells, 
including those of the anterior pituitary, the parafollicular cells of 
the thyroid, the pancreatic islets, the gastrointestinal endocrine 
cells and the lung endocrine cell (K cell) (Pearse 1969).
Pearse originally postulated that cells belonging to the APUD system 
may have a common embryologic origin in the neural crest. This view 
however did not go unchallenged and subsequently embryological and 
histological evidence have indicated that the neuroendocrine cell 
populations of the gastrointestinal tract are probably endodermally 
derived (Sidhu, 1979), and given that the bronchopulmonary tree
arises from the primitive oesophagus it has been tentatively suggested 
that the respiratory tract APUD cells are also endodermally derived 
(Gould et al, 1983). Moreover, careful analysis of neuroendocrine- 
related biochemical properties in all the major histological forms of 
lung cancer reveal the presence of immunoreactive peptide hormones 
(Yamaguchi et al 1983) and amine synthesis capacity (Baylin et al 
1980) although concentrations are usually less than those detected in 
SCLC. The demonstration that neuroendocrine features can be found in 
non-SCLC as well as SCLC favours the "common stem cell" hypothesis of 
lung cancer histogenesis.
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The "Common Stem Cell” Origin of SCLC.
The probability of a separate histogenesis for SCLC has become less 
secure with the recent data demonstrating that neuroendocrine features 
can be found in nonSCLC as well as SCLC. One of the key APUD cell 
properties, the presence of the enyzme DDC, is not restricted to SCLC 
but is present in surgical and autopsy tissues from all forms of lung 
cancer, albeit at lower concentrations (Baylin et al 1980). 
Furthermore, DDC activity has been found in 12% of nonSCLC cell lines, 
but limited to adenocarcinomas and large cell carcinomas and not 
observed in squamous cell carcinomas (Gazdar et al 1988). Moreover, 
irnnunoreactive gastrin-releasing peptide, also believed to be 
restricted to SCLC, was detected in about 17% of nonSCLC surgical and 
autopsy tissues (Yamaguchi et al 1983).
A closer link between SCLC and nonSCLC has also been suggested by the 
findings that SCLC and nonSCLC can co-exist within the same patient 
and even within the same tumour deposit. Moreover, it has been 
proposed that transitions may occur between SCLC and nonSCLC in vivo 
(Abeloff et al 1979). In a group of patients with biopsy diagnosed 
SCLC it was found that at autopsy 12% had completely nonSCLC 
histology, whereas 15% of the autopsies showed mixed SC/nonSCLC 
histology. The remaining 73% showed SCLC histology at autopsy. 
Furthermore, it was found that where no SCLC was present at autopsy 
the level of DDC activity was markedly lower than the levels found in 
SCLC. These changes in the pathological and biochemical 
characteristics of these lung cancers could reflect the emergence of 
another tumour which was present from the outset, the development of a 
second tumour, or an effect of cytotoxic therapy or differentiation of 
the initial tumour.
The apparent change from SCLC towards nonSCLC has been found to occur 
in vitro as well as in vivo. A cell line, OH-1, established from a 
patient with SCLC underwent a subtle morphological change which was
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associated with a complete loss of neuroendocrine differentiation (as 
judged by electron microscopy studies and a 12 fold loss of DDC 
activity) after 16 months in culture (Goodwin & Baylin, 1982). 
Moreover, this morphological change and loss of neuroendocrine 
differentiation was accompanied by the emergence of radiation 
resistance.
Also, a cell line, OH-2, established from a patient diagnosed as 
having SCLC displayed characteristic features of nonSCLC in culture 
and as xenografts in nude mice (Goodwin et al 1983). The cells grew 
as anchorage-dependent monolayer, lacked high levels of DDC activity 
and grew typical large cell undifferentiated lung carcinomas in nude 
mice. Interestingly, analysis of the cell surface phenotype, 
previously shown to distinguish between SCLC and nonSCLC in culture 
(Baylin et al 1982), showed that both the parent OH-2 cells and OH-2 
clones expressed the complete cell surface protein phenotype 
characteristic of SCLC. Importantly, each clone and the parent line 
simultaneously expressed some of the surface proteins characteristic 
of cultured nonSCLC. This suggests that SCLC and a form of large cell 
carcinoma may be linked through a change in cellular differentiation.
SCLC growing in cell culture possesses biological properties that 
allow classification into two categories: classic and variant (Carney 
et al 1985). Recent ix\ vitro studies have introduced a new subclass 
ofN SCLC called transitional cell type (Bepler et al 1987). Two SCLC 
cell lines were established from different metastatic sites within 15 
days from the same patient. These two lines (designated SCLC-22H and 
SCLC-21H) had distinct biochemical, morphological and kinetic 
features. At diagnosis the patient*s tumour revealed pure small cell 
morphology. When the tumour specimen resulting in the SCLC-22H cell 
line was taken, the patient’s tumour showed morphological features of 
mixed SC/LC. The SCLC-22H line had morphological features of the 
classic and variant cell types, biochemical and kinetic features of
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the classic cell type and molecular biological features of the variant 
cell type. The tumour specimen taken 15 days later showed more 
obvious SC/LC features, and the resulting cell line SCLC-21H exhibited 
all properties of the variant cell type. At autopsy the patients 
tumour had converted into a mixed SC/LG tumour with a dominance of 
large cell-like elements in all metastases examined. It was proposed 
that the patient1 s tumour may have slowly altered its whole biological 
behaviour from one characteristic for the classic cell type to one 
characteristic for the variant cell type. Cell line SGLC-22H was 
established during the transitional phase, which would account for its 
mixed classic/variant properties, and cell line SCLC-21H was 
established after the transition and thus expresses all variant 
properties. If, as Goodwin proposed, SCLC is linked to large cell 
carcinoma through a change in cellular differentiation then SCLC-22H 
may prove to be a valuable tool in understanding this link.
The transitional SCLC cell type has been described recently again in 
reference to the proposed link between SCLC and a form of large cell 
carcinoma. A cell line, SCLC-MO, was established from a patient with 
SCLC (Watanabe et al 1988). Following 9 months continuous culture of 
the parent cells in suspension, some cells attached to the flask. 
These adherent cells were routinely cultured as a monolayer for an 
additional 8 months and then cloned. Two clones that differed in the 
antigenic phenotype from the parent cell line were selected and 
established; MOAl and M0A2. When the parent cell line and MOAl were 
transplanted into nude mice, an intermediate cell type histology was 
found. In contrast, M0A2 showed a picture of large cell 
carcinoma. SCLC-MO exhibited biological features of a transitional 
phase between classic and variant type SCLC: expressed low levels of
DDC, high levels of NSE and CKBB and had classic type morphology. The 
MOAl clone was characteristic of variant SCLC in that it lacked 
DDC but still expressed NSE and CKBB and grew as a monolayer. M0A2 
however was more characteristic of nonSCLC in that it expressed low
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DDC activity, lacked NSE and CKBB and grew as a monolayer, the cells 
were larger than MOAl. Analysis of the cell surface phenotype with a 
series of monoclonal antibodies, which have been used previously to 
distinguish between classic SCLC, variant SCLC and nonSCLC supports 
this classification of SCLC-MO, MOAl and M0A2. The presence of
several marker chromosomes shared by these three lines supports the 
belief that MOAl and M0A2 sublines originated from the parent SCLC-MO 
line and not as a result of cell selection from a heterogeneous cell 
population, which cannot however be ruled out. Therefore, these
results suggest that a there may be a transition from SCLC to nonSCLC 
via a transitional SCLC cell type/variant cell type.
These in_ vitro findings could be explained by a change in cellular 
differentiation which may underly the progression of the early-passage 
neuroendocrine cells to the late passage non-neuroendocrine cells. 
Alternatively, a process of cell selection could account for the time- 
related morphological and biochemical changes, small numbers of the 
non-neuroendocrine type cells could be present in the early passages 
and with time come to predominate in the cultures. However, in many 
cases the parent SCLC cell line has been maintained for many months 
without the appearance of the non-neuroendocrine cells. Moreover, 
the change from neuroendocrine type cells to non-neuroendocrine cells 
has often occurred quite suddenly which might suggest a mechanism 
other than simple cell selection with time. Furthermore, as discussed 
above, OH-1 cells established from human SCLC, underwent a subtle 
morphological change which was associated with a virtually complete 
loss of neuroendocrine differentiation which was accompanied by the 
emergence of radiation resistance. Following irradiation of the early 
passage cells the cells that regrew retained their neuroendocrine 
phenotype, suggesting that radiation-resistant non-neuroendocrine 
cells were not selected for. The evidence seems to suggest therefore 
that, SCLC and a form of large cell carcinoma appear linked through a 
continuum of differentiation events that (1) may explain clinically
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important transitions that occur between the major types of human lung 
cancer and (2) provide evidence for a common cellular origin of 
endocrine and nonendocrine cells in the bronchial mucosa.
The use of monoclonal antibodies have been used extensively to try and 
determine the origin of SCLC and the relation to nonSCLC. MOC-1, a 
monoclonal antibody raised against a human SCLC cell line, was found 
to react with a subset of cells in the normal lung with a histological 
appearance consistent with that of the K cell (de Leij et al. 1985). 
Outside the lung the MOC-1 antibody reacted with a subset of normal 
endocrine cells (in the adrenal, thyroid, ovary and pancreas) as well 
as neural cells (brain and peripheral Schwann cells). Since some of 
these positively reacting cells are ectodermally derived whereas 
others are of proven endodermal origin the MOC-1 related antigen is 
not a cell lineage specific antigen. Instead, the common 
expression of the antigen by cells with a neural, endocrine or 
neuroendocrine function suggests that the antigen relates to a 
neuroendocrine differentiation state of these cells. The presence of 
the MOC-1 antigen on neoplastic tissue paralleled its normal tissue 
distribution, indicating that the antigen is generally retained upon 
malignant transformation. In lung cancer, the MOC-1 antigen was found 
in nearly all SCLC tissue examined. In addition adenocarcinoma and 
mixed adenosquamous carcinoma could also express the antigen, whereas 
pure squamous cell carcinoma generally did not. Since the antigen 
detected by the MOC-1 antibody is not related to a specific 
embryological lineage the question about the cell lineage of SCLC 
remains unanswered. However, the apparent reactivity by both 
endodermal and neural crest derived cells to the MOC-1 antibody 
suggests that both cell lineages may have similar differentiation 
possibilities. Moreover, since all major histologically different 
lung cancers can express an antigen, which in the normal lung is 
confined to APUD cells, suggests that these different normal and
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malignant lung cells are interrelated, which is in favour of a 
"common stem cell" theory of lung cancer histogenesis.
The concept of a "common stem cell" origin of lung cancer was further 
supported by the findings of Waibel, 0*Hara & Stabel, (1987) They 
described two antibodies which react with SCLC cell lines and tissues; 
LAM2 and LAM8. LAM2 was found to be an epithelial type membrane 
antigen reacting with lung carcinomas of every histology and 
adenocarcinomas of the breast, colon and ovary. The uniform 
expression of the LAM2 antigen in SCLC as well as in nonSCLC suggests 
that this phenomenon is common to lung tumours independent of their 
differentiation. In contrast, LAM8 was found to be a tumour 
associated antigen reacting with SCLC tissue only.
The use of monoclonal antibodies in the study of SCLC has highlighted 
four major groups of antigens: (1) antigens expressed by other
epithelial structures such as normal bronchial epithelium, nonSCLC and 
nonpulmonary carcinomas e.g. LAM-2, (2) antigens associated with 
neuroendocrine differentiation e.g. MOC-1, (3) antigens commonly 
expressed in cells of macrophage differentiation of natural killer
cells e.g. Leu-7 (see below), (4) antigens which are tumour
associated, based on the absence of expression in normal bronchial 
epithelial tissues, other carcinomas and tissues of neuroendocrine 
differentiation e.g. LAM-8.
In the past few years, it has been recognised that in most cases 
carcinoma cells contain similar patterns of keratin subtypes as their 
normal cellular counterparts. This suggests that analysis of keratin 
content may help delineate the relationship between the lung 
carcinomas. SCLC cells contain a characteristic set of keratins
(Elias, Cohen & Bernal 1988). This keratin pattern has been detected 
in SCLC cells and tissues and in classic and variant SCLC histologies, 
but not in nonSCLC or non-lung tumours although some individual
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keratins are shared. Normal bronchial epithelial cells contain all 
the keratins expressed by SCLC, bat in addition exhibit keratins that 
are observed in nonSCLC histologies. This finding is consistent with 
the concept of a "common stem cell" origin for the lung cancer 
histologies. Moreover, the presence of keratin, a fundamental marker 
of epithelial differentiation, casts serious doubt on the 
interpretation that SCLC has a monocytic origin simply due to the 
presence of surface antigens shared with monocytes (Ruff & Pert,
1984).
The Haemopoietic Origin of SCLC.
Several groups have examined SCLC cell lines for the presence of 
certain cell surface antigens, using monoclonal antibodies, in an 
attempt to determine the origin of SCLC. Ruff and Pert, 1984, found 
that several myeloid cell-associated monoclonal antibodies including 
0KM1, which binds to the receptor for a complement fragment C3bi on 
granuloyctes and monocytes, were present on human SCLC cell lines but 
not on representatives of nonSCLC cell lines nor normal foetal lung. 
They suggested that these cell surface similarities indicated that 
SCLC was not of lung origin but actually derived from a haemopoietic 
stem cell. However, examination of a large panel of well 
characterised cell lines from SCLC tumours for the expression of 
several myeloid cell-associated antigens (including Leu-7, associated 
with natural killer cells, C3bi defined by 0KM1, and two myeloid cell 
specific antigens, My23 antigen and AML-1-99 defined antigen) failed 
to confirm the findings of Ruff and Pert (Ball, Sorenson & 
Pettengill, 1986). Furthermore, they found that the overall 
expression of myeloid cell-associated and histocompatibility antigens 
on the SCLC cell lines examined was variable. It was suggested that 
although two apparently diverse cell types expressed the same antigens 
this did not necessarily place them in the same lineage, as proposed
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by Ruff & Pert. Rather, an alternative explanation may be that the 
function served by the antigens is shared by different tissues. Since 
the functions of the Leu-7 and My23 antigens are unknown, studies that 
seek to determine the functional role of these antigens may play a 
part in explaining why lung cancer, natural killer cells and 
phagocytic cells should share such cell surface molecules.
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Phenotypic Modulator Agents.
Dibutyryl Cyclic Adenosine 3 *: 51 -Monophosphate,
Dibutyryl cyclic adenosine 3*: 51 -monophosphate (dbcAMP) has been shown 
to modulate the growth, differentiation and cAMP-dependent protein 
kinase activity in various tumour cells (Haddox, Magun & Russell, 
1980; Boonstra et al 1987; Prashad, Lotan & Lotan 1987; Tagliaferri et 
al 1988). The mechanism by which dbcAMP suppresses growth and
promotes differentiation of these tumour cells is unknown but it has 
been suggested that these changes were due to increased levels of 
cellular cAMP. Cyclic AMP has been implicated in the regulation of 
the growth and differentiation of various normal and-malignant cells. 
The mechanism by which cAMP modulates these fundamental cellular 
processes is not fully understood. However, it has been proposed that 
most, if not all, of the effects of cAMP are mediated by protein 
kinase A of which there are two forms, type 1 and type 2, in many 
mammalian tissues. The enzymes are complexes containing each two
catalytic subunits and two regulatory subunits. The catalytic
subunits of type 1 and type 2 protein kinase A are identical, but the 
regulatory subunits are different. The activation of protein kinase A 
by cAMP is initiated by the binding of cAMP to the regulatory subunits 
of the holoenzyme which leads to the release of the active catalytic 
subunits from the complex. Recent studies however indicate that an 
increase in cellular cAMP levels does not necessarily determine cell 
transformation and it is more likely that it is cAMP-dependent protein 
kinase which plays an important role in these processes. Prashad et 
al, (1987) showed that exogenously added dbcAMP increased the
intracellular cAMP level in neuroblastoma cells and also induced the 
synthesis of type 1 regulatory cAMP-binding protein. Since growth of 
these cells was inhibited by dbcAMP and their differentiation was 
stimulated it has been proposed that the free type 1 regulatory cAMP- 
binding protein may play a role in the regulation of these cellular
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processes. More recently dbcAMP was found to inhibit the growth and 
alter the morphology characteristic of untransformed fibroblasts in 
transformed NIH/3T3 cells. In this case, these changes were found to 
correlate with an increase of the type 2 regulatory cAMP-binding 
protein and a decrease in the type 1 regulatory cAMP-binding protein. 
It has been shown that a mixture of type 1 and type 2 kinases are 
present in most mammalian cells and perhaps a selective modulation of 
these enzymes in the different cell types may be a crucial function of 
cAMP.
Hexamethylene Bisacetamide.
Hexamethylene bisacetamide (HMBA) is one of the most effective polar- 
planar compounds that trigger cell differentiation. It is a low 
molecular weight (i.e. < 300 dal tons) compound with a polar
hydrophilic moiety and a planar hydrophobic portion. HMBA has been 
widely studied, it has activity in both solid tumour derived and 
leukemic cultured cell lines including neuroblastoma (Palfrey, Kimbi & 
Littauer 1977), glioblastoma multiforme (Rabson et al 1977), Friend 
murine erythroleukemia (MEL) (Reuben et al 1976) and the human 
promyelocytic leukemia, HL-60 (Collins et al 1980). HMBA has been 
selected for phase 1 clinical trials since it had the maximum 
differentiation potency in a series of bisacetamides, and also because 
it is possible to achieve concentrations of HMBA in patient plasma 
equal to the concentrations required for induction of differentiation 
in vitro.
The precise mechanism of action of HMBA is unknown. Bisacetamides are 
taken up by the cell, an intracellular concentration equal to the 
extracellular concentration is achieved by 6-8 hours (Reuben,
1979). Cellular uptake of HMBA appears to be necessary for action 
since HMBA linked to glutathione (which cannot penetrate the cell 
membrane) is inactive (Gabrilove, 1986). Commitment to
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differentiation is both concentration and time dependent. It takes at 
least 10 hours after equilibration before differentiation is detected. 
The lag time may indicate that there is a need for continuous HMBA 
presence during a sequence of biochemical changes and/or that 
induction is cell-cycle dependent.
It has been recently shown that changes in intracellular polyamines 
are an intimate part of the differentiation programme induced in MEL 
cells by HMBA, and they appear to be associated with a regulatory 
event in this process (Meilhoc, Moutin & Osborne 1986). The first 
polyamine-biosynthetic enzyme, ornithine decarboxylase, is negatively 
controlled by synthetic cst-w diamines as well as by the natural 
polyamines. Since HMBA is a diace ty la ted diamine, its deacetylation 
would produce molecules that could potentially regulate polyamine 
biosynthesis.
N-Acetyl-l,6-diaminohexane and 1,6-diaminohexane formed by 
deacetylation of HMBA are shown to accumulate rapidly inside MEL cells 
(Meilhoc et al 1986) and HL-60 cells (Egorin et al 1988). In the 
absence of HMBA, exogenous N-acetyl-l,6-diaminohexane was able to 
induce the complete differentiation process in both MEL and HL-60 
cells. Moreover, N-acetyl-l,6-diaminohexane was able to cause changes 
in polyamine biosynthesis in MEL cells (Meilhoc et al 1986). This 
therefore implies that the catabolites of HMBA may be directly 
responsible for the changes in polyamine biosynthesis and maybe for 
initiating other events regulatory for the differentiation of these 
cells.
A complete characterisation of HMBA catabolism has recently been 
carried out both in vivo and in vitro. After intravenous 
administration of HMBA to humans the urine contained the parent 
compound and at least five metabolites formed by deacetylation and 
oxidation pathways. Metabolites identified included the major
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metabolite 6-acetamidohexanoic acid, its monodeacetylated product N- 
acetyl-1.6-diaminohexane, its bis-acetylated product 1,6-diaminohexane 
and 6-aminohexanoic acid and its lactam, caprolactam (Gallery et al 
1986). A number of leukemic cell lines have also been shown to take 
up HMBA and to convert it to the same metabolites identified in the 
plasma and urine of patients treated with HMBA (Egorin et al 1988). 
One enzyme likely to carry out the sequential deacetylation of HMBA to 
N-acetyl-l,6-diaminohexane and 1,6-diaminohexane is N^-
acetylspermidine deacetylase. This particular enzyme metabolises a 
substrate produced by nuclear acetylases which are also involved in 
acetylation of his tones. Therefore HMBA may inhibit histone
deacetylation and thereby maintain the his tones in an hyperace tylated 
state, which in turn might facilitate transcription of chromatin.
However this possible mechanism of action for HMBA induced changes in 
gene expression and differentiation requires further studies.
Sodium Butyrate.
Sodium butyrate, (NaBut), a four carbon fatty acid, is a natural
occurring fatty acid and is formed by the hydrolysis of ethylbutyrate. 
Recent studies on mammalian cells in culture show that this fatty acid 
affects morphology, growth rate and gene expression. Sodium butyrate 
is a potent differentiation agent in some cancer cells such as 
colorectal tumours (Tsao et al 1983), erythroleukaemia (Leder & Leder 
1975), human hepatoma (Nakagawa et al 1985) and human medullary 
thyroid carcinoma (Nakagawa et al 1988). The mechanism by which NaBut 
acts on cells is not completely understood, but in some systems the 
effects of this agent have been related to its inhibitory action on 
histone deacetylase, leading to hyperacetylation of chromatin- 
associated his tones and thereby to changes in gene expression (Riggs 
et al 1977). However a causal relationship between the accumulation 
of polyace tylated his tones in the presence of NaBut and the inhibition
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of DNA synthesis and the switching of malignant cells to non-malignant 
differentiating cells requires further work.
Retinoic acid.
The retinoids comprise a group of compounds including retinoic acid, 
retinol (vitamin A) and a series of natural and synthetic derivatives 
that together exert profound effects on development and 
differentiation in a wide variety of systems (Spom & Roberts 1983). 
Although early studies focussed on the effects of retinoids on 
epithelial growth and differentiation, their actions have been shown 
to be more widespread than previously suspected. Many recent studies 
have examined the effects of these molecules on a variety of cultured 
cell lines including neuroblastomas, melanomas and fibroblasts. The 
mechanism of action of the retinoids is unknown but the recent 
identification of a human retinoic acid receptor belonging to the 
family of nuclear receptors suggests that the hormone/receptor complex 
may control differentiation by inducing regulatory events as a result 
of activation of specific sets of genes (Petkovich et al 1987).
Dexamethasone.
Steroid hormones act via specific and seemingly mobile receptor 
proteins. Steroids enter all cells from the blood by passive 
diffusion. If specific receptors are present, a high affinity hormone 
receptor complex is formed which, after a conformational change or 
activation, is translocated to the nucleus to occupy large numbers of 
so called acceptor sites, composed of DNA and non-histone nuclear 
proteins. Dexamethasone is a synthetic analogue of the naturally 
occur rang corticosteroids. Dexamethasone has been shown to induce 
growth inhibition in a number of cell lines, including human lung 
adenocarcinoma (Jones, Anderson & Addison 1978), human glioma 
(Freshney et al 1980) and breast cancer cells (Darbre & King 1987).
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Furthermore, dexamethasone has been shown to have a differentiation 
inductive effect and a repressive effect on malignancy associated 
properties in human gliomas and in lung carcinoma (Freshney,
1985).
Chemosensitivity o f SCLC.
This study involved examining the effect of phenotypic inducer 
treatment of some SCLC cell lines on the cells* sensitivity to various 
cytotoxic agents. As discussed earlier, adriamycin, vincristine and 
VP16 are among the chemotherapeutic agents used in the treatment of 
SCLC.
Adriamycin belongs to a group of antibiotics, the antracyclines, 
which are isolated from Streptomyces peucetius. Adriamycin is the 14- 
hydroxy derivative of daunorubicin. Daunorubicin is produced by S. 
peucetius but after treatment with the mutagen, n-nitroso-N-methyl
urethane, a modified strain of the organism develops which secretes
adriamycin. Daunorubicin appears to owe its cytotoxicity to 
daunorubicinol, a metabolite formed by enzymatic reduction of the keto 
group at C13. This compound intercalates itself between adjacent base 
pairs of the DNA molecule which becomes partly untwisted so that 
further synthesis of DNA, and hence RNA, is interfered with. 
Adriamycin is more potent than daunorubicin in inhibiting the
synthesis of nucleic acids. It also owes its cytotoxic activity to a
reduction product (doxorubicinol) that intercalates itself into the 
DNA molecule. Adriamycin has numerous biological activities, 
including targeting to specific enzymes like topoisomerase II and the 
generation of free radicals, and because of this diversity of effects
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it is difficult to assign a single activity as being the cytotoxic 
action.
Drugs that block the replication of DNA stop mitosis in the S stage of 
interphase whereas drugs that impair protein synthesis inhibit the 
cell growth that occurs in the G1 or G2 stages of interphase. One 
group of drugs that inhibit the metaphase of mitotic division is the 
vinca alkaloids (vincristine and vinblastine from the periwinkle 
plant). The vinca alkaloids bind to microtubules and cause them to 
disrupt into subunits. These drugs therefore inhibit those cellular 
processes that depend on microtubules including mitosis. Since 
micro tubules are involved in a number of cellular functions, 
inhibition of spindle formation is only one aspect of the action of 
these drugs.
The double helical structure of DNA poses several mechanical problems 
for the functioning of the molecule. The principal difficulty is that 
the helix cannot replicate itself unless reversible swivelling takes 
place around the replication fork, thereby preventing entanglement of 
daughter DNA molecules during mitotic segregation. Similarly, a 
swivel mechanism is probably required during gene transcription to 
prevent the nascent RNA transcript being serially wrapped and dragged 
around the helix. Two types of such molecular swivels have been 
characterised. Type I topoisomerases are ubiquitous intranuclear 
enzymes that effect the transient breaking and rejoining of single DNA 
strands in living cells, allowing the helix to change its twist. 
These enzymes have been heavily implicated in the mediation of gene 
transcription, although they do not appear essential for cell 
survival. Type II topoisomerases induce transient double-stranded 
breaks in DNA, with subsequent relaxation of DNA twist via strand- 
passage of duplex DNA. DNA replication, recombination, transcription 
and repair have all been linked with topoisomerase II activity, and
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this enzyme is probably required for cell survival (Epstein,
1988).
Topoisomerases have now been recognised as targets of several commonly 
used antitumour drugs. For topoisomerase II, these agents include the 
epipodophyllotoxin VP-16 and the intercalating anthracycline 
derivative adriamycin. Although the cytotoxicity of such agents may 
not prove to be mediated exclusively via topoisomerases, it is the 
formation of a stabilised enzyme:DNA intermediate (and not inhibition 
of enzyme per se) that appears to be responsible for topoisomerase- 
mediated component of toxicity. This enzyme:DNA intermediate, or 
cleavable complex, can be revealed as DNA strand-breaks in DNA damage 
assays even though such breaks seem likely to be physiologically 
concealed in vivo. Pronounced increases in cellular topoisomerase II 
activity have been associated with cell proliferation both in vivo and 
in vitro, and this proliferative activity has in turn been associated 
with increased tumour cell sensitivity to topoisomerase-II-interactive 
drugs (Sullivan et al 1986; Markovits et al 1987).
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Project Aim.
Histological variants of SCLC have long been recognised including the 
oat cell type and the intermediate types. However, no significant 
difference has been observed in the clinical presentation, extent of 
disease, sites of metastases nor response to therapy among these 
histological subtypes of SCLC (Carney et al 1980). In contrast, in 
those patients in whom a mixture of SC and large cell carcinoma are 
detected at diagnosis the prognosis for these patients is 
significantly worse than for those patients with "pure” SCLC (Radice 
et al 1982). These mixed-histology patients have a significantly 
lower complete response rate to cytotoxic therapy and poorer survival.
As discussed previously, mixed cell types of SCLC with large cell or 
other histological types of lung cancer are frequently recognised at 
autopsy in patients who initially presented with pure SCLC in their 
biopsy specimen (Abeloff et al, 1979). It is unclear whether this 
observation represents the evolution of two separate lung cancers or 
the transformation of the initial "pure" SCLC to another cell type. 
Similar to patients who initially present with a mixed cell type, 
patients with SCLC who relapse from initial cytotoxic therapy are 
frequently resistant to the effects of further cytotoxic therapy. 
SCLC has been shown to undergo a similar transition in vitro (Goodwin 
& Baylin 1982) and in nude mice heteroplants (Goodwin et al. 1983). 
In particular, an established line of human SCLC (OH-1) underwent a 
subtle morphological change which was accompanied by a profound loss 
of neuroendocrine differentiation and the emergence of radiation 
resistance (Goodwin & Baylin 1982). Furthermore, comparison of five 
classic SCLC cell lines, which included two large cell variant SCLC 
cell lines, revealed that the large cell variants, which had lost APUD 
properties, were more resistant to radiation compared to the classic 
SCLC cell lines. Therefore a change in SCLC morphology and/or 
neuroendocrine properties towards the large cell nonneuroendocrine
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types could thus be a factor in the inevitable resistance to therapy 
that emerges with time in patients with SCLC.
The changes in pathological and biochemical characteristics of SCLC 
with the associated changes in sensitivity to radiotherapy and/or 
chemotherapy, could reflect the emergence of another tumour \diich was 
present from the outset, the development of a second tumour, 
differentiation of the initial tumour or an effect of cytotoxic 
therapy on the morphology of SCLC. The aim of this work was to 
investigate whether these changes observed in SCLC could be the result 
of an alteration in the phenotype of the SCLC cells. The major 
question addressed in this study is: Can the SCLC phenotype be altered 
and if so does this affect chemosensitivity ?
Various markers of the SCLC phenotype were selected. SCLC cell lines 
were treated with drugs known to induce phenotypic alterations in 
other cell types. Following treatment, the levels of the SCLC 
phenotypic markers were measured. Changes in the levels of these 
markers were taken as representing an alteration in the SCLC 
phenotype. The chemosensitivity of the SCLC cell lines was measured 
following phenotypic inducer treatment, to determine whether 
phenotypic change altered chemosensitivity.
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CHAPTER 2. 
MATERIALS AND METHODS.
Tissue Culture.
Materials
RPMI 1640 lOx 
L-Glutamine 200mM (lOOx)
HEPES Buffer Solution 1M 
Foetal Calf Serum 
Sodium Bicarbonate 7.5%
Phosphate Buffered Saline:-
8/1
NaCl 8.0
KH2P04 0.2
Na2HP042H20 1.45
KC1 0.2
Hoechst 33258
Cell Maintenance:-
The human small cell lung cancer (SCLC) cell lines used in this study 
are characterised in Table 1. The cell lines are all derived from 
pleural effusions and have been categorised as classic SCLC by their 
in vitro characteristics (Carney et al, 1985). The SCLC cell lines 
were maintained as non-adherent cultures in Roswell Park Memorial 
Institute medium 1640 (RPMI 1640) supplemented with 10% foetal calf 
serum (FCS), in gas phase of 2% C02 98% air, at 37°C. The selection 
of 2% C02 to buffer with the bicarbonate in the medium, instead of the 
commonly used 5% C02  ^ provided pH stability during microtitration 
plate manipulations particularly with HEPES. The cells
  Northumbria Biologicals Ltd.
— Gibco, Europe Ltd.
  Gibco, Europe Ltd.
  Biocon, UK Ltd.
  Gibco, Europe Ltd.
 BDH
—  Sigma
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were passaged once per week and the medium was changed between 
subcultures.
Table 1 : SCLC Cell Lines Used in This Study.
Cell Lines Pathology Origin Reference
NCI-H187 SCLC PE Carney et al,0.985)
(classic) (C.R. 45, pp 2913).
NCI-H69 SCLC PE Carney et al, (1985)
(classic) (C.R. 45, pp 2913-2923).
NCI-H128d SCLC PE Carney et al, 0-985)
(classic) (C.R. 45, pp 2913-2923).
Mycoplasma Staining; -
The cells were tested for mycoplasma contamination once a month. The 
medium from exponentially growing cultures of SCLC cells was added to 
35mm petri dishes containing an indicator cell line (A549 
adenocarcinoma cell line) known to be free of mycoplasma. After 2-3 
days the indicator cells were fixed with 1 part acetic acid to 3 parts 
methanol and stained using the Hoechst 33258 fluorescent dye. The 
Hoechst dye binds specifically to DNA. Mycoplasma contamination could 
be detected by the presence of extranuclear fluorescence (Chen, 1977).
Cultures were mycoplasma free at the time of all experiments.
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Cell Freezing; -
A using stock of each cell line was stored in liquid nitrogen, -196°C. 
Every three months the culture stock was replaced by cells thawed from 
the freezer.
Cell Counting:-
For day to day estimation of cell number cultures were repeatedly 
pipetted to disaggregate the cell clumps and the cell number was 
measured using an electronic particle counter (Coulter Counter Z^).
Determination of the growth cycle was carried out either by electronic 
cell counting, total protein determination or by use of the MTT 
assay:-
a. Cell Growth by Electronic Cell Counting.
Cell suspensions were seeded into 24 well plates at 5xlcA cells/ml in 
RPMI 1640 supplemented with 10% FCS and incubated at 37°C in 2% CO2 . 
At regular intervals throughout the growth curve 0.4ml samples were 
removed from the appropriate wells, following repeated pipetting, and 
19.6mls of PBS were then added. The cell number was determined by 
electronic particle counting.
Where the effect of various drugs on the growth of SCLC cell lines was 
examined, the cells were plated out in medium containing the drug and 
the drug was present throughout the growth curve.
In order to measure cell growth accurately by electronic cell counting 
a single cell suspension is required. This requirement was found to 
be the main drawback of electronic cell counting for the SCLC cell 
lines. Since the cell lines grew as floating aggregates a single
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cell suspension was not easily obtained. Photographs 1,2,3 & 4 show 
that H187 and H69 can be disaggregated fairly well, although a 
complete single cell suspension was still not achieved. For these 
cell lines electronic cell counting was used as an estimation of cell 
growth. This was supported by the finding that measurement of the 
growth curve by electronic cell counting showed good correlation with 
the increase in total cellular protein (Figs 1 & 2). However, 
electronic cell counting was found to be unreliable for estimating 
cell growth of H128d which grew as tight aggregates. Photographs 5 & 
.6 show that even after repeated pipetting of H128d large aggregates 
remained.
b. Cell Growth by Total Protein.
o
Cell suspensions were seeded into 25cm tissue culture flasks. On 
appropriate days thereafter the cells were harvested and washed twice 
with PBS. The cell pellet was dissolved in 0.5M NaOH and acid soluble 
protein was determined using the Biorad Protein Assay (see later).
c. Cell Growth by MIT Assay.
Cell suspensions were plated out at 5x10^ cells/ml into 96 round 
bottomed microtitration plates in PPMI 1640 with 10% FCS, incubated at 
37°C in 2% CO2 . At regular intervals throughout the growth curve one 
plate was harvested and an MTT assay (see below) was carried out to 
determine cell number. Where the effect of drugs on the growth of 
SCLC cell lines was examined, the cells were plated out at twice final 
concentration and the drug was added to the plate at twice final 
concentration. Following the appropriate incubation period, the drug 
was removed by spinning the plates at 200g for 5mins, aspirating the 
supernatant and resuspending the cells in fresh medium. The plates 
were fed on alternate days thereafter.
- ' V
W '* * i 1  J
100 jim
Photograph Is- H187 Cells (lOx objective).
H187 cells were grown in RPMI 1640 medium supplemented with 10% FCS. 
The cells were photographed in late log phase of growth.
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Photograph 2:- H187 Cells Disaggregated by Repeated Pipetting (lOx 
objective).
H187 cells were grown to late log phase, and then pipetted up and down 
using a 10ml glass pipette. A cell suspension consisting of single 
cells and aggregates of two or three cells was produced.
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Photograph 3:- H69 Cells (lOx objective).
H69 cells were grown in RPMI 1640 medium supplemented with 10% FCS. 
The cells are in late log phase of growth.
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Photograph 4:- H69 Cells Diaggregated by Repeated Pipetting (lOx 
objective).
H69 cells were grown to late log phase of growth. The cells were then 
pipetted up and down using a 10ml pipette to disaggregate the cell 
clumps. The H69 cell suspension consisted of single cells and 
aggregates of varying cell number.
Photograph 5:- H128d Cells (lOx objective)
H128d cells were grown in RPMI 1640 supplemented with 10% FCS. The 
cells were grown to late log phase of growth.
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Photograph 6:- H128d Cells Disaggregated by Repeated Pipetting (lOx 
objective).
H128d cells were grown to late log phase. The cells were then 
pipetted up and down using a 10ml pipette. The cell suspension 
consisted of aggregates of various sizes.
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A microtitration assay has a number of advantages which makes it an 
attractive means of determining cell growth. It is less time 
consuming, a large number of replicates can be handled easily, it 
enables the determination of the effect of a number of drugs 
simultaneously and it can be semi-automated.
Measurement of cell growth by microtitration based on the MTT assay 
was found to correlate well with electronic cell counting (Figs 3 & 4, 
and Table 2). Therefore, the MIT assay could be used to determine the 
growth cycle of the SCLC cell lines. Furthermore, since the MIT assay 
only measures viable cells one could distinguish between dead and live 
cells, which is not possible by electronic cell counting.
Table 2; Doubling Times (td) of SCLC Cell Lines.
Cell Line. td by electronic cell td by MIT assay
counting (days) (days)
H187 2.33 + 0.15, (n=6) 2.57 + 0.32, (n=4)
H69 3.02 + 0.22, (n=5) 3.80 + 0.22, (uf4)
(results represent the mean of n determinations + standard error).
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Figure 1:- Growth Curves of H187 Cells.
The cells were seeded into either 24 well plates or 25cm^ flasks at 
3x10 cells/ml. On the appropriate days the cell growth was measured 
by cell counting (24 well plate) using an electronic counter or by 
measuring protein content (25cm flask).
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Figure 2:- Growth Curves of H69 Cells.
n
The cells were seeded into either 24 well plates or 25cm flasks at 
3xlCr cells/ml. On the appropriate days the cell growth was measured 
by cell counting (24 well plate} using an electronic counter or by 
measuring protein content (25cm flask).
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Figure 3:- Growth Curves of H187 Cells.
The cells were seeded into either 24 well plates or into 96 round 
bottomed well plates. On the appropriate days the cell growth was 
measured by cell counting (24 well plate) or by carrying out an MTT 
assay (96 well Plate).
Growth Curve: H69
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Figure 4:- Growth Curves of H69 Cells.
The cells were seeded into either 24 well plates or into 96 round 
bottomed well plates. On the appropriate days the cell growth was 
measured by cell counting (24 well plate) or by carrying out an MIT 
assay (96 well Plate).
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Bombesin Assay.
Assay of Bombesin Levels by the Degree of Mitogenicity in Swiss 3T3 
Cells.
Rozengurt and Sinnet-Smith (1983) showed that bombesin was a potent 
mitogen for Swiss 3T3 cells. Bombesin was found to induce DNA 
synthesis in quiescent cultures of these cells in a concentration 
dependent manner, with the maximal effect being achieved at 3nM. This 
effect has been shown to be receptor mediated, antagonised by [D Arg-*-, 
D Pro^ , D Trp^, Leu-^] substance P (Zachary & Rozengurt 
1985). Therefore, since bombesin can stimulate Swiss 3T3 cell 
mitogenesis, could this be used as a means of determining unknown 
levels of bombesin?
SCLC cell lines are known to produce and secrete bombesin (Moody et 
al, 1981). Therefore, if conditioned medium from exponentially 
growing cultures of SCLC cells was added to quiescent cultures of 3T3 
cells would it be possible to quantify the amount of bombesin present 
by the degree of mitogenesis which may occur?
Swiss 3T3 cells were rendered quiescent by removal of serum. 24hrs 
later known amounts of bombesin were added to the cells and the cells 
were incubated for 24hrs at 37°C in 2%C0 2 « The cell number was 
measured at regular intervals thereafter using the MTT assay.
Protocol:-
1. Swiss 3T3 cells were trypsinised in 0.25% trypsin in PBS and 
resuspended in RPMI 1640 10% FBS at a final concentration of 5x10^ 
cells/ml.
2. The cells were aliquotted into 96 well plates, 200pl/well.
Optimum M»T Concentration:— 
Swiss 3T3 Cells.
A570nm
a. 3
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Figure 5:- Optimum MTT Concentration for Maximum Formazan Production 
in Swiss 3T3 Cells.
Swiss 3T3 cells were seeded into 96 well plate at * 5x10^ cells/ml 
(1x10 cells/well) and incubated for 24 hours at 37°C in 2% CC>2 * 
After the incubation period MTT was added to the plate at various 
concentrations. Following, a 4hour incubation period the absorbance 
at 570nm was determined, as a measure of the amount of formazan 
produced.
Each point represents a mean of 8 determinations + standard error.
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3. The plates were incubated at 37°C in T/££>2 f°r 24hrs to allow cell 
adhesion and the initiation of cell proliferation.
4. After 24hrs the medium was replaced with serum free medium to 
render the cells quiescent.
5. Bombesin was added to the cells at a concentration range 10“*% - 
10"-^ %, incubated for 24hrs.
6 . The cell number was determined using the MTT assay (see below).
Note:- The optimum concentration of MIT for maximum formazan 
production in 3T3 cells was taken as 4.5mg/ml, fig 5.
Results and Conclusions
Following a 24hr exposure of 3T3 cells to bombesin no stimulation of 
cell proliferation was found, even although a marked increase in cell 
number was found by Rozengurt and Sinnet-Smith (1983) after a 24hr 
exposure. Perhaps DNA synthesis had been stimulated in these cells 
but the effect was not significant enough to be manifested into an 
increase in cell number after 24hrs. However even longer exposure 
times to bombesin did not result in a increase in Swiss 3T3 cell 
mitogenesis.
Since our Swiss 3T3 cells did not respond to bombesin they could not 
be used to determine unknown levels of bombesin in SCLC.
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Radioinmunoassay of Bombesin.
Materials:-
Bombesin RIA Kit -- INCstar Ltd.
Acetic Acid -- BDH
Radioimmunoassay (RIA) depends on the precise antigen specificity of
1 oc
antibodies. A known amount of radioactive antigen -L 'JI-Bombesin, is 
added with a fixed amount of antibody, rabbit antibombesin, to a 
sample containing an unknown quantity of unlabelled antigen, bombesin. 
The unlabelled bombesin competes with the labelled bombesin for 
antibody binding sites so that the greater the amount of bombesin in 
the unknown sample the smaller the amount of radioactive bombesin 
bound to the antibody. The antibody with bound bombesin is 
precipitated using a second antibody, goat anti-rabbit immunoglobulin. 
The radioactivity in the precipitate is counted using a gamma counter. 
The amount of bombesin in the sample is calculated from a standard 
curve, where known amounts of unlabelled bombesin are added to the
HOC
-L I-bombesin/rabbit antibombesin incubation mixture.
This assay has a number of advantages. It is specific and 
reproducible and it can be used to measure both cellular and secreted 
bombesin levels.
Cells were harvested, washed and cellular bombesin acid extracted. 
The amount of bombesin in the cells was measured by RIA.
Protocol: - Adapted from method of Bepler e£ al? 1987.
1. The cells were harvested by centrifugation 200g for 5mins, and the 
cell pellet washed twice with PBS.
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2. The pellet was resuspended in 1ml 2M Acetic Acid, and boiled for 
lOmins.
3. The samples were clarified by centrifugation at 10,000g. 
Supernatant lyophilised and stored at -70°C.
4. The freeze dried extract was dissolved in 1ml PBS, and the amount 
of bombesin was assayed by RIA following the manufacturers 
instructions.
Briefly, a sample of cell extract for analysis was added
-j oc
simultaneously to rabbit antibombesin and x I-bombesin and 
incubated at 4°G overnight. The second antibody, goat antirabbit, 
was added and following a 20min incubation at 25°C the samples were 
centrifuged, decanted and the precipitate counted.
5. The acid soluble protein was measured using the Biorad 
Protein Assay (see later).
The results are expressed as pg bombesin/ jig acid soluble protein.
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Creatine Kinase.
Materials;-
Creatine Kinase —  Sigma
Creatine Kinase Electrophoresis ;
Cardiotrac-CK (CK isoenzyme substrate set)
3 in 1 Electrophoresis Control Serum ("level II")
MOPSO Buffer Set —  Coming Diagnostics Ltd.
Creatine phosphate acts as a storage form of high energy phosphate 
groups in vertebrate muscle and other tissues. When energy is 
required it is creatine kinase (CK) which is responsible for 
transferring a high energy phosphate group from creatine phosphate to 
adenosine diphosphate (ADP) to form adenosine triphosphate (ATP) and 
creatine.
CK
Creatine Phosphate + ADP------> ATP + Creatine
The soluble cytoplasmic forms of CK occur as dimers consisting of 
three possible combinations of two antigenically distinct chains, M 
(muscle form) and B (brain form).
MM, MB and BB.
In order to establish the amount of CK isoenzyme activity initially 
one has to measure total CK activity. Total CK activity is measured 
indirectly by means of a NAD linked reaction. CK catalyses the 
reaction between creatine phosphate and ADP, forming creatine and ATP, 
in the presence of hexokinase (HK). The ATP formed phosphorylates 
glucose to glucose-6-phosphate (G-6-P). Glucose-5-phosphate
dehydrogenase (G-6-PDH) then catalyses the oxidation of G-6-P in the
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presence of nicotinamide adenosine diphosphate (NAD) • During this 
oxidation an equimolar amount of NAD is reduced to NADH.
CK
Creatine Phosphate + ADP--- > Creatine + ATP
HK
ATP + Glucose ----- > ADP + G-6-P
G-6-PDH
G-6-P + NAD ----------> 6PG + NADH
The increase in amount of NADH is measured as a change of absorbance
at 340nm. The rate of change in absorbance is directly proportional
to CK activity.
Having established the total CK activity the percentage of each CK 
isoenzyme is measured. The CK isoenzymes are separated by gel 
electrophoresis. The distinctly separate zones can be detected by 
overlaying the agarose gel with creatine kinase substrate. The 
identification of the CK isoenzymes by this method also involves a NAD 
linked reaction, as above. In this case the zones with CK activity 
fluoresce under U.V. light and can be quantified using a scanning 
fluorimeter.
Protocol;-
Extraction of Cellular Creatine Kinase.
CK was extracted from the cells by the same method used to extract 
DOPA decarboxylase (see below). Extraction by freeze thawing 3x was 
found not to affect the enzyme activity.
Figure 6:- Electrophoretic Scan of the Creatine Kinase Isoenzymes.
The scan shows the result of electrophoretic separation of the three 
CK isoenzymes in control human serum. The first peak represents the 
MM isoenzyme, followed by the MB isoenzyme and lastly the BB 
isoenzyme.
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Assay of Creatine Kinase Activity.
CK activity was quantified from a standard U.V. kinetic assay supplied 
by Sigma. The assay was performed following the manufacturers 
instructions. Briefly, a sample of the cell extract for analysis was 
added to the creatine kinase reagent (Sigma) and incubated at 30°C for 
5mins in a spectrophotometer (Gilford 250). During this time, 
absorbance readings at 340nm were taken every 30 seconds. An increase 
in absorbance at 340nm represented an increase in the formation of 
NADH. One unit of CK activity was defined as the amount of enzyme 
which produced one jjmole of NADH per minute under the conditions of 
the assay procedure.
Isoenzyme distribution of enzymatic CK was determined by 
electrophoresis using reagents and equipment supplied by Coming 
Diagnostics Ltd. The assay was performed following the manufacturers 
instructions. The isoenzymes were separated by electrophoresis on 
preformed 1% w/v agarose sheets (Coming Diagnositics) at 9V/cm for 23 
mins in a 0.05M M0PS0 [3-(N-Morpholino)-2-hydroxypropane sulfonic 
acid] buffer, pH 7.8. The CK isoenzymes were identified by overlaying 
the gel with creatine kinase substrate (Coming) and measuring the 
NADH produced using a scanning fluorimeter (Helena Densitometer). 
Figure 6 is an example of an fluorimetric scan of the CK isoenzymes.
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DOPA Decarboxylase Assay.
Materials:-
Pyridoxal 5*phosphate —  Sigma
L-^-3,4- dihydroxyphenylalanine (L-DOPA)   Sigma
DL-j9-3,4- dihydroxyphenylalanine (DL-DOPA)   Sigma
D-£-3,4- dihydroxyphenylalanine (D-DOPA)   Sigma
3-Hydroxytyramine (dopamine) —  Sigma
Nialamide —  Sigma
EDTA -- BDH
Sodium tetraphenylboron -- BDH
Heptan-3-one -- BDH
Borax -- BDH
KH2P04 -- BDH
Na2HP04 -- BDH
NaH2P04 -- BDH
Dihydroxyphenylalanine L-3,4-[ring -2,5,6-%]
([%] L-DOPA) -- Du Pont
(2,5,6-%) dopamine —  Amersham UK
Ecoscint —  National Diagnostics
DOPA decarboxylase (DDC) was first discovered in the kidney; it also 
occurs in large amounts in the liver as well as in adrenergic neurones 
and chromaffin cells. The enzyme appears to be free in the cytoplasm 
and not associated with any subcellular structure. It requires 
pyridoxal 5‘phosphate for activity, and is specific for the L-forms of 
amino acids.
DDC decarboxylates L-DOPA to dopamine with the loss of carbon dioxide.
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DDC
L-DOPA------------ > Dopamine
co2
-CHo-CH-NH.
HO- COOH
OH
H0-
OH
DDC activity can be determined by the rate of formation of dopamine 
from L-DOPA.
DDC was extracted from the cells. The activity of the enzyme was 
determined using radioactively labelled L-DOPA and separating the 
radioactive dopamine formed from the unchanged amino acid. The amount 
of dopamine formed was directly related to the activity of the enzyme.
1. Extraction of Cellular DDC.
Protocol:-
1. Cells were harvested by centrifugation at 200g for 5mins.
2. The cell pellet was washed twice with ice cold PBS.
3. Finally the cell pellet was resuspended in 1ml borate buffer pH7.6 
(minimum), in 15ml plastic test tubes, and an aliquot removed and 
stored for assay of protein and DNA content.
45
4. The remaining cell/buffer suspension was frozen thawed 3x using 
solid CO2 (Drikold)/methanol and a 37°C water bath. Freeze thawing 
3x was found to cause 100% lysis of the cells, examined by trypan 
blue exclusion. It did not have any adverse effect on the enzyme 
activity.
5. The sample was then transferred to Eppendorf tubes and centrifuged 
at 8000g, for 5mins.
6 . The supernatant was assayed for DDC activity.
2. Enzyme Substrate Reaction.
Incubation Mixture (final concentrations)
Borate Buffer —  0.025M Borax + 0.05M KH2PO4 pH 7.6
Pyridoxal 5*Phosphate —  IOOjjM
Nialamide —  125jjM
EDTA --1.5mM
L-DOPA -- 1200pM
^-L-DOPA —  30pCi/ml
Protocol: -
1. The reaction mixture (above) was prepared, omitting the pyridoxal 
5*phosphate.
2. 45jTL samples were aliquoted out into 15ml glass stoppered 
centrifuge tubes.
3. The samples were then incubated at 37°C for 5mins.
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4. 200pl of the DDC extract was added to lOOpl of pyridoxal
51phosphate (1200pM) and mixed thoroughly. (Adding pyridoxal 
5'phosphate to the enzyme minimises any reaction with the 
substrate).
5. 15pl of the enzyme/pyridoxal 5'phosphate mixture was then added to 
the appropriate tubes to start the reaction.
6 . The samples were incubated at 37°C for 1 hour.
7. The reaction was stopped by adding 5mls ice cold sodium phosphate
buffer lOmM pH 6.5. The tubes were then transferred to ice.
Blanks:-
a. Reagent Blank - Incubation mixture without enzyme incubated
for 1 hour.
b. Sample Blank - Incubation mixture incubated for 1 hour, add
enzyme extract after incubation period.
Similar results were obtained in both cases.
The quantity of DOPA carried over into the dopamine extracted samples
has been found to be equivalent to that extracted in the blanks 
(Laduron & Belpaire 1968). Tnerefore it is necessary to subtract the 
value of the blank from the samples in order to obtain an accurate 
value of the dopamine formed. This also accounts for any nonenzymatic 
decarboxylation of DOPA which may occur.
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3.Extraction of Dopamine,
The amine, dopamine, is extracted from the unchanged amino acid, DOPA, 
by liquid cation exchange with sodium tetraphenyl boron (Fonnum 1969). 
Sodium tetraphenyl boron forms a complex with cations that is 
insoluble in water but soluble in organic solvents such as higher 
ketones. In a weak acid buffer dopamine becomes protonated whereas 
DOPA undergoes internal exchange and forms a Zwitterion. Sodium 
tetraphenylboron complexes with dopamine to form an insoluble salt. 
DOPA does not combine with the sodium tetraphenylboron as the 
Zwitterion has no overall charge. Addition of an organic solvent 
separates DOPA and dopamine : the dopamine/tetraphenylboron complex 
dissolves in the organic phase whereas the DOPA remains in the aqueous 
phase. Dopamine is not extracted by ketone in the absence of sodium 
tetraphenylboron•
Sodium tetraphenylboron in heptan-3-one (ketone) was added to the 
samples. The organic layer was extracted, washed and the %-dopamine 
present counted.
Protocol:-
1. 1ml of heptan-3-one containing 25mg sodium tetraphenylboron was 
added to each sample tube.
2. The samples were mixed gently by inversion for approximately 
lmin.
3. The two phases were separated by centrifugation at 1500g for 
5mins at 4°C.
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4. The aqueous phase was removed using a Pasteur pipette and 
discarded.
5. The organic phase was washed with 2mls of lOmM sodium phosphate 
buffer pH 7.4, containing lmg sodium tetraphenylboron, (any DOPA 
remaining is back extracted into the aqueous phase).
6 . The samples are centrifuged at 1500g for 5 mins at 4°G.
7. An 0.5ml aliquot was removed from the organic layer and lOmls 
Ecoscint was added. The radioactivity present was counted for 
lOmins using a scintillation counter (Packard Liquid Scintillation 
Spectrometer).
Note:- Heptan-3-one quenches by 50%
Extraction Efficiency:-
% recovery of dopamine 76.3%
% recovery of DOPA 0.33%
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MIT Cytotoxicity Assay. 
Materials
MIT ([3-(4,5-Dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide)
Glycine 
NaCl
Dimethyl sulphoxide (DMSO), Analar grade 
96 round bottomed well microtitration plates
(Cat.N0 16332 OA)
Cytotoxic Drugs.
Adriamycin —  Farmitalia, Carlo Erba Ltd.
Vincristine Sulphate —  David Bull Laboratories
Vepesid (Etoposide VP16-213) —  Bristol-Myers Pharmaceuticals
Clonogenic and biochemical assays have been widely used to measure the
chemosensitivity of tumour cell lines.
Clonogenic assay measures cell survival by proliferative capacity. It 
is a widely accepted method but is time-consuming and it is difficult 
to automate. Another problem with this assay is that some cells have 
a low plating efficiency, so that there is low survival in the 
untreated controls. A clonogenic assay as a measure of 
chemosensitivity was not suitable for SCLC cell lines. The cells grew 
as tight aggregates and it was difficult to obtain a single cell 
suspension, a prerequisite of the clonogenic assay. Repeated 
pipetting reduced the cell viability.
—  Sigma
—  BDH
—  BDH 
  BDH
—  Nunclon
50
Biochemical assays based on the principle of micro titration have been 
used to measure radiolabelled precursor incorporation into nucleic acid 
or protein as a measure of cell survival. A microtitration assay 
provides a means for quick assessment of cytotoxicity. It allows 
measurement of a number of variables easily e.g. drug concentration, 
drug exposure time and cell density. Replicate samples can be handled 
easily and it can be semiautomated. However in many cases these 
assays involve a number of manipulations and can therefore introduce 
variability into the system. The recent introduction of a 
microtitration colorimetric assay based on the ability of living 
metabolically active tumour cells to reduce a tetrazolium based 
compound (MIT) to a purple formazan product (Mosman 1983; Carmichael 
et al, 1987), has provided a real alternative to the clonogenic assay 
for assaying chemosensitivity of tumour cells, including SCLC cell 
lines.
The MTT assay has been shown to correlate well with the clonogenic 
assay (Plumb et al, 1987). Tnere is a linear relationship between 
cell number and the amount of formazan produced for both adherent (Fig 
7) and non-adherent cell lines (Fig 8 , Milroy personal 
communication), i.e. the amount of formazan produced is directly 
proportional to cell number. This allows the MIT assay to be used not 
only as a chemosensitivity assay but also as an estimation of cell 
number, especially where cell counting by conventional means is 
inappropriate (non-adherent cell lines which grow as tight 
aggregates).
The assay involved the use of 96 well microtitration plates. The 
cells were seeded into the plates and treated with the appropriate 
drug at various concentrations, for the required time. At the end of 
the assay cell survival was measured by adding MIT directly to the 
medium in the wells and incubating for 4 hours. Formazan crystals 
were formed in the viable cells. The medium was removed and the
Linearity o-f the MTT Assay
Swiss 3T3 Cells.
A570nm
1.0
0.3
0.2
0.0
0.0 0.5 l.a 1.5 2.0 2.5 5.0
cells/well <x!0E-4>
Figure 7:- Linear Relationship Between the Cell Number of a Monolayer 
Culture and the Amount of Formazan Produced from MIT.
Swiss 3T3 cells were seeded into two 96 well plates in RPMI 1640 + 
10% FCS, using a multichannel pipette. The cells were diluted 
serially across the plate by altering the delivery volume of the 
multichannel pipette. Medium was added to the plates to give a final 
volume of 200pl. After 48hrs, an MTT assay was carried out on one 
plate, the other plate was used to determine cell number. The amount 
of formazan formed, as measured by absorbance at 570nm, was plotted 
against the cell number.
Linearity o-f the MTT Assay:-
H187 Cells.
A570nm
0.4
0.Z
0-0
4.02.0 6.0 8.0
cells/well CxL0E—4>
Figure 8:- Linear Relationship Between the Cell Number of a
Suspension Culture and the Amount of Formazan Produced 
from MTT.
H187 cells were seeded into two 96 well plates in RPMI 1640 + 10% 
FCS, using a multichannel pipette. The cells were diluted serially 
across the plate by altering the delivery volume of the multichannel 
pipette. Medium was added to the plates to give a final volume of 
200pl. After 48hrs, an MIT assay was. carried out on one plate, the 
other plate was used to determine cell number. The amount of 
formazan formed, as measured by absorbance at 570nm, was plotted 
against the cell number. Data was kindly provided by R.M. Milroy.
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formazan crystals were solubilised with DMSO. The formazan production 
was analysed using a microtitration plate reader (Biorad).
Protocol:-
1. Cell Plating:-
a. Monolayer Cultures: A cell suspension of appropriate cell
concentration was prepared.
200pl aliquots were dispensed into a 96 
well plate using a multi-channel dispenser. 
The cells were left for 2 days to allow 
cell adhesion and proliferation.
b. Suspension Cultures: The cells were seeded into 96 round
bottomed well plates, lOOpM, at 2x final 
concentration.
2. Drug Addition:-
(cells were in exponential growth at the time of drug 
addition).
a. Monolayer Cultures: Medium was removed from the wells &
replaced with fresh medium containing drug. 
The cells were incubated for the 
appropriate period at 37°C in 2% CC>2 .
b. Suspension Cultures: Drug was added at the time of cell seeding.
lOOpl of the drug, 2x final concentration, 
was added to the appropriate wells.
The plates were then incubated for the 
appropriate period at 37°C in 2% CC^ .
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For drug exposure times longer than 24hrs, fresh drug was added every 
24hrs at the final concentration.
3. Recovery Period:-
A recovery period is an essential part of the chemosensitivity assay. 
It allows the distinction between proliferating cells and cells that 
may appear viable but have lost their proliferative capacity, 
following a toxic insult. Also, after the drug is removed lethal 
damage may still accumulate, the effect of which would be lost if a 
recovery period was not included. It is important to allow time for 
cell death and the loss of metabolic activity. It is also possible 
that the effect of a drug could be reversed following removal. This 
effect would be lost if no recovery period was allowed.
The recovery period for each cell line was chosen to allow 
approximately 2-3 population doubling times. The cells were still in 
exponential growth at the end of the experiment.
Monolayer cultures were fed every day.
Suspension cultures were fed on alternate days:-
the plates were centrifuged at 2 0 0g for 
5mins, 150pl of the medium was removed, 
and replaced with 150pl of fresh medium.
4. MIT Assay:-
1. On the final day medium was replaced by medium containing lOmM 
HEPES.
(addition of HEPES to the medium was found to reduce the 
scatter between replicate samples (Plumb, personal 
communication) ).
Optimum MTT Concentration: 
SCLC Cell Lines. 
A578nm
H1S7
H69
H129d
0.5
0.1
5.00. & 3.01.0
MTT cone mg/ml
Figure 9:- Effect of MIT Concentration on the Formazan Produced in 
SCLC Cell Lines.
SCLC cell lines were incubated with various concentrations of MTT, 
4hrs, 37°C, 2% CC^ . The amount of formazan produced by the cells in 
the presence of varying MTT concentrations was measured by the 
absorbance at 570nm.
Cytotoxicity Curve: 
H1S7 + VP16
A578nm
0.7
0.5
0.2
0 1 10 160 1060 10000 
VP16 cone nM
Figure 10:- Cytotoxicity Curve of H187 Cells after a 24 hour Exposure 
to VP16.
This is a cytotoxicity curve obtained from the MTT assay shown in 
photographs 7&8. The ID ^q is taken as the concentration of drug 
which reduced the control absorbance at 570nm by 50%. In this 
instance the ID^ q was found to be 90nM.
Each point represents the mean of 8 replicate samples + standard 
error.
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2. 50pl of MTT was added to each well of the plate at a 
concentration of MTT which allows maximum formazan production 
(Fig 9):-
NCI-H187 3.0mg/ml 
NCI-H69 3.0mg/ml 
NCI-H128d 4.0mg/ml.
3. The plates were incubated for 4 hours in the dark. Photograph 7.
4. Medium containing unreduced MTT was removed (suspension cultures 
were centrifuged at 200g for 5mins).
5. 200pl of DMSO was added to solubilise the formazan crystals 
followed by 25pl glycine buffer - 0.1M glycine + 0.1M NaCl pH 
10.5 (addition of buffer is required to ensure the formazan,
\diich can exist in two forms, is present in one form. (Plumb, 
personal communication)). Photograph 8.
6. The formazan production was measured using a micro titration plate 
reader (Biorad Model 2550 EIA Reader).
7. The ID q^ for a cytotoxic drug was determined by plotting the 
absorbance at 570nm against the concentration of drug (Fig 10).
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Photograph 7:- MIT Microtitration Plate Before DMSO Addition.
H187 cells were plated into a 96 well microtitration plate and exposed 
tp VP16 for 24 hours. The cells were allowed a 5 day recovery period 
at which time 3.0 mg/ml of MTT was added to each well. The photograph 
shows the viable H187 cells as purple dots in the centre of the 
appropriate wells.
B - blank C - control wells (no VP16).
Photograph 8:- MTT Microtitration Plate After DMSO Addition.
DMSO has been added to the microtitration plate shown in Photograph 7. 
DMSO has solubilised the purple formazan crystals \diich are present in 
viable cells. The intensity of purple colour in each well gives a 
measure of the viable cells present.
B - blank C - control wells (no VP16).
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Biorad Protein Assay,
Materials;
Protein Dye Concentrate 
Bovine Serum Albumin 
NaOH
Biorad
Sigma
BDH
The Biorad Protein Assay is based on the observation by Bradford (1976), 
that the binding of Coomassie Brilliant Blue G-250 to protein causes a 
shift in the absorption maximum of the dye from 465nm to 595nm. The 
increase in absorption at 595nm is a measure of the amount of protein 
present.
Since the assay only measures soluble protein the protein was first 
solubilised in 0.5M NaOH. A standard curve was performed for every 
assay where the standard, Bovine Serum Albumin (BSA), was also 
dissolved in 0.5M NaOH.
The assay was performed following the manufacturers instructions. 
Briefly, the protein content was measured by mixing an aliquotted 
volume of the unknown protein solution with the Dye Reagent 
Concentrate and the absorbance at 595nm was measured. At high protein 
concentrations diluted Dye Reagent Concentrate (1:4 with distilled 
water) was used and the absorbance was read on a spectrophotometer 
(Gilford 250). Where the concentration of protein was low, undiluted 
Dye Reagent Concentrate was used and the absorbance was measured using 
a microtitration plate reader (Biorad Model 2550 EIA Reader).
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DNA Assay.
As of the method of Le Pecq & Paoletti (1966), modified by Karsten & 
Wollenburger (1972) and then Gardner & Plumb (19791
Materials: -
Ethidium Bromide   Sigma
Deoxyribonucleic Acid (Calf Thymus Type 1) —  Sigma
Ribonuclease A (Bovine Pancreas Type 111-A) —  Sigma
Protease (Streptomyces Griseus Type XIV) —  Sigma
PBS reagents------------------------------ -- BDH
NaCl —  BDH
The amount of nucleic acid can be determined using a dye that becomes 
fluorescent only when it binds to nucleic acid. The intensity with 
which a sample fluoresces is directly proportional to the amount of 
nucleic acid present.
Ethidium bromide (2,7-diamino-9-phenylphenanthridine 10-ethyl bromide) 
was added to the cell sample containing DNA. The resulting 
fluorescence was due to both ENA and DNA. The fluorescence due to DNA 
alone was measured following treatment of the cell sample with RNAase.
Protocol:-
1. The following solutions were prepared:-
a. Phosphate Buffered Saline:
g/i
CaCl2 2H20 0.13
KC1 0.2
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kh2po4 0 .2
MgCl26H20 0 . 1
NaCl 8 .0
Na2HP04 1.15
b. Ethidium Bromide - 2.5mg in 200ml PBS
c. DNA - 5mg in 100ml 0.9% NaCl (overnight 4°C).
d. Protease - 6mg in 100ml PBS (reduces protein nucleic acid
interactions).
e. RNAase - 20mg in 1ml H20.
2. To 0.2ml of - DNA standard,
- PBS blank,
- homogenised cell sample - 1.0ml PBS
0.8ml Protease
0.04ml PNAase
were added and incubated for 1 hour.
3. 2ml of ethidium bromide was then added to each tube, and mixed.
4. The fluorescence was read at - excitation wavelength 360nm
emission wavelength 587nm 
using fluorophotometer (Shimadzu RF-540).
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Other Materials:
Dexamethasone sodium phosphate (Decadron) — 
N,Nf-Hexamethylene bisacetamide 
N-Butyric acid, sodium salt 
Retinoic acid, all trans Type XX 
Verapamil HC1
N^-21-O-Dibutyryl adenosine 3f:5!-cyclic 
monophosphate, sodium salt 
Millex - GS 0.22pm Filter Unit
Merck, Sharp & Dohme Ltd
Sigma
Sigma
Sigma
Abbott Laboratories Ltd
Sigma
Millipore
Statistical Analysis.
All statistical analysis was carried out using a two tailed Students 
t-test. Where the results are expressed as a percentage of the 
control the two tailed Students t-test was carried out by comparing 
the experimental data to a known value i.e. 1 0 0.
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CHAPTER 3.
DEVELOPMENT OF THE DOPA DECARBOXYLASE ASSAY.
The DDC assay was carried out following the method of Emson, Burrows & 
Fonnum (19741 This method described the assay of DDC activity in motor 
neurons of the locust, it was therefore important to confirm that the 
method was suitable for the assay of DDC activity in human SCLC cell 
lines, and if not make the necessary modifications.
1. Selection of Radioactive Substrate.
Emson et al assayed DDC activity using (2-^C) DOPA as a substrate in 
an incubation medium containing (final concentrations)
Sodium phosphate buffer (NaPi) pH7.6
Pyridoxal 51phosphate
Nialamide
EDTA
D,L-(2-14C) DOPA (52mCi/mM)
60mM
IOOjjM
125jjM
1.5mM
400pM
Due to the lack of availability of DL-(2- 4^C) DOPA it was necessary to 
select another radioactive I y labelled substrate. Two labelled forms 
were found:-
(i) L-3,4-[ring-2,5,6-%]-D0PA (ii) 1-[14C]-D0PA
ch2-ch-cooh
H* NIL
label
CH2-CH-C‘'OOH
H NIL
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If one used the radiolabelled substrate (i) the extraction of [%]- 
dopamine was required as a measure of the DDC activity, whereas (ii) 
required the extraction of [-^C]-carbon dioxide. One main 
disadvantage of using [1-^C]-D0PA in a radioassay is that one cannot 
distinguish between enzymatic and nonenzymatic decarboxylation of 
DOPA. Nonenzymatic decarboxylation of DOPA has been reported (Okuno & 
Fujisawa 1983), although this can be minimised if the assay is 
preformed in the presence of EDTA. Another disadvantage in using [1- 
^C]-DOPA was the hazard of possible escape of radioactive CO2 . 
Therefore form (i) was selected as the labelled substrate for the DDC 
assay.
2. Specificity of DOPA Decarboxylase.
As DDC is reported to act only on the L-isomer of aromatic amino 
acids, it was useful to determine if our enzyme reaction was specific 
for the L-isomer of DOPA. If this was the case it would support the 
initial assumption that is was in fact DDC that was being assayed. 
Therefore does the presence of D-DOPA or DL-DOPA have any effect on 
the formation of dopamine ?
DDC was prepared from NCI-H128d cells, a SCLC cell line with high DDC 
activity. DDC was added to a reaction mixture (final 
concentrations):-
NaPi buffer pH7.6 --60mM
Pyridoxal 5’Phosphate —  lOOpM
Nialamide —  125jjM
EDTA --1.5mM
%-L-DOPA (%-D-DOPA not available)  25pCi/ml
L-DOPA, DL-DOPA or D-DOPA -- 400pM
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The reaction was allowed to continue for 30mins, at which time the 
reaction was stopped and the dopamine formed extracted.
Results.
Isomer mean cpm + S.E.
DL-DOPA
L-DOPA
D-DOPA
The presence of D-DOPA resulted in higher levels of %-dopamine formed 
compared to L-DOPA or DL-DOPA. At first glance this was quite 
alarming considering the putative specificity of DDC for L-isomers. 
The increase in the amount of product formed could be due to either an 
increased rate of reaction in the presence of D-DOPA or the result of 
an increase in the specific activity of %-L-DOPA. The former 
explanation is unlikely since an increased rate of reaction was not 
seen in the presence of the racemic mixture. If the increase in 
product formed is due to an increase in the specific activity of the 
radioactively labelled substrate and not to an increase in the 
reaction rate then the concentration of D-DOPA in the reaction mixture 
should be unimportant. That is, as long as the concentration of L- 
DOPA remains constant then varying the concentration of D-DOPA should 
not alter the amount of dopamine formed.
DDC was prepared as before. Two reaction mixtures were prepared, one 
with a %-L-DOPA specific activity of 25Ci/mol and the other with a 
specific activity of 75Ci/mol. A DDC assay was performed with 
increasing concentrations of D-DOPA. After 30mins the reaction was 
stopped and the dopamine formed extracted.
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Figure 11:- Effect of Alteration in D-DOPA Concentration on the
Formation of Dopamine from a Constant Amount of L-DOPA.
The activity of DDC extracted from H128d cell line was examined in the 
presence of increasing concentrations of D-DOPA. The dopamine formed 
is expressed as counts per minute.
Each point represents the mean of 3 determinations + standard error.
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Figure 11 shows that increasing concentrations of D-DOPA, up to 0.6mM, 
increased the formation of dopamine. If our assumption was true that 
DDC is specific for L-isomers then why does D-DOPA affect the amount 
of %-dopamine formed? Perhaps DOPA is being metabolised by other 
enzymes resulting in the depletion of the substrate for DDC; D-DOPA 
may be competing with L-DOPA for these enzymes with the result that 
more L-DOPA is available for decarboxylation by DDC.
Alternatively, it has been reported that DOPA can react withDDCs1 
coenzyme pyridoxal 5*phosphate with the formation of a 
tetrahydroisoquinoline derivative (Schott & Clark 1952), this could 
have two effects both resulting in a fall in product formed. Firstly, 
if the concentration of DOPA is low then reaction with the coenzyme 
could sufficiently reduce the substrate concentration to cause a 
decreased rate of reaction and subsequently a decrease in dopamine 
formed. Secondly, this reaction could essentially be removing 
pyridoxal 5*phosphate from the reaction mixture which could indirectly 
reduce the amount of product formed by reducing enzyme activity. 
Therefore by increasing the concentration of DOPA in the form of the 
D-isomer, less L-DOPA will react with the coenzyme and subsequently 
more L-DOPA will be available for decarboxylation by DDC.
Somerville, (1964), showed that if borate was used to complex the active 
m hydroxy on DOPA it was possible to suppress the reaction of DOPA 
with its coenzyme. When this experiment was repeated but the reaction 
mixture was prepared using a borate buffer instead of the NaPi buffer 
addition of D-DOPA had no effect on the amount of dopamine formed. 
Moreover, when the borate buffer was directly compared to the NaPi 
buffer it was found that under the same assay conditions the dopamine 
formed in the presence of borate buffer was 4 fold greater than that 
found using the NaPi buffer. Therefore since the D-DOPA effect can be 
inhibited by addition of borate buffer it can be concluded that the L- 
DOPA is being lost from the system via conversion to a
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tetrahydroquinoline derivative and not by enzymatic metabolism by 
other enyzmes.
In order to optimise the conditions for the DDC assay borate buffer 
was selected for use in the assay.
3. Selection of the Substrate Concentration.
In an enzyme-substrate reaction the rate of reaction varies with 
substrate concentration. If the concentration of L-DOPA was too low 
the enzyme DDC would not be fully saturated and the reaction rate 
would be submaximal. However, at high L-DOPA concentrations the DDC 
would be fully saturated and the rate of reaction would be at its 
maximum and the amount of product formed per unit time constant. 
Therefore it was necessary to determine a suitable L-DOPA 
concentration that would not limit the rate of reaction.
DDC was prepared from H128d cells. The enzyme was incubated with the 
reaction mixture (final concentrations):-
The reaction was allowed to continue for 30mins, at which time it was 
stopped and the dopamine formed extracted.
Figure 12 shows the effect of increasing substrate concentration on 
the rate of catalysis of L-DOPA. In order to ensure near maximum rate
Borate Buffer pH7.6 
Pyridoxal 51phosphate 
Nialamide 
EDTA
%-L-DOPA   30pCi/ml
—  IOOjjM
—  125pM
—  1.5mM
—  0.025M Borax + 0.05M KH2P04
+ various concentrations of L-DOPA
DOPA Decarboxylase 
Sat ur at i on Cur ve. 
pmols dopamine^min
ea
40
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C DOPA 3  j j l M
Figure 12:- Effect of Substrate Concentration on the Rate of Catalysis 
of L-DOPA.
A DDC aasay was preformed with various concentrations of L-DOPA. The 
rate of reaction, V, was determined by measuring the dopamine formed 
per minute.
Each point represents the mean of 3 determinations + standard error.
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of reaction in the DDC assay, 1200pM L-DOPA was selected as a suitable 
substrate concentration since it did not limit the reaction rate. The 
results from Figure 12 were further analysed using a Lineweaver-Burke 
Plot (Figure 13). Analysis of the data in the Lineweaver-Burke Plot, 
using a computer programme which draws the best-fit line, found that:-
Maximum rate of reaction Vmax = 118.6 pmol dopamine/min 
Dissociation Constant = 3.03 x 10~^M
Note:-
The dissociation constant for DDC was found to be similar to 
that found for the enzyme by other workers :-
for DDC
Bovine adrenal medulla
(Laduron & Belpaire 1968). 5.7 x lCT^M
Hog kidney (Christenson, Dairman &
Udenfriend 1970).
Pig kidney cortex (Okuno & Fujisawa 1983).
4. Selection of the Coenzyme Concentration.
DDC requires the presence of pyridoxal 5*phosphate for full activity. 
The concentration of pyridoxal 5* phosphate in the reaction mixture was 
therefore an important factor in ensuring full enzyme activity. 
Therefore, what pyridoxal 5*phosphate concentration is sufficient to 
allow maximum enzyme activity ?
1.9 x 1 0"4M 
0.4 x 10-4M
DOPA Decarboxylase: 
Enzyme Kinetics. 
1/V
70. O’
-5.0 5.0 10.0
l^s
Figure 13:- Effect of Substrate Concentration on the Rate of Catalysis 
of L-DOPA: Lineweaver-Burke Plot.
By plotting 1/V versus 1/[S] (reciprocal of the substrate 
concentration) the dissociation constant and the maximal reaction 
rate Vmax can be derived. Rate of reaction, V, is expressed as pmols 
of dopamine formed per minute and the substrate concentration (S) is 
in jjM.
Each point represents the mean of 3 determinations + standard error.
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DDC was prepared from H128d cells. The enzyme was incubated with the 
reaction mixture (final concentrations)
Borate Buffer pH7.6 
Nialamide 
EDTA.
L-DOPA 
%-L-DOPA
+ various concentrations
The reaction was stopped after 30mins and the dopamine formed 
extracted.
Figure 14 shows that in the absence of pyridoxal 5‘phosphate the 
amount of dopamine formed was significantly reduced, illustrating the 
necessity of the coenzyme for full DDC activity. The level of 
dopamine formed reached a plateau in the presence of 50pM pyridoxal 
5‘phosphate. Therefore lOOpM pyridoxal 5‘phosphate was selected to 
ensure optimal enzyme activity.
5. Selection of Nialamide and EDTA Concentration.
It was important that once the dopamine was formed it was not 
metabolised by other enzymes which may have been present. There are 
two principal enzymes concerned with the catabolism of catecholamines 
catechol-O-methyl transferase (GOMT) and monoamine oxidase (MAO). 
COMT is a cytoplasmic enzyme which requires adenosyl methionine and 
magnesium or other divalent cations for activity. The presence of 
EDTA not only minimises the nonenzymatic decarboxylation of DOPA 
(discussed earlier), but also inhibits the activity of COMT by 
chelating divalent cations. MAO is a mitochondrial enzyme which is 
inhibited by nialamide.
—  0.025M Borax + 0.05M KH2P04 
  125pM
—  1.5mM
—  1200pM 
  30pCi/ml
of Pyridoxal 5‘Phosphate.
E-Prect o-P Pyridoxal 5 ?Phosphate 
on Dopamine Formation- 
cpm Cxi BE-4)
5d ies i m
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Figure 14:- Effect of the Coenzyme Concentration on the Formation of 
Dopamine from L-DOPA by DDC.
A DDC assay was carried out in the presence of increasing 
concentrations of pyridoxal 5*phosphate. The dopamine formed was
extracted and counted.
The dopamine formed is expressed as counts per minute.
Each point represents a mean of 3 determinations + standard error.
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Figure 15, 16 & 17:- Measurement of the Reaction Rate for SCLC Cell
Lines over the Incubation Period.
DDC was extracted from SCLC cell lines: H187, H69 and H128d. The
amount of dopamine formed at various intervals throughout the 
incubation period was measured. The rate of formation of dopamine 
from L-DOPA is represented by the amount of dopamine formed (nmols) 
versus time (minutes).
Each point represents the mean of 3 determinations + standard error.
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DDC was extracted from H128d. A DDC assay was carried out with or 
without EDTA or nialamide. The assay was allowed to continue for 
30mins, at which time the dopamine formed was extracted and measured.
In the absence of either nialamide or EDTA there was no change in the 
amount of dopamine formed. It would therefore appear that during the 
incubation period dopamine is not metabolised. Furthermore, the 
amount of dopamine formed was not affected by the presence of 125pM 
nialamide and 1.5mM EDTA. EDTA and nialamide were retained in the 
reaction mixture at the concentrations specified by Emson et al 1974, 
to eliminate the possibility of dopamine catabolism and also to 
prevent the nonenzymatic decarboxylation of DOPA (EDTA).
6. Linearity of the DDC Assay.
In order to use the DDC assay to measure enzyme levels in SCLC cell 
lines it was essential that the rate of reaction was linear with time.
A DDC assay was carried out with DDC extracted from H187, H69 and 
H128d cells. The reaction was stopped at regular intervals throughout 
the incubation period, and the amount of dopamine formed was extracted 
and measured.
The DDC reaction rate was found to be linear over the incubation 
period for the enzyme extracted from the three SCLC cell lines (Fig 
15, 16 & 17).
66
CHAPTER 4.
THE EFFECT OF PHENOTYPIC MODULATORS ON THE GROWTH 
OF SCLC CELL LINES
The differentiation of most adult stem cells is associated with the 
loss of proliferative capacity (Wier & Scott 1986, Till 1982). 
Furthermore, a growth suppressive effect has often accompanied the 
induction of differentiation in many cell systems following treatment 
with various differentiating agents. For example, induction of 
differentiation in mouse neuroblastoma cell lines following treatment 
with either HMBA (Palfrey et_ al, 1977) or dbcAMP (Prashad et al, 
1987) was accompanied by inhibition of cell proliferation. Also, 
NaBut was shown to induce a more differentiated phenotype in human 
medullary thyroid carcinoma cells and also decrease cellular 
proliferation (Nakagawa et al, 1985). Dexamethasone, another 
phenotypic inducer, has been shown to induce a more differentiated 
phenotype in some non small cell lung cancer cell lines with an 
accompanied cytostatic effect (J.fftean personal communication, 
1987). How then does treatment of the SCLC cell lines with the 
various putative phenotypic inducers affect cellular proliferation?
The effect of a number of phenotypic inducers, HMBA, dbcAMP, NaBut 
and dexamethasone, on the proliferation of the SCLC cell lines was 
examined. Cell growth was measured using the MIT assay or by 
electronic cell counting, in the presence of drug for 72hrs, and for 
a further 7 days (approx.) in the absence of drug. A 72hr exposure 
time was selected as this was the exposure time used to examine the 
effect of the phenotypic inducers on the SCLC phenotype. When 
electronic cell counting was used to determine cell growth, the drug 
was present throughout the growth curve.
Both H187 and H69 cell lines exhibited growth suppression in the 
presence of 5mM HMBA (Figs 18 & 19). During 5mM HMBA exposure H187 
cells experienced a growth delay, but following drug removal on day 3
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Figure 18:- The Effect of HMBA. on the Growth of H187 Cells.
H187 cells were seeded into 96 well plates in the presence or absence 
of either IniM HMBA or 5mM HMBA at a final cell concentration of 5xlCr 
cells/ml. The cells were incubated at 37°C in 2% CO2 throughout the 
experiment. On day 3 the HMBA was removed from the cells by spinning 
the microtitration plates at 200g for 5 minutes, aspirating the 
supernatant and replacing with fresh medium. The cells were fed on 
alternate days thereafter. The growth of the cells was measured at 
regular intervals throughout the growth curve using the MIT assay.
The results represent mean of 8 replicate samples + standard error.
The figure is a representative from 3 experiments.
E-F-Fect o-F HMBA on the Growth 
o-F H69.
* control 
+ l.SmH HPIBft 
a 5.0mrt HMBA
10
Time <days>
Figure 19:- The Effect of HMBA. on the Growth of H69 Cells.
H69 cells were seeded into 96 well plates in the presence or absence 
of either ImM HMBA or 5mM HMBA at a final cell concentration of 5x10 
cells/ml. The cells were incubated at 37°C in 2% CO2 throughout the 
experiment. On day 3 the HMBA was removed from the cells by spinning 
the microtitration plates at 200g for 5 minutes, aspirating the 
supernatant and replacing with fresh medium. The cells were fed on 
alternate days thereafter. The growth of the cells was measured at 
regular intervals throughout the growth curve using the MTT assay.
The results represent mean of 8 replicate samples + standard error. 
The figure is a representative from 3 experiments.
Table 3: Doubling Times (t^ ) of SCLC Cell Lines Following Treatment 
with Phenotypic Inducers.
Cell Line Control (days) Phenotypic 
Inducer P.I.
tj) (days) following 
P.I. Treatment
H187 2.57 + 0.32 DbcAMP 0.5mM 
l.OmM
4.0 + 0.7 r, 
5.3 + 0.8 **
NaBut 0.5mM 
l.OmM
3.5 + 0.6 ,
4.5 + 0.66 w
HMBA l.OmM 
5.0mM
2.7 + 0.43 
3.6 + 0.7
H69 3.80 + 0.22 DbcAMP 0.5mM 
l.OmM
4.35 + 0.4 ^  
6.0 + 0.7
NaBut 0.5mM 
l.OmM
4.12 + 0.15,,,
. 6.47 + 0.4 ..
HMBA l.OmM 
5.0mM
3.60 + 0.15 
4.70 + 0.43
SCLC cell lines were seeded into 96 round bottomed well plates in the 
presence and absence of the appropriate drug. The cells were exposed 
to the phenotypic drugs for 72 hours. The growth of the cells was 
measured using the MIT assay during drug exposure and for 
approximately one week after drug exposure. The doubling times were 
calculated from the exponential part of the growth curve following 
drug removal.
Results represent the mean of tj) + standard error from 4 separate 
experiments.
Statistical analysis was carried out using the Students t-test.
* P<0.05 ** PC0.02 *** P<0.002
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the cells entered an exponential growth phase with a doubling time 
similar to the untreated cells (Table 3). The effect of ImM HMBA 
on the growth of H187 cells was also examined but it was found that 
at this concentration HMBA did not have a growth suppressive effect. 
A slightly different pattern was found following treatment of H69 
cells with HMBA. During 5mM HMBA exposure H69 cells had a decreased 
proliferation rate. However when HMBA was removed, unlike HMBA 
treated H187 cells, H69 cells did not immediately enter an 
exponential growth phase. The H69 growth rate gradually increased 
and exhibited a control growth rate approximately 4 days after HMBA 
withdrawal. It may be that HMBA induces a growth suppressive effect 
only on a certain population of H69 cells, and the pattern of H69 
cell growth following HMBA treatment is the net result of a 
heterogenous population of cells growing at different rates. The 
uninduced H69 cells continue to proliferate at the control level and 
eventually outgrow the HMBA growth suppressed population and hence 
the return to the control proliferative rate. The effect of ImM HMBA 
on the growth of H69 cells was also examined and it was found that at 
this concentration HMBA had no effect on the H69 cell growth.
Following exposure of the SCLC cell lines to dbcAMP two different 
patterns of growth suppression were found. When H187 cells were 
exposed to dbcAMP the growth rate of the cells was reduced and this 
was maintained even after drug removal (Fig. 20). This growth 
suppressive effect of dbcAMP was found to be dose dependent where ImM 
dbcAMP induced a greater cytostatic effect than 0.5mM dbcAMP. Table 
3 shows that the doubling times of the ImM dbcAMP treated H187 cells 
was increased significantly. Therefore, dbcAMP treated H187 cells 
exhibited a suppressed proliferation rate which was maintained for at 
least 11 days after drug removal. In the presence of either 0.5mM or 
l.OmM dbcAMP H69 cells exhibited a growth delay (Fig. 21). On removal 
of the drug on day 3, the cells entered an exponential growth phase. 
However, even after 7 days in drug free medium the cells did not
E-F-Fect o-F DbcAMP on the Growth
o-F H187. .
A570nm
i
0
12 148 180 2 4 6
Time <days>
Figure 20:- The Effect of DbcAMP on the Growth of H187 Cells.
H187 cells were seeded into 96 well plates in the presence or absence 
of either 0.5mM or l.OrriM dbcAMP at a final cell concentration of 
5x10 cells/ml. DbcAMP was removed on day 3 and the cells were fed 
on alternate days thereafter. The growth of the cells was measured 
using the MIT assay.
The results represent the mean of 8 replicate samples + standard 
error.      -
The figure is a representative from 3 experiments. :
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Figure 21:- The Effect of DbcAMP on the Growth of H69 Cells.
H69 cells were seeded into 96 well plates in the presence or absence 
of either 0.5mM or 1 .OmM dbcAMP at a final cell concentration of 
5x10 cells/ml. DbcAMP was removed on day 3 and the cells were fed 
on alternate days thereafter. The growth of the cells was measured 
using the MIT assay.
The results represent the mean of 8 replicate samples + standard 
error.
The figure is a representative from 3 experiments.
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resume the control growth rate and in fact the doubling time of l.OmM 
dbcAMP treated H69 cells was significantly different from the 
untreated controls.
NaBut had a marked effect on the growth of the SCLC cell lines.
Treatment of H187 cells with either 0.5mM or l.OmM NaBut resulted in
growth suppression which was maintained for 7 days after drug removal 
on day 3 (Fig. 22). This cytostatic effect of NaBut on the growth of 
H187 cells was dose dependent since l.OmM NaBut induced a greater 
growth suppressive effect than 0.5mM. Following l.OmM NaBut 
treatment the H187 cell doubling time was significantly increased 
(Table 3). A growth suppressive effect was also noted in NaBut 
treated H69 cells. NaBut 0.5mM did not significantly alter the 
growth rate of H69 cells (Table 3). However in the presence of l.OmM 
NaBut the H69 cell growth was completely suppressed (Fig. 23). When 
the drug was removed on day 3 the cells exhibited a reduced growth
rate for a further 24 hours after which time the cells entered an
exponential growth phase. Table 3 shows that l.OmM NaBut treated H69 
cells have a significantly longer doubling time than the untreated 
controls. This pattern of NaBut induced growth suppression in H69 
cells was not unlike that found following HMBA exposure. Therefore it 
may be that NaBut induced a cytostatic effect in only a certain 
proportion of H69 cells and eventually the remaining uninduced cells 
outgrew the slower growing population. It was also possible that the 
observed growth delay was due to a cytotoxic effect of NaBut. This 
was found not to be the case. The cell viability was examined by 
trypan blue exclusion on day 3 and found to be greater than 90%.
Finally, the effect of dexamethasone on the growth of the SCLC cell 
lines was examined. The growth of the cells was measured by 
electronic cell counting and the drug was present throughout the 
experiment. Dexamethasone, 25jjM, reduced the H187 cell growth rate 
and the saturation density (Fig. 24). The cell concentration at
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Figure 22:- The Effect of NaBut on the Growth of H187 Cells.
H187 cells were seeded into 96 well plates at a final cell 
concentration of 5x10 cells/ml. The cells were grown in the
presence or absence of either 0.5mM or l.OmM NaBut for 3 days. The 
cells were fed on alternate days following drug removal. The growth 
of the cells was determined using the MIT assay.
The results represent the mean of 8 replicate samples + standard 
error.
I The figure is a representative from 3 experiments.
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Figure 23:- The Effect of NaBut on the Growth of H69 Cells.
H69 cells were seeded into 96 well plates at a final cell 
concentration of 5x10 cells/ml. The cells were grown in the
presence or absence of either 0.5mM or l.OmM NaBut for 3 days. The 
cells were fed on alternate days following drug removal. The growth 
of the cells was determined using the MIT assay.
The results represent the mean of 8 replicate samples + standard 
error.
The figure is a representative from 3 experiments.
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plateau phase of growth in the drug-treated cells was found to be 
significantly different from the untreated controls. Dexamethasone, 
however, had no effect on the growth of H69 cells (Fig. 25). It was 
found that glucocorticoid receptors were present in H187 cells, in 
low levels, but were absent from H69 cells (S. Cowan, personal 
communication). It may be that the selective effect of dexamethasone 
on the growth of H187 cells compared to H69 cells is due to the 
glucocorticoid receptor concentration.
The effect of the various phenotypic inducers on the growth of H128d 
cells was also examined, however the aggregate nature of this cell 
line proved to be a major obstacle in measuring cell growth. As 
discussed in the methods section H128d cells grow as large tight 
aggregates. Attempts to disaggregate H128d cells resulted in a 
suspension consisting of smaller aggregates of various sizes. Rapid 
seeding of this disaggregated Hl82d cell suspesion into a MIT 
microtitration plate gives an even distribution of cells across the 
plate. However for a growth experiment at least six microtitraton 
plates were required and it was found that even dispensing of the 
H128d cell suspension into replicate microtitration plates was not 
obtained. This error between plates became more noticeable as the 
growth curve proceeded and unfortunately satisfactory growth curves 
of H128d cells in the presence and absence of phenotypic inducers 
were not obtained.
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Figure 24:- The Effect of Dexamethasone on the Growth of H187 Cells.
H187 cells were seeded into 24 well plates at a final cell 
concentration of 5x10 cells/ml. The cells were grown in the
presence of 25pM dexamethasone for approximately 12 days. The cell 
growth was determined by electronic particle counting.
The results represent the mean of 3 replicate samples + standard 
error.
! The figure is a representative from 3 experiments.
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Figure 25:- The Effect of Dexamethasone on the Growth of H69 Cells.
H69 cells were seeded into 24 well plates at a final cell 
concentration of 5x10 cells/ml. The cells were grown in the
presence of 25pM dexamethasone for approximately 12 days. The cell 
growth was determined by electronic particle counting.
The results represent the mean of 3 replicate samples + standard 
error.
The figure is a representative from 3 experiments.
Table 4: Control Levels of L-DOPA Decarboxylase Activity in the SCLC 
Cell Lines.
Cell Line. L-DOPA Decarboxylase Activity
jjIU/mg protein jiIU/pg DNA
H187 (n=9) 200.9 + 31.8 3.2 + 0.53
H69 (n=ll) 3977.6 + 349.0 65.7 + 12.3
H128d (n=ll) 8085.2 + 808.1 101.4 + 15.2
The DDC activity in the three SCLC cell lines is expressed as 
international units (lU)/mg protein or IU/pg DNA, where one IU is 
equivalent to one pmole of product formed per minute.
The results represent the mean DDC activity + standard error from n 
independent experiments.
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CHAPTER 5.
EFFECT OF PHENOTYPIC MODULATORS ON THE EXPRESSION 
OF SCLC PHENOTYPIC MARKERS.
Part Is- The Effect of Phenotypic Inducers on the DDC Activity in some 
SCLC Cell Lines.
The aim of this project was to investigate whether the SCLC phenotype 
could be altered by phenotypic inducers and whether an alteration in 
the SCLC phenotype had any effect on chemosensitivity. In order to 
examine the .ffect of phenotypic inducers on the SCLC phenotype it was 
necessary to select suitable phenotypic markers. It has been 
proposed that SCLC cells belong to the group of peptide hormone- and 
amine-synthesising cells which Pearse called the amine precusor uptake 
and decarboxylation (APUD) system (Pearse, 1969). L-DOPA decarboxylase 
(DDC) is a key enzyme step in the synthesis of biogenic amines and as 
such plays an integral role in the APUD concept. Furthermore, DDC 
activity has been reported to be present in SCLC cell lines at 
relatively higher activity than in other lung tumours (Baylin et al, 
1980). DDC activity was therefore selected as a marker to represent 
the SCLC phenotype.
Table 4 shows the control DDC activities of the SCLC cell lines used 
in this study. The DDC activity is expressed either as plU/mg protein 
or jilU/pg DNA. The three cell lines expressed marked differences in 
their control levels of DDC activity. The highest expressor of DDC 
activity was found to be H128d, which had a DDC activity level 40 fold 
greater than H187, the lowest expressor. H69 was found to have an 
intermediate level of DDC activity, approximately 2 fold lower than 
H128d.
The DDC activity of the three SCLC cell lines was measured during the 
growth cycle to determine whether the enzyme activity was altered by
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Figure 26s- Growth Curve of H187 Cells.
H187 cells were seeded into 25cm^  flasks at low density. On the 
appropriate days the cells were harvested and the, cell growth was 
determined by measuring protein content using the Bradford Protein 
Assay.
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Figure 27:- Growth Related Expression of DDC and CKBB Activities in 
H187 Cells.
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H187 cells were grown from low density in 25cm flasks (see Fig. 24). 
At regular intervals throughout the growth curve H187 cells were 
harvested and their DDC and CKBB activities determined. The results 
represent the mean enzyme activity + standard error of 3 replicate 
samples.
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Figure 28:- Growth Curve of H69 Cells.
o
H69 cells were seeded into 25cm flasks at low density. On the 
appropriate days the cell growth was determined by measuring protein 
content using the Bradford Protein Assay.
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Figure 29:- Growth Related Expression of DDC and CKBB Activities in 
H69 Cells.
H69 cells were grown from low density in 25cm^  flasks (see Fig. 25). 
At regular intervals throughout the growth cycle H69 cells were 
harvested and their DDC and CKBB activities determined. The results 
represent the mean enzyme activity + standard error of 3 replicate 
samples.
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Figure 30:- Growth Curve of H128d Cells.
H128d cells were seeded into 25cm^  flasks at low density. On the 
appropriate days the cell growth was determined by measuring protein 
content using the Bradford Protein Assay.
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Figure 31:- Growth Related Expression of DDC and CKBB Activities in 
H128d Cells.
H128d cells were grown from low density in 25cm^ flasks (see Fig. 
27). At regular intervals throughout the growth cycle H128d cells 
were harvested and their DDC and CKBB activities determined. The 
results represent the mean enyzme activity + standard error of 3 
replicate samples.
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increasing cell density. The cells were seeded into 25cm^ flasks at 
low density and grown for approximately 11 days. The cell growth was 
determined by measuring the protein content at intervals throughout 
the growth curve (Figs. 26, 28 & 30), and concurrent measurement of 
the cellular DDC and CKBB activity was carried out (Figs. 27, 29 & 
31).
Figures 27 & 29 show that during the H187 and H69 growth cycle the 
cellular DDC activity did not change significantly. Some fluctuation 
in H187 DDC activity was noticed at low cell densities, however this 
may be due in part to the preparation procedure. Since the H187 DDC 
activity was found to be low, several flasks of cells had to be pooled 
together in order to have enough assayable material at low cell 
densities. This introduced a number of steps which lengthened the 
preparation procedure which may have indirectly affected the enzyme’s 
activity. Figure 31 shows that the DDC activity in H128d increased as 
the cell density increased. However, after about 6 days the DDC 
activity did not significantly change. The cellular DDC activity was 
therefore measured during the late log phase of the growth cycle, 
where the enzyme activity showed minimum fluctuation. The DDC
activity has previously been shown not to fluctuate during the cell 
cycle (Baylin e£ al 1980).
The effect of a number of phenotypic inducers on the DDC activity in 
some SCLC cell lines was examined. The SCLC cell lines were treated 
with the appropriate drug in late log phase for 72hrs, approximately 
72hrs after cell seeding. A 72hr exposure time was selected
because in other systems at least a 3 day drug exposure time was 
required before phenotypic change was observed (Lever 1979, Fibach et 
al 1977 and Nakagawa et al 1985). Following treatment of the cell 
lines with or without the appropriate phenotypic inducer the DDC 
activity was calculated as jilU/mg protein and IU/pg DNA. It is 
possible that expression of enzyme activities as IU/mg protein may 
give a false impression of changes in enzyme activity, since the
Table 5: Effect of HMBA Treatment on the L-DOPA Decarboxylase
Activities in SCLC Cell Lines.
[HMBA] mM.
Cell Line. 0.1 0.5 1.0 5.0
H187 119.6 81.1 + 7.5 94.5 + 15 95.3 + 14.5
H69 93.4 + 9.7 87.5 + 4.0* 77.3 + 5.7* 49.3 + 9.8*
H128d 87.0 + 1.8 89.1 + 5.1 94.5 + 8.0 71.2 + 7.1
SCLC cell lines were grown to late log phase and exposed to HMBA for 
72hrs. The cells were then washed 2x with PBS and their DDC activities 
determined.
The results are expressed as the % control DDC activity, where the 
control values are taken as 100. The results represent the mean of 3 
replicate experiments + standard error.
Statistical analysis was carried out using the Students t-test.
* P<0.05
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Figure 32:- The Effect of HMBA. on the DDC Activity of H69 Cells-
H69 cells were exposed to HMBA at various concentrations for 72hrs. 
Following drug exposure the cells were washed 2x with PBS and their 
DDC activity determined.
The results are expressed as the % control DDC activity where the 
control value equals 100. The results represent the mean of 3 
experiments + standard error.
Statistical analysis was carried out using the Students t-test.
* P<0.05
Table 6 s Effect of DbcAMP Treatment on the L-DOPA Decarboxylase
Activities in some SCLC Cell Lines.
[dbcAMP] mM.
Cell Line 0.05 0.1 0.5 1.0
H187 111.3 + 8.4 133.7 + 4.4 162.4 + 4.2*** 1 9 4 *5 + 22*3*
H69 101.5 + 11.0 95.0 + 0.7 79.9 + 5.4* 69.7 + 2.6***
H128d 89.2 83.7 93.4 + 16.0 149.6 + 7.7*
SCLC cell lines in late log phase of growth were incubated with dbcAMP 
for 72hrs. Following the incubation period the cells were washed 2x 
with PBS and their DDC activities determined.
The results are expressed as the % of control DDC activity, where the 
control values are taken as 100. The results represent the mean of 3 
replicate experiments + standard error.
Statistical analysis was carried out using the Students t-test.
" P<0.05 'w' PC0.02    P<0.01
72
observed changes may have been due to an alteration in the amount of 
protein per cell. If the drugs were to either increase or decrease 
the protein content per cell this would obviously alter the specific 
activity of the enzyme without actually altering the amount of enzyme 
protein. In order to ensure that this was not the case the enzyme 
activity was also expressed per y.g DNA. Irrespective of whether the 
enzyme activity was calculated as jilU/mg protein or IU/pg DNA any 
change found in enzyme activity compared to the controls was found to 
be the same.
; The DDC activity of the drug treated cells is expressed as a 
percentage of the control, where the control value is taken as 1 0 0%.
The SCLC cell lines were incubated with a range of HMBA concentrations 
for 72hrs. Table 5 shows that HMBA treatment did not significantly 
affect the DDC activity in either H187 or H128d. However, when H69 
cells were exposed to HMBA a dose dependent decrease in the DDC 
activity was found (Fig. 32). Moreover, this dose dependent decrease 
in the DDC activity in H69 cells following HMBA treatment was found to 
be significant. The maximum effect was found following 5mM HMBA 
treatment, where a 2 fold decrease was noted.
When the DDC activities in the SCLC cell lines were examined following 
treatment with dbcAMP a different pattern of phenotypic change was 
observed. Table 6 shows that dbcAMP altered significantly the DDC 
activity in H187 and significantly reduced the DDC activity in H69 in 
a dose dependent manner (Fig. 33). Incubation of H187 with lmM dbcAMP 
resulted in an 100% increase in the DDC activity. In contrast, lmM 
dbcAMP treatment reduced the DDC activity in H69 by 30%. The DDC 
activity in H128d was found to be unaffected by dbcAMP at lower 
concentrations, however at the highest concentration examined, lmM, 
the DDC activity increased by approximately 50% (Tab. 6 ).
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Figure 33:- The Effect of DbcAMP on the DDC Activity in SCLC Cell 
Lines.
SCLC cell lines were incubated with various concentrations of dbcAMP 
for 72hrs. The cells were then harvested and their DDC activities 
determined.
The results are expressed as the % control DDC activity where the 
control value is taken as 100. The results represent the mean of 3 
replicate experiments + standard error.
Statistical analysis was carried out using the Students t-test.
* P<0.05 **.P<0.02 *** P<0.01
Table 7: Effect of Sodium Butyrate Treatment on the L-DOPA
Decarboxylase Activities in SCLC Cell Lines.
[NaBut] mM.
Cell Line 0.1 0.5 1.0
H187 96.8 + 13.6 115.4 + 9.9 129.9 + 11.1
H69 74.8 + 23.0 48.7 + 12.2'' 51.0 + 4.2
H128d 101.2 + 11.7 76.0 + 8.3 72.8 + 2.3
SCLC cell lines in late log phase were treated with NaBut for 72hrs. 
The cells were harvested, washed 2x with PBS and their DDC activities 
determined.
The results are expressed as the % control DDC activity, where the 
control value is taken as 100. The results represent the mean of 3 
replicate experiments + standard error.
Statistical analysis was performed using the Students t-test.
* P<0.05 ** PC0.02 *** P<0.01
Table 8: The Effect of Dexamethasone on the L-DOPA Decarboxylase
Activity in the SCLC Cell Lines.
25
95.4 + 4.0
90.5 + 10
83.3 + 0.8
SCLC cell lines were grown to late log phase and exposed to 
dexamethasone for 72hrs. The cells were then washed 2x with PBS and 
their DDC activities determined.
The results are expressed as the % control DDC activity, where the 
control values are taken as 100. The results represent the mean of 3 
replicate experiments + standard error.
Statistical analysis was carried out using the Students t-test.
[Dexamethasone] 
Cell Line 0.25 2.5
H187 107.6 + 0.8 113.5 + 12.6
H69 88.3 + 15.1 95.3 + 11.6
H128d 97.1 + 1.6 92.3 + 5.3
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The SCLC cell lines were also exposed to NaBut, another phenotypic 
inducer. It was found that NaBut significantly reduced the DDC 
activity in both H69 and H128d but had no effect in H187 (Tab. 7). 
The maximum effect of NaBut on the DDC activity in H69 was at 0.5mM 
where a greater than 50% reduction was found. H128d cells were not 
as sensitive to NaBut as H69 cells, following l.OmM NaBut exposure 
only a 27% fall in the DDC activity was observed.
When the cells were incubated with dexamethasone for 72hrs their DDC 
activity did not change significantly (Tab. 8 ).
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Part 2;- The Effect of Phenotypic Inducers on the Creatine Kinase 
BB Activity in some SCLC Cell Lines.
As discussed earlier, SCLC can be distinguished from most other lung 
cancers by the presence of high levels of the key amine-handling cell 
enzyme L-DOPA decarboxylase, SCLC can also be characterised by the 
presence of high levels of creatine kinase in the form of its BB 
isoenzyme (CKBB) (Gazdar et al, 1981).
CK catalyses the transfer of a high energy phosphate bond from 
creatine phosphate to ADP. It has been suggested that CK is present 
in all body tissues and organs, and its levels and the relative 
proportion of its isoenzymes, CKMM CKMB and CKBB alter during 
embryonic development and differentiation and show considerable 
organ-to-organ variation Apart from striated muscle, brain, bladder 
and gastrointestinal tract most organs have low levels of enyzme 
predominantly in the form of CKBB (Shatton, Moms & Weinhouse 1979),
As mentioned above, high levels of CKBB have been found in tumour 
specimens and cultures of SCLC. Electrophoretic analysis of the CK in 
normal and neoplastic lung samples showed that CK is predominantly in 
the CKBB form (Gazdar et al 1981). Therefore the CK activity found 
in SCLC tumours and cultures is quantitatively but not qualitatively 
different from those in normal and other lung cancers. CKBB was 
selected as a biochemical marker of the SCLC phenotype for a number of 
reasons. In contrast to DDC, high levels of CKBB have not been 
identified in lung cancers and cultures other than those of the SCLC 
lineage. Furthermore, some SCLC tumours have been reported to undergo 
an alteration in their morphology both in vivo and in vitro (Abeloff 
et al. 1979) with an accompaning loss of many distinctive SCLC 
features including DDC, however high levels of CKBB are maintained. 
Therefore CKBB was selected as a biochemical marker to represent the 
SCLC phenotype.
Table 9: Control Levels of Creatine Kinase BB Activity in the SCLC 
Cell Lines.
Cell Line Creatine Kinase BB Activity
IU/mg protein mlU/pg DNA
H187 (n=10) 1.13 + 0.09 19.2 + 2.2
H69 (n=12) 2.42 + 0.21 41.4 + 6.7
H128d (n=12) 1.39 + 0.11 18.5 + 2.6
The CK BB activity in the three cell lines is expressed as 
international units (lU)/mg protein or IU/pg DNA, where one IU is 
equivalent to one janole of NADH produced per minute.
The results represent the mean CK BB activity + standard error from n 
independent experiments.
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The control CKBB activities in the SCLC cell lines used in this study 
are given in Table 9. CKBB activity is expressed as international 
units IU/mg protein and as mlU/pg DNA. In either case H69 cells were 
found to have the highest CKBB activity, approximately twice that of 
the other two lines, H187 and H128d. The percentage of the CKBB 
isoenzyme in H187, H69 and H128d was found to be 81.3 + 2.8, 85.4 + 
5.1 and 88.8 + 2.8 respectively (mean CKBB activity + standard error 
of 8 replicate experiments).
In order to determine the effect of phenotypic inducers on the CKBB 
levels in the SCLC cell lines it was important to determine whether 
the CKBB activity fluctuated at all during the growth cycle of the 
cells. If the CKBB activity did change over the growth cycle of the 
cells it would be important to ensure that the control cells and the 
drug treated cells were at the same point in the growth cycle so that 
any change in the CKBB activity was due to phenotypic change and not 
to cell density. Figures 27, 29 & 31 show that the CKBB activity of 
the SCLC cell lines did not change significantly during the growth 
cycle. Some fluctuation was found at low cell densities but this may 
have been due to low sample volumes. Therefore in order to ensure 
constant control levels of CKBB activity the enzyme was assayed 
following phenotypic inducer treatment in late log phase (day 6 
onwards). The cells were incubated with the appropriate phenotypic 
inducer for 72hrs, following which time the cells were harvested and 
their CKBB activity determined. As in the case of the DDC results, 
CKBB activity was also calculated both as IU/mg protein and mlU/^ ig 
DNA. In either case any change in the CKBB activity following 
phenotypic inducer treatment was found to be the same. The results 
are presented as a percentage of the control CKBB activity where the 
control activity is taken as 100%.
The effect of HMBA on the CKBB activities in the SCLC cell lines was 
examined. HMBA was found to change the CKBB activity significantly in
Table 10: Effect of HMBA. Treatment on the Creatine Kinase BB
Activities in SCLC Cell Lines.
Cell Line. 0.1
[HMBA] mM.
0.5 1.0 5.0
H187 79.0 + 8.8
H69 115.7 + 1.6**
H128d 90.4 + 3.8
110.7 + 4.4 102.7
127.0 + 5.7** 120.5
88.0 + 1.8* 83.8
+ 14 156.2 + 11.8*
+ 4.9* 100.3 + 14.6
+ 0.9* 69-7 + 2.0***
SCLC cell lines were grown to late log phase and then incubated with 
HMBA for 72hrs. The cells were harvested, washed 2x with PBS and their 
CK BB activities determined.
The results are expressed as the % control CK BB activity where the 
control value is taken as 100. The results represent the mean of 3 
replicate experiments + standard error.
Statistical analysis was carried out using the Students t-test.
* PC0.05 **P<0.02 *** P<0.01
E-F-Fect o-F HMBA on the CK BB Activity 
in SCLC Cell Lines. 
V. control CKBB activity
J*
V*" H12Sd
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80
40
20
0.0 0. 10
HMEA conc. mM
Figure 34:- The Effect of HMBA on the CKBB Activity in some SCLC 
Cell Lines.
SCLC cell lines were exposed to various concentrations of HMBA for 
72hrs. Following drug exposure the cells were wahed 2x with PBS and 
their CKBB activities determined.
The results are expressed as the % control CK BB activity where the 
control value is taken to be 100. The results represent the mean of 
3 experiments + standard error.
Statistical analysis was carried out using the Students t-test.
* P<0.05 ** p<0.02 *** PC0.01
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all three cell lines examined, although the pattern of HMBA-induced 
change in each case is different (Tab. 10). HMBA, 5rriM, significantly 
increased the CKBB activity in H187. However, HMBA induced a change 
in the CKBB levels of H69 at lower concentrations. A significant 
increase in the CKBB levels in H69 was found, with a peak effect at 
0.5mM (Fig. 34). This effect was lost when the HMBA concentration was 
increased above l.OmM, and, in fact, 5mM HMBA had no effect on the 
CKBB activity in H69. The pattern of HMBA induced CKBB change in 
H128d was different. The CKBB levels in H128d were signficantly 
reduced in a dose dependent manner by HMBA (Fig. 34).
Following treatment of the SCLC cell lines with dbcAMP a selective 
change in the CKBB activity was found. DbcAMP significantly increased 
the CKBB activity in H187 in a dose dependent manner (Fig. 35). The 
maximum effect was found following treatment with lmM dbcAMP, where a 
62% increase in activity was found. DbcAMP did not significantly 
effect the CKBB activity in the other two cell lines examined (Tab. 
11).
With NaBut a selective change in the CKBB activity was again found. 
NaBut increased significantly the CKBB activity in H187 in a dose 
dependent manner (Fig. 36). The greatest effect was seen following 
exposure of H187 cells to l.OmM NaBut, where a 46% increase in CKBB 
acitivity was found. NaBut treatment did not significantly affect the 
CKBB activity in the other two lines examined (Tab. 12).
Finally, the effect of dexamethasone on the CKBB activities in the
SCLC cell lines was examined. However, dexamethasone up to 25pM was 
found to have no effect on the CKBB activity in the SCLC cell lines 
examined (Tab. 13).
The effect of retinoic acid on the DDC and CKBB activities in H69
cells was also examined. However, it was found that the drug treated
cells had the same enzyme activities as the untreated controls.
The E-P-fect o-F DbcAMP on the CK EB
Activity in H187
X control CKBB activity
203
160
140
1.00
db c AMP c one. mM
Figure 35:- The Effect of DbcAMP on the CKBB Activity of H187 
Cells,
H187 cells were incubated with dbcAMP for 72hrs. Following drug 
exposure the cells were washed and their CKBB activity determined.
The results are expressed as the % control CKBB activity where the 
control value is taken to be 100. The results represent the mean of 
3 experiments + standard error.
Statistical analysis was performed using the Students t-test.
* P<0.05 ** p<0.02 *** p<0.01
Table 11: Effect of DbcAMP Treatment on the Creatine Kinase BB
Activities in SCLC Cell Lines.
[dbcAMP] iriM.
Cell Line 0.05 0.1 0.5 1.0
H187 107.2 + 7.5 124.2 + 13.0 143.8 + 3.2*** 161.9 + 15. V
H69 153.4 146.6 + 9.2 137.1 + 19.1 108.1 + 17.0
H128d 66.2 73.4 84.1 + 10.5 124.4 + 9.9
SCLC cell lines were treated in late log phase with dbcAMP for 72hrs. 
The cells were harvested, washed and their CK BB activities 
determined.
The results are expressed as the % control CK BB activity, where the 
control value is 100. The results represent the mean of 3 replicate 
experiments + standard error.
Statistical analysis was performed using the Students t-test.
* P<0.05 ** P<0.02 *** P<0.01
The E-F-fect o-f NaBut on the CK BB 
Activity in H1S7. 
Ym control CKBB activity
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Figure 36:- The Effect of NaBut on the CKBB Activity in H187.
H187 cells were incubated with NaBut for 72hrs. Following the drug 
incubation period, the cells were harvested and their CKBB activity 
determined.
The results are expressed as the % control CKBB activity vdiere the 
control value is taken to be 100. The results represent the mean of 
3 experiments + standard error.
Statistical analysis was carried out using the Students t-test.
* P<0.05 ** p<0.02
Table 12: Effect of Sodium Butyrate Treatment on the Creatine Kinase
BB Activities in SCLC Cell Lines.
[NaBut] mM.
Cell Line 0.1 0.5 1.0
H187 129.1 + 3.9** 140.9 + 7.1* 146.4 + 8.3'
H69 110.3 + 9.2 93.6 + 2.4 96.2 + 13.6
H128d 105.7 + 9.1 92.4 + 22.2 102.3 + 12.3
SCLC cell lines were treated with NaBut for 72hrs in late log phase of 
growth. The cells were then harvested, washed 2x with PBS and their 
CK BB activities determined.
The results are expressed as the % control CK BB activity, where the 
control value is taken as 100. The results represent the mean of 3 ' 
replicate experiments + standard error.
Statistical analysis was performed by the Students t-test.
Table 13: The Effect of Dexamethasone on the CKBB Activities in the
SCLC Cell Lines.
[Dexamethasone] jjM 
Cell Line 0.25 2.5 25
H187 117.3 + 5.0 121.0 + 10.0 117.4 + 9.9
H69 100.0 + 5.4 103.6 + 11.3 100.0 + 5.4
H128d 100.7 + 9.0 103.3 + 17.0 98.9 + 16.8
SCLC cell lines were grown to log phase and exposed to dexamethasone 
for 72hrs. The cells were then washed 2x with PBS and their CKBB 
activities determined.
The results are expressed as the % control DDC activity, where the 
control values are taken as 100. The results represent the mean of 3 
replicate experiments + standard error.
Statistical analysis was carried out using the Students t-test.
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Part 3:- The Effect of Phenotypic Inducers on the Bombesin-Like
Inmunoreactivity in Some SCLC Cell Lines.
Bombesin is a 14-amino acid peptide which was initially isolated from 
the skin of a frog (Anastasi et al 1971). In mammals, bombesin-like 
immunoreactivity has been found predominantly in the brain (Moody et 
al, 1979) lung (Wharton 1978) and intestine (McDonald et al
1979). In the human lung, bombesin-like inmunoreactivity (BLl) has 
been found in the bronchial and bronchiolar epithelium both as single 
cells and as groups (Wharton et al, 1978). It is readily found in 
full term foetal and neonatal lung, but is greatly reduced or even 
absent in the adult lung. Moreover, in neonates with the acute 
respiratory distress syndrome, there is a significantly lower bombesin 
content in all regions of the respiratory tract compared to either 
normal full-term infants or 24- to 28-week-old fetuses and it has been 
proposed that bombesin-like peptides may have a role in the normal 
development of the human lung (Ghatei et al 1983). The mammalian 
equivalent to bombesin is believed to be gastrin-releasing peptide 
(GRP). GRP is a 27-amino acid peptide with a carboxy-terminal 
heptapeptide sequence similar to bombesin.
Human SCLC cell lines have been shown to contain significant levels of 
BLI, while the non-SCLC cell lines examined had undetectable BLI 
(Moody ££ al} 1981). It has been suggested that bombesin is an 
autocrine growth factor in SCLC cell lines since some cell lines 
produce bombesin (Moody et al, 1981 )and for the following reasons: (1) 
some SCLC cell lines have high affinity bombesin receptors which bind 
detectable bombesin (Moody et al, 1985), (2) some SCLC cell lines have 
been reported to respond to bombesin in vitro (Weber et al 1985; 
Carney et al 1987), and (3) a monoclonal antibody to bombesin which 
binds to the C-terminal region inhibits the clonal growth of SCLC in 
vitro and the growth of SCLC xenografts in vivo. Since the presence
Table 14s Control Levels of Bombesin-like Inmunoreactivity in the
SCLC Cell Lines.
Cell Line Bombesin-like Inmunoreactivity
pg/pg acid soluble protein
H187 (n=3) undetectable
H69 (n=3) 8.4 + 1.18
H128d (n=3) 57.2+8.6
The bombesin-like inmunoreactivity (BLI) of the three SCLC cell lines 
used in this study were examined by radioimmunoassay.
The results represent the mean BLI of n independent experiments.
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of BLI distinguished SCLC from other lung cancer types, BLI was 
selected as another marker to represent the SCLC phenotype.
Table 14 shows the control levels of BLI in the SCLC cell lines used 
in this study. The BLI is expressed as pg/pg soluble protein. BLI 
was undetectable in H187 but was found in both H69 and H128d. H128d
was found to have the highest level of BLI which was approximately 7 
fold higher than the BLI found in H69.
The effect of a number of phenotypic inducers on the BLI in the SCLC 
cell lines was examined. However due to the cost of the RIA a limited 
investigation was carried out. Based on the results of phenotypic 
inducer treatment on the DDC and CKBB activities in the SCLC cell 
lines, only the drugs which produced the most significant change in 
the enzyme levels were examined for their effect on the BLI. Table 15 
summarises the effect of phenotypic inducer treatment on the BLI in 
the three SCLC cell lines examined.
DbcAMP lmM was found to significantly increase both the DDC and CKBB 
activities in H187. When H187 cells were treated with dbcAMP lmM for 
72hrs detectable levels of BLI were found compared to an undetectable 
BLI level in the untreated control cells. Therefore dbcAMP lmM 
treatment increased the BLI in H187 cells.
The effect of phenotypic inducer treatment on the BLI in H69 cells was 
examined. Although both dbcAMP and NaBut reduced the DDC activity 
significantly in H69 cells, treatment for 72hrs with these drugs had 
no effect on the BLI. HMBA has previously been shown to increase the 
CKBB activity significantly and reduce the DDC activity significantly 
in H69 cells (see above) and when H69 cells were treated with 5mM HMBA 
for 72hrs a significant decrease in the BLI was found.
Table 15: The Effect of Phenotypic Inducer Treatment on the Bombesin
Like Inmunoreactivity (B.L.I.) in some SCLC Cell Lines.
Cell Line Control Levels Phenotypic Inducer B.L.I.
of B.L.I. P.I. Treatment following P.I.
treatment.
H187 Undetectable dbcAMP l.OmM 0.064 + 0.04
H69 8.4 + 1.18 dbcAMP l.OmM 
NaBut l.OmM 
HMBA 5.0mM
8.8 + 1.7 
7.6 + 2.4 
2.3 + 0.7*
H128d 57.2 + 8.6 dbcAMP l.OmM 
NaBut l.OmM 
HMBA 5.0mM
43.9 + 11.8 
51.6 + 16.4 
92.4 + 26.7
SCLC cell lines were incubated with the appropriate phenotypic inducer 
for 72hrs. The cells were then harvested and their BLI determined.
The results represent the mean BLI pg/pg acid soluble protein + 
standard error from 3 independent experiments.
Statistical analysis was performed using the Students t-test.
* P<0.01
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When the effect of phenotypic inducer treatment on the BLI in H128d 
was examined it was found that the BLI in H128d did not change in 
response to treatment of any of the phenotypic inducers selected.
Bombesin-like peptides have been shown to be secreted by SCLC cells in 
culture (Moody e£ al, 1983). These studies however investigated the 
effects of the various phenotypic drugs on the cellular BLI levels and 
did not examine the effect of drug treatment on the secretion of BLI. 
It is possible that these drugs may have altered the secretion rate of 
BLI from the SCLC cells which may account for the differences found. 
Interestingly, dbcAMP has been shown to increase the secretion of 
bombesin-like peptides from a SCLC cell line and a role for cAMP in 
the mechanism of bombesin-like peptide secretion has been implicated 
(Korman et al 1986). DbcAMP treatment of the SCLC cell lines did not 
significantly reduce the levels of BLI and in. fact increased the BLI 
in H187 cells. Therefore if dbcAMP increased the secretion of BLI 
from the SCLC cell lines this must have been matched with an increased 
synthesis of BLI. If the reduction in BLI in H69 cells following 
exposure to HMBA was due to an increased secretion of BLI then the 
synthesis rate of BLI did not match the secretion rate. It will be 
important to determine the effects of these drugs on the secretion of 
BLI from these cell lines. Moreover, how will the presence of 
cycloheximide affect the BLI levels following exposure to these 
drugs ?
Table 16 summarises the phenotypic changes found following incubation 
of the SCLC cell lines with either HMBA, dbcAMP or NaBut for 72hrs. 
Taking DDC, CKBB and BLI as representing the SCLC phenotype, 
phenotypic inducer treatment caused an alteration in the phenotype of 
the SCLC cell lines examined. There does not however appear to be any 
consistent pattern of phenotypic change induced by these drugs taking 
the SCLC cell lines as a whole this may reflect differences in the 
position of the SCLC cell lines within the lung cancer lineage.
Table 16: Summary of the Significant Phenotypic Changes.
Phenotypic Inducer.
HMBA dbcAMP NaBut
Marker DDC CKBB BLI DDC CKBB BLI DDC CKBB BLI
Cell Line
H187 NE t ND f i t  NE f ND
H69 \ t I 1 NE NE I NE NE
H128d NE I NE t NE NE I NE NE
Table 16 summarises the significant phenotypic changes observed 
following treatment of some SCLC cell lines with either HMBA, dbcAMP or 
NaBut.
Key:- NE - no effect, ND - not done.
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However, within a cell line the change in the phenotypic markers in 
response to the phenotypic inducers does appear to be consistent. For 
example, the CKBB activity in H187 cells always increases in response 
to drug treatment, and the DDC activity in H69 cells always decreases 
following exposure to the phenotypic inducers. The exception to the 
rule is Hl28d DDC activity, where both an increase and decrease have 
been found following exposure to phenotypic drugs.
Table 17: Effect of Cycloheximide on the Phenotypic Drug Induced
Changes in the SCLC Phenotype.
Cell Drug(s) DDC Activity
Line Added plU/mg pIU/jjgDNA
protein
CKBB Activity 
IU/mg mlU/ggDNA 
protein
H187 control 119.8 + 4.8 , 1.96 + 0.08 1.29 + 0.07 , 21.0 + 1.1
cyclohex.
0.5pg/ml 104.8 + 6.3 , 1.59 + 0.2 1.32 + 0.03
dbcAMP
lmM 317.1 + 19.6 , 5.28 + 0.5 1.89 + 0.05
dbcAMP
cyclohex. 121.7 + 17.6 , 1.85 + 0.2 1.38 + 0.10
H69 control 2535.9 + 224 , 45.7 + 1.98 2.95 + 0.37
cyclohex.
0.5pg/ml* 2655.6 + 142 , 37.2 + 5.5 3.12 + 0.22
HMBA
5mM 1105.8 + 59 , 17.5 + 2.8 2.92 + 0.37
HMBA +
cyclohex. 2321.4 + 243 , 38.6 + 1.6 3.49 + 0.48
19.6 + 2.9
31.5 + 2.7
23.8 + 1.9
52.9 + 2.9
47.5 + 6.9
46.0 + 6.4
42.4 + 3.1
H187 and H69 cells were treated with lmM dbcAMP and 5mM HMBA, 
respectively, in the presence and absence of 0.5pg/ml cycloheximide 
for 72 hours. The DDC and CKBB activity of the cells was then 
determined.
The results represent the mean enzyme activity + standard error from 3 
determinations.
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Part 4:- The Effect of Cyclohexiinide on the Phenotypic Drug Induced
Changes in the SCLC Phenotype,
In order to investigate 'whether de novo protein synthesis was required 
for the changes in the DDC and CKBB activities found in some SCLC cell 
lines following phenotypic inducer treatment, the SCLC cell lines were 
exposed to the appropriate phenotypic inducer with or without 
cycloheximide. Cycloheximide blocks the peptidyl transferase reaction 
on ribosomes and so inhibits the elongation phase of translation in 
eukaryotes.
Following phenotypic inducer treatment of the SCLC cell lines it was 
found that the most significant changes in the SCLC DDC and CKBB 
activities were noted after lmM dbcAMP treatment of H187 cells and 5mM 
HMBA treatment of H69 cells. Therefore it was examined whether 
inhibition of protein synthesis had any effect on the changes in the 
enzyme activities seen.
H187 cells were treated with and without lmM dbcAMP in the presence 
and absence of 0.5jig/ml cycloheximide (Tab. 17). As noted earlier, 
lmM dbcAMP significantly increased the DDC and CKBB activities in H187 
cells. In the presence of cycloheximide the dbcAMP induced enzyme 
changes were inhibited. This therefore suggests that the changes in 
DDC and CKBB activities in H187 cells following treatment with lmM 
dbcAMP require de novo protein synthesis.
H69 cells were treated with and without 5mM HMBA in the presence and 
absence of 0.5pg/ml cycloheximide (Tab. 17). As before HMBA 
significantly reduced the DDC activity in H69 cells. This effect was 
found to be completely inhibited by the presence of cycloheximide. 
Therefore, HMBA induced alteration in DDC activity in H69 cells 
appears to require de novo protein synthesis.
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CHAPTER 6.
THE EFFECT OF PHENOTYPIC INDUCERS ON THE MORPHOLOGY OF 
THE SCLC CELL LINES,
Considerable heterogeneity is observed in the gross appearances of 
SCLC cell lines. In general, most cell lines grow as floating 
aggregates of tightly to loosely packed cells that may frequently 
demonstrate areas of central necrosis. There are however a few SCLC 
cells lines which grow attached to the substrate. Carney et al in
1985 described four distinct SCLC morphological classes, type 1,2,3 
and 4. Type 1 cell lines grow as tightly packed spherical aggregates 
of floating cells. In the larger type 1 aggregates areas of central 
necrosis are frequently seen. Type 2 cell lines grow as relatively 
densely packed floating aggregates with an indefinite and irregular 
outline. These cell lines do not display areas of central necrosis. 
Type 3 cell lines grow as loosely adherent floating aggregates growing 
in small clumps and intertwined cords, central necrosis is absent in 
these cell lines. Type 4 cell lines grow attached to the substrate.
The three cell lines used in this study could be distinguished from 
each other by their morphological characteristics. H128d cells grew 
as tight aggregates with a spherical shape where individual cells could 
not be seen (Photograph 5). In the larger H128d aggregate an area of 
central necrosis was not uncommon. These cells are classed as type 1 
cells. H69 cells, however, grew in suspension as irregular shaped 
aggregates where the individual cells within an aggregate could not be 
easily identified (Photograph 13). These cells are classed as type 2 
cells. Finally, H187 cells grew as irregular floating aggregates with 
a morphology that resembled a ,lbunch of grapes" (Photograph 9). 
Individual H187 cells could be identified within an aggregate. H187 
cells are classed as type 3 cells.
100 ym
Photograph 9:- Control H187 Cells (lOx objective).
H187 cells in late log phase of growth.
1 0 0 pm
Photograph 10:- H187 Cells After 72Hr Exposure to 5nM HMBA (lOx 
objective).
H187 cells in late log phase were exposed to 5mM HMBA for 72hrs. 
Cells were photographed on day 3.
Photograph 11:- H187 Cells After 72hr Exposure to lmM DbcAMP (lOx
objective).
H187 cells in late log phase were exposed to lmM dbcAMP for 72hrs. 
Cells were photographed on day 3.
Photograph 12:- H187 Cells After 72hr Exposrue to lrcM NaBut ( lOx 
objective).
H187 cells in late log phase were exposed to lmM NaBut for 72hrs. 
Cells were photographed on day 3.
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Since the three cell lines used in this study had distinctive 
morphological features it was of interest to investigate whether the 
cellular morphology changed following phenotypic inducer treatment. 
The SCLC cell lines were exposed to the appropriate phenotypic inducer 
for 72hrs after which time the cellular morphology was viewed using a 
phase contrast microscope, lOx objective.
Following treatment with 5mM HMBA the H187 cellular morphology was 
found to change (Photograph 10). The cells grew as irregular floating 
aggregates more densely packed than the untreated controls. In the 
untreated H187 cells individual cells within an aggregate could be 
easily identified (Photograph 9); this was not the case in the HMBA 
treated cells. Moreover, when H187 cells were exposed to either lmM
dbcAMP or lmM NaBut a similar morphological change was observed; the
» **
cells grew as more densely packed irregular shaped floating 
aggregates. Therefore, when H187 cells were exposed to either HMBA, 
dbcAMP or NaBut the cellular morphology changed from type 3 to type 2.
When H69 cells were treated with phenotypic inducers for 72hrs 
morphological changes were also observed. 5mM HMBA treated H69 cells 
(Photograph 14) adopted a morphology more typical of type 1 SCLC cell 
lines. The H69 aggregates lost their irregular shape and became more 
spherical. Incubation with lmM dbcAMP for 72hrs did not appear to 
have any effect on the H69 cellular morphology (Photograph 15). The 
dbcAMP treated H69 cells retained the type 2 SCLC cell line 
morphology. When H69 cell were treated with lmM NaBut the aggregates 
became more spherical in shape compared to the untreated controls 
(Photograph 16), however this effect was not as marked as following 
exposure to HMBA. Therefore when H69 cells were exposed to some 
phenotypic inducers the morphological changes seen implied a shift 
from a type 2 SCLC cell line towards a type 1 SCLC cell line.
100 pm
Photograph 13:- Control H69 Cells (lOx objective).
H69 cells in late log phase of growth.
100 urn
Photograph 14:- H69 Cells After 72hr Exposure to 5mM HMBA (lOx 
objective).
H69 cells in late log phase were exposed to HMBA for 72hrs. The cells 
were photographed on day 3.
Photograph 15:- H69 Cells After 72hr Exposure to lmM DbcAMP (lOx
objective).
H69 cells in late log phase were exposed to lmM dbcAMP for 72hrs. The 
cells were photographed on day 3.
100 Jjm
Photograph 16:- H69 Cells After 72hr Exposure to lmM NaBut (lOx 
objective).
H69 cells in late log phase were exposed to lmM NaBut for 72hrs. The 
cells were photographed on day 3.
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Finally, H128d cells were exposed to 5mM HMBA, lniM dbcAMP and lmM 
NaBut for 72hrs and the cellular morphology examined. However, in 
this cell line no morphological changes were noticed following 
phenotypic inducer treatment, the cells remained growing as tight 
spherical aggregates typical of type 1 SCLC cell lines.
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CHAPTER 7.
THE EFFECT OF PHENOTYPIC CHANGE ON THE CHETOSENSITIVriY 
OF THE SCLC CELL LINES.
The aim of this project was to investigate whether the SCLC phenotype 
could be altered by phenotypic inducer agents, and if so \diether this 
change in the SCLC phenotype had any effect on chemosensitivity. 
Having determined that the SCLC phenotype could be altered following 
treatment with various inducers the effect of this phenotypic change 
on chemosensitivity was investigated.
SCLC is one of the few solid tumours which shows an initial exquisite 
sensitivity to radiation and/or chemotherapy. This characteristic 
separates SCLC from the other three major forms of human lung 
carcinomas: squamous cell, adeno- and large cell undifferentiated.
The eventual goal in the treatment of SCLC is to develop effective 
systemic therapy that will produce high response rates and a high 
percentage of long term disease free survivors. Currently, the 
results that can be obtained with maximally delivered combination 
chemotherapy (with or without additional radiotherapy) are limited by 
the available agents. The most widely used drug combinations include 
traditionally three of the following four drugs: vincristine,
adriamycin, cyclophosphamide or etoposide (VP16).
HMBA, dbcAMP and NaBut have been shown to alter the growth rate, DDC 
CKBB activities, levels of BLI and the cellular morphology of some 
SCLC cell lines. The effect of these phenotypic changes on the 
adriamycin, vincristine and VP16 chemosensitivity of the SCLC cell 
lines was examined to determine whether phenotypic change had any 
effect on the SCLC chemosensitivity.
The cells were exposed to the appropriate phenotypic inducer for 
72hrs. The cells were then washed and resuspended in drug free
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Figure 37:- Cytotoxicity Curves for SCLC Cell Lines Exposed to 
Adriamycin for 24hrs.
SCLC cell lines were exposed to adriamycin for 24hrs and the cells 
were allowed to recover for the appropriate period (H187 4 days, H69 
and H128d 7 days). An MTT assay was carried out to determine the 
adriamycin chemosensitivity of the cell lines.
The results represent mean of 8 replicate samples + standard error.
Table 18: Effect of Phenotypic Change on the Adriamycin
Chemosensitivity of the SCLC Cell Lines - 24hr exposure.
Cell Line. Control ID q^ Phenotypic ID^ q Adr nM following 
Adriamycin nM. Inducer P.I. pretreatment of P.I.
l.OmM 5.0mM
H187 36.0 + 3.6 HMBA 50.6 + 2.0 26.6 + 9.0
H69 45.0 + 7.3 HMBA 43.2 + 5.0 49.0 + 6.6
H128d 70.0 + 2.5 HMBA 95.0 + 18.0 72.0 + 16.1
0.5mM l.OmM
H187 dbcAMP 45.0 + 11.4 53.0 + 14.0
H69 dbcAMP 43.6 + 5.0 39.3 + 2.9
H128d dbcAMP 101.1 + 19.6 115.0 + 25.0
0.5niM l.OmM
H187 NaBut 78.0 + 26.0 29.0 + 10.0
H69 NaBut 71.2 + 16.0 44.0 + 1.15
H128d NaBut 83.0 + 2.5 67.0 + 23.0
The SCLC cell lines were treated with the appropriate phenotypic 
inducer for 72hr. The cells were then washed 2x with PBS and 
resuspended in drug free medium. The cells were plated out at 5xlCr 
cells/ml and exposed to adriamycin for 24hrs. After the appropriate 
recovery period, cell survival was measured using the MIT assay.
The results represent the mean ID^ q + standard error from 3 replicate 
experiments.
Statistical analysis was carried out using the Students t-test.
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Figure 38:- The Effect of DbcAMP Pretreatment on the Adriamycin 
Chemosensitivity of H187 cells.
H187 cells were pretreated with lmM dbcAMP for 72hrs. The cells were 
then washed 2x with PBS and resuspended in drug free medium. The 
cells were plated out into 96 well plates at a final cell 
concentration of 5x10 cells/ml. The cells were exposed to 
adriamycin for 24hrs and following drug removal, allowed to recover 
for 4 days. An MIT assay was performed to determine the adriamycin 
chemosensitivity of dbcAMP treated and untreated H187 cells.
The results represent the mean" of 8 replicate samples + standard
error.
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Figure 39:- The Effect of HMBA. Pretreatment on the Adriamycin 
Chemosensitivity of H69 Cells,
H69 cells were pretreated with or without 5niM HMBA for 72hrs. The 
cells were washed 2x with PBS and resuspended in drug free medium. 
The cells were then plated out into 96 well plates at a final cell 
concentration of 5x10 cells/ml, and exposed to adriamycin for 24hrs. 
After a 7 day recovery period an MTT assay was performed to determine 
the affect of HMBA pre treatment on the H69 adriamycin
chemosensitivity.
The results represent the mean of 8 replicate samples + standard
error.
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medium, and plated out into microtitration plates. The cells were 
then exposed to the appropriate cytotoxic agent (adriamycin, 
vincristine or VP16) and their chemosensitivity was determined using 
the MTT assay.
Typical cytotoxicity curves for the three SCLC cell lines following a 
24hr exposure to adriamycin as shown in Figure 37. The three curves 
are similar except at high adriamycin concentrations, where the H187 
cytotoxicity curve levels off. This implies that there are still 
viable H187 cells remaining at high concentrations of adriamycin 
following a 24 hour exposure. The mean adriamycin ID^q 1 s following a 
24hr exposure of the three SCLC cell lines were found to be 36nM, 45nM 
and 70nM for H187, H69 and H128d respectively (Table 18). Statistical 
analysis of the SCLC cell lines ID^q1s using the Students t-test 
showed that the H187 and H69 ID^ q 1 s were not significantly different. 
However, comparison of the H187 ID^q with the H128d ID^q s showed that 
the chemosensitivity of these two lines were significantly different, 
p<0.001. Moreover, the H69 adriamycin ID^q was found to be 
significantly different from the H128d ID^ q, p<0.01.
When the SCLC cell lines were pretreated for 72hrs with the 
appropriate phenotypic inducer the adriamycin ID q^ was not 
significantly different from the untreated controls (Tab. 18). More 
specifically, dbcAMP pretreatment of H187, previously shown to cause 
the most significant change in the H187 cellular phenotype, did not 
affect the chemosensitivity of H187 to adriamycin. It is possible 
however that phenotypic inducer treatment may have caused a shift in 
the chemosensitivity of a selective H187 cell population without an 
associated shift in the adriamycin ID q^ , perhaps with the emergence of 
an resistant fraction. This however is unlikely since the 
cytotoxicity curve obtained for dbcAMP treated H187 cells mimicked 
that of the untreated control cells (Fig 38). If a resistant fraction 
was present following phenotypic inducer treatment this may have been
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Figure 40:- Cytotoxicity Curves for SCLC Cell Lines Exposed to 
Adriamycin for 72hrs.
SCLC cell lines were exposed to adriamycin for 72hrs and then allowed 
to recover. An MIT assay was carried out to determine the adriamycin 
chemosensitivity of the cell lines.
The results represent mean of 8 replicate samples + standard error.
Table 19: Effect of Phenotypic Change on the Adriamycin
Chemosensitivity of the SCLC Cell Lines - 72hr exposure.
Cell Line Control ID q^ Phenotypic ID q^ Adr nM following
Adriamycin nM. Inducer P.I. pretreatment of P.I.
H187 9.06 + 0.29 dbcAMP l.OmM 9.5 + 2.5
H69 22.6 + 1.73 dbcAMP l.OmM
NaBut l.OmM 
HMBA 5.0mM
H128d 25.3 + 8.2 dbcAMP l.OmM
NaBut l.OmM
SCLC cell lines were incubated with the appropriate phenotypic 
inducer for 72hrs. The cells were then washed 2x with PBS and 
resuspended in drug free medium and plated into 96 well plates at a 
final cell concentration of 5x10^  cells/ml. The cells were exposed 
to adriamycin for 72hrs. After the appropriate recovery period an 
MTT assay was performed to determine cell survival.
The results represent the mean ID^ q + standard error from 3 replicate 
experiments.
Statistical analysis was performed using Students t-test.
26.0 + 4.6
28.3 + 5.2
24.0 + 6.4
29.6 + 15.1
39.3 + 16.0
Table 20 : The Effect of Phenotypic Change on the Vincristine
Chemosensitivity of the SCLC Cell Lines.
Cell Line Control ID50 Phenotypic
Vmcris tine nM Inducer F. I •
ID50 ^ nc ^  following 
pretreatment with P.I.
72hr Exposure:- 
H187 0.56 + 0.14 dbcAMP l.OmM 0.27 + 0.08
24hr Exposure:- 
H69 1.17 + 0.19 NaBut l.OmM 
HMBA 5.0mM
2.03 + 0.3 
0.89 + 0.11
SCLC cell lines were pre treated for 72hrs with the appropriate 
phenotypic inducer. The cells were then harvested, washed 2x with 
PBS and resuspended in drug free medium. The cells were plated out 
into 96 well plates at a final cell concentration of 5x10 cells/ml 
and exposed to vincristine for either 24hrs (H69) or 72hrs (H187). 
After the appropriate recovery period- the vincristine 
chemosensitivity was determined using the MIT assay.
The results represent the mean ID q^ + standard error of 3 replicate 
experiments.
Statistical analysis was carried out using the Students t-test.
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Figure 41:- The Effect of DbcAMP Pretreatment on the H187 Vincristine 
Chemosensitivity.
H187 cells were pretreated with dbcAMP lmM for 72hrs. The cells were 
harvested, washed 2x with PBS and resuspended in drug free medium. 
The cells were plated out into 96 well plates at a final cell 
concentration of 5xlCr cells/ml. The cells were exposed to 
vincristine for 72hrs and after a 4 day recovery period an MTT assay 
was carried out to examine the effect of dbcAMP pretreatment on the 
vincristine chemosensitivity of H187 cells.
The results represent mean of 8 replicate samples + standard error.
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Figure 42:- Hie Effect of HMBA Pretreatment cm the H69 Vincristine 
Chemosensitivity.
H69 cells were exposed to 5mM HMBA for 72hrs. The cells were then 
washed, and resuspended in drug free medium. HMBA treated and 
untreated H69 cells were seeded into 96 well plates at a final cell 
concentration of 5xlCr cells/ml. The cells were exposed to 
vincristine for 24hrs. After drug removal the cells were allowed to 
recover for 7 days. An MIT assay was carried out to determine the 
vincristine chemosensitivity of the HMBA treated and untreated H69 
cells.
The results represent mean of 8 replicate samples + standard error.
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apparent by a tailing off of the cytotoxicity curve at high adriamycin 
concentrations compared to the untreated controls. Therefore dbcAMP 
induced phenotypic change in H187 has no effect on the 
chemosensitivity of H187 to adriamycin. Furthermore, pretreatment of 
H187 cells with either HMBA or NaBut had no effect on the H187 
adriamycin chemosensitivity. These findings were further supported by 
examination of the effect of phenotypic change on the chemosensitivity 
in H69 and H128d cell lines. In- spite of the fact that HMBA caused a 
significant change in the phenotype of H69 cells, pretreatment of H69 
with either l.OmM or 5.0mM HMBA failed to alter H69 adriamycin 
chemosensitivity (Table 18). Moreover the cytotoxicity curves of H69 
with or without HMBA pre treatment did not differ (Fig 39). DbcAMP or 
NaBut pretreatment of H69 cells had no effect on the cells* 
chemosensitivity to adriamycin (Table 18). The chemosensitivity of 
H128d to adriamycin was not significantly altered by pretreatment with 
the phenotypic inducers (Table 18).
It may be however that phenotypic inducer treatment does alter the 
SCLC chemosensitivity but a 24hr exposure to adriamycin is 
insufficient to allow the effect to be seen. Therefore the effect of 
phenotypic change on the chemosensitivity of the SCLC cell lines was 
examined following a 72hr exposure to adriamycin. Figure 40 shows the 
typical cytotoxicity curves obtained for the three SCLC cell lines 
following a 72hr exposure to adriamycin. The control cytotoxicity 
curves were found to be similar even at high adriamycin 
concentrations. It was found that H187, H69 and H128d had a mean 
adriamycin ID^ q of 9nM, 22.6nM and 25.3nM respectively (Tab. 19). 
Statistical analysis of the SCLC cell lines ID^q 1 s showed that the 
H187 ID5 0 was significantly different to both the H69 ID^q (p<0.002) 
and the H128d ID50 (P<0.05). However the H69 ID^q was not 
significantly different from the H128d ID^q unlike that found 
following a 24hr exposure to adriamycin.
Table 21 s The Effect of Phenotypic Change on the VP16
Chemosensitivity of the SCLC Cell Lines - 24hr Exposure.
SCLC cell lines were pretreated with the appropriate phenotypic 
inducer for 72hrs. The cells were then harvested, washed 2x with
plates at a final cell concentration 01 _>ajlu ucj.j.&>/lux. iuc uena 
were exposed to VP16 for 24hrs. The VP16 chemosensitivity was 
determined following the appropriate recovery period using the MIT 
assay.
The results represent the mean ID^ q + standard error from 3 replicate 
experiments.
Statistical analysis was performed using the Students t-test.
Cell Line Control IDcq 
VP16 nM
Phenotypic 
Inducer P.I
ID5 0 VP16 nM following 
pre treatment with P. I.
H187 102.0 + 9.0 dbcAMP l.OmM 166.0 + 1 2 . 0
H69 860.0 + 140 HMBA 5.0mM 925.0 + 130
PBS, resuspended in drug free medium
*■ P<0.02
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The cells were pretreated with the phenotypic inducers seen previously 
to cause the greatest shift in the cellular phenotype and then exposed 
to adriamycin for 72hrs. It was found however that even after a 72hr 
exposure to adriamycin no change in the cells* chemosensitivity to 
adriamycin was seen (Table 19).
Although phenotypic change did not appear to affect the adriamycin 
chemosensitivity of the cell lines it may alter the response of the 
SCLC cell lines to other cytotoxic drugs. Therefore, the effect of 
phenotypic inducer treatment on the vincristine and VP16 
chemosensitivity of the SCLC cell lines was examined.
As most pronounced changes in cellular phenotype were found following 
treatment of H187 with dbcAMP and treatment of H69 with either HMBA or 
NaBut, these combinations were selected to investigate the effect of 
phenotypic change on the vincristine chemosensitivity.
In order to determine the effect of phenotypic change on the 
vincristine chemosensitivity of H187 cells a 72hr exposure time was 
required. When dbcAMP treated H187 cells were exposed to vincristine 
for 24hrs the cytotoxicity curve was very shallow and the ID q^ could 
not be accurately derived. Since vincristine is a cell cycle specific 
drug, acting at the M phase of the cell cycle, an alteration in the 
cycle time or position of the cells within the cell cycle could affect 
the cytotoxicity exerted. DbcAMP has been shown to significantly 
affect the growth of H187 cells and this may affect the vincristine 
cytotoxicity found following a 24hr exposure. When a 72hr exposure to 
vincristine was adopted a cytotoxicity curve for the dbcAMP treated 
and untreated H187 cells was obtained where the ID^ q could be 
determined (Fig 41).
Pretreatment of H187 with l.OmM dbcAMP did not have any effect on the 
cells* vincristine chemosensitivity. Table 20 shows that the
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Figure 43s- Effect of DbcAMP Pretreatment on the VP16 
Chemosensitivity of H187 Cells.
H187 were exposed to lmM dbcAMP for 72hrs. The cells were washed and 
resuspended in drug free medium. DbcAMP treated and untreated H187 
cells were seeded into 96 well plates at a final cell concentration 
of 5x10 cells/ml. Following a 24hr exposure to VP16 and a recovery 
period of 4 days, the cells VP16 chemosensitivity was determined 
using the MTT assay.
The results represent mean of 8 replicate samples + standard error.
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Figure 44:- Effect of HMBA. Pretreatment on the VP16 Chemosensitivity 
of H69 Cells.
H69 cells were pretreated with 5mM HMBA for 72hrs. The cells were 
then washed and resuspended in drug free medium. HMBA treated and 
untreated cells were seeded into 96 well plates at a final cell 
concentration of 5x10 cells/ml, exposed to VP16 for 24hrs and 
allowed to recover for 7 days. An MIT assay was used to determine 
the VP16 chemosensitivity of the H69 cells.
The results represent mean of .8 replicate samples + standard error.
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vincristine ID^q 1 s of dbcAMP treated and untreated H187 cells did not 
differ significantly. Furthermore, the cytotoxicity curve obtained 
for dbcAMP treated H187 cells followed the same pattern as the 
cytotoxicity curve of the untreated controls (Fig 41). When the 
effect of pretreatment of H69 cells with either 5.0mM HMBA or l.OmM 
NaBut on the vincristine chemosensitivity was examined it was found 
that there was no effect. Table 20 shows that the vincristine ID^q of 
the treated and untreated H69 cells did not differ significantly. 
Moreover, the cytotoxicity curves obtained for the HMBA treated and 
untreated H69 cells were superimposable (Fig 42).
Finally the effect of phenotypic change on the VP16 chemosensitivity 
of the SCLC cell lines was examined. Again dbcAMP treated H187 cells 
and HMBA treated H69 cells were selected as examples of phenotypically 
changed cells. Treatment of H187 with l.OmM dbcAMP significantly 
reduced the VP16 chemosensitivity of these cells. Table 21 shows that 
following pretreatment of H187 with l.OmM dbcAMP the VP16 ID q^ is 
significantly increased. This is illustrated in Figure 43 which shows 
the cytotoxicity curves obtained for dbcAMP pretreated and untreated 
H187 cells following a 24hr exposure to VP16. However, pretreatment 
of H69 with 5.0mM HMBA did not significantly affect the cells VP16 
chemosensitivity (Tab. 21). The cytotoxicity curves obtained for HMBA 
pretreated and untreated H69 cells were found to be similar (Fig 44).
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CHAPTER 8 .
DISCUSSION.
The main objective of this study was to determine whether the SCLC 
phenotype could be altered, and if so, whether this alteration had any 
effect on chemosensitivity. The cells were exposed to various 
phenotypic inducers and markers of the SCLC phenotype were then 
measured. Changes in the levels of the phenotypic markers were taken 
as representing a change in the SCLC phenotype. Having established 
that the SCLC phenotype could be altered by certain drugs, the effect 
of this phenotypic change on the chemosensitivity was investigated.
A variety of phenotypic inducer agents were examined to determine
whether they could alter the SCLC phenotype, these included HMBA, 
dbcAMP, NaBut, dexamethasone. DDC activity, CKBB
activity and bombesin-like immunoreactivity were selected as markers 
of the SCLC phenotype. In addition, the cellular morphology and the 
growth characteristics of the cell lines were also examined following 
phenotypic inducer treatment.
Following phenotypic inducer treatment an alteration in the SCLC
phenotype was found. As a group this phenotypic change did not appear 
to follow a consistent pattern since in some cell lines a particular 
drug caused an increase in the level of a specific SCLC marker whereas 
in others a decrease of the same marker was found. The SCLC cell 
lines selected in this study were described as classic SCLC cell lines 
(Carney et al 1985). They nevertheless exhibited considerable 
diversity with respect to biochemical markers, morphology and growth 
characteristics. In particular differences in DDC activity were found 
over a 40-fold range. Similarly, the cellular bombesin-like 
immunoreactivity of the cell lines differed over a 50-fold range. As 
mentioned previously the morphology of the cell lines also differed
quite considerably, being classed as type 1, 2 or 3 by
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Carney’s classification (Carney et al 1985). The CKBB activity of the 
SCLC cell lines however was found to be more consistent. Perhaps it 
is not surprising that a consistent pattern of SCLC phenotypic change 
following drug treatment was not found when one considers the
differing nature of the cell lines. Within each cell line however, a
distinctive pattern of phenotypic change did emerge. A similar change 
was found in the phenotypic markers of the cell lines, with respect to
the direction (that is an increase or decrease) as opposed to the
magnitude of change, irrespective of the inducer used. For example, 
the DDC activity in H69 cells was found to decrease following 
treatment with either HMBA, dbcAMP or NaBut; an increase in DDC 
activity was never seen. Also, an increase in the H187 cellular CKBB 
activity was always found following phenotypic drug treatment; a 
decrease was never seen. Since the cell lines were found to respond 
quite differently to the various inducer agents the effect of the 
phenotypic drug treatment on the individual cell lines will be
discussed.
Alteration of the SCLC Phenotype.
(i) NCI-H187
The H187 cell. line expressed the lowest DDC activity and BLI of the 
three lines studied. However, the CKBB activity of H187 was found to 
be similar to that found in the other two lines. H187 cells grew as 
irregular floating aggregates with a morphology that resembled a 
"bunch of grapes”. When H187 cells were exposed to HMBA for 72 hours 
a number of phenotypic changes were noted. Firstly, a growth
suppressive effect was found following incubation with 5mM HMBA.
Following drug removal the cells reentered the exponential phase of 
growth with a doubling time similar to the untreated controls.
Treatment with 5niM HMBA resulted in a significant increase in the 
CKBB activity of H187, however no effect was seen on the DDC activity.
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The levels of DDC and CKBB do not appear to be concomitantly 
controlled. A morphological alteration was also found in H187 cells 
following HMBA exposure. The drug treated cells resembled type 2 cell 
morphology as opposed to the control cells which are classified as 
type 3. It is possible that the changes in the H187 cell phenotype 
are due to an indirect effect of the growth suppression found 
following exposure to HMBA. However, the cytostatic effect of HMBA on 
the growth of H187 cells was minimal and, as will be discussed later, 
there does not appear to be a direct correlation between the degree of 
cytostasis and the changes found in marker expression. Moreover, 
since the DDC activity in the H187 cells was not altered by HMBA 
treatment, it would appear that the control of this phenotypic marker 
is not directly related to the cytostatic effect induced by HMBA. In 
the other two SCLC cell lines the DDC activity was found to be 
generally repressed following treatment with the phenotypic inducers. 
In H187 the DDC activity is already low and it may be that the DDC 
cannot be further repressed.
The most active phenotypic inducer in H187 cells was found to be 
dbcAMP. DbcAMP exerted a growth suppressive effect in a dose 
dependent manner which was not reversed when the drug was removed. 
DbcAMP also significantly increased DDC and CKBB activities in a dose 
dependent manner. Furthermore, detectable levels of BLI were found in 
H187 cells following exposure to dbcAMP. The H187 cellular morphology 
was also altered. H187 cells treated with dbcAMP resembled type 2 
cell morphology similar to that found following exposure to HMBA. 
Therefore, following exposure to dbcAMP the H187 phenotype changed in 
a number of repects; DDC activity increased, CKBB activity increased, 
BLI increased, the cellular morphology changed from type 3' to type 2 
and the growth rate decreased. As discussed above, these changes in 
the H187 phenotype may be the result of an indirect effect of the 
cytostasis induced by dbcAMP. DbcAMP exerts quite a distinctive 
growth suppressive effect, during and following drug exposure. Since
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the DDC and CKBB activities were found not to fluctuate during the 
growth cycle (Fig. 27) the changes in the levels of both enzymes 
cannot be explained by differences in the position of the cells in the 
growth cycle at the time the enzymes were assayed. Moreover, the 
degree of cytostasis exerted by dbcAMP was greater than that found 
following HMBA treatment but the change in CKBB activity was found to 
be similar.
One problem with using dbcAMP is that butyric acid is formed by the 
hydrolysis of dbcAMP and so the observed effects may in fact be due to 
the presence of butyrate rather than cAMP. When the effect of NaBut 
on the H187 phenotype was examined it was found than NaBut could also 
alter the H187 phenotype. NaBut had a cytostatic effect on the growth 
of H187 cells. Interestingly, H187 cells treated with 1.0 mM NaBut had 
a similar doubling time to 0 .5 mM dbcAMP treated cells, so it is 
possible that the cytostatic effect of dbcAMP was due to the presence 
of butyrate. However not all the dbcAMP effects on H187 cells could 
be attributed to the presence of butyrate. NaBut up to l.OmM had no 
effect on the DDC activity. DbcAMP at 0.5mM, however, significantly 
increased the DDC activity in H187 cells (Table 6 ). However, NaBut 
l.OmM was found to significantly increase CKBB activity to a similar 
level found following dbcAMP exposure. NaBut treatment was found to 
alter the H187 cellular morphology to that found with the other 
inducer agents. Hence, NaBut also appears to be able to change the 
phenotype of H187 cells. While butyrate may also contribute to the 
dbcAMP induced phenotypic change of H187 cells, this does not exclude 
activity due to cAMP itself. With hindsight, it may have been useful 
to examine the effect of NaBut on the BLI in these cells to see if the 
change induced by dbcAMP could be attributed to the presence of 
butyrate.
Dexamethasone was found to induce a cytostatic effect in H187 cells at
high cell density. However, dexamethasone was found to have no effect
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on either the DDC or CKBB activities in H187 cells. Therefore, 
cytostasis does not appear to be a prerequisite or sufficient for the 
changes in enzyme activity found following phenotypic inducer 
treatment.
(ii) NCI-H69
H69 cells expressed an intermediate level of DDC activity and BLI, and 
a similar CKBB activity to the other two lines studied. H69 cells 
grew in suspension as irregular shaped aggregates where the individual 
cells within an aggregate could not be easily identified. The 
phenotypic inducer which had the greatest effect on H69 cells was 
found to be HMBA. HMBA induced a cytostatic effect in H69 cells 
during drug exposure, but following drug removal the cells entered an 
exponential growth phase similar to the untreated controls. HMBA was 
also found to significantly reduce the DDC activity in H69 cells in a 
dose dependent manner. This effect was noted at noncytostatic drug 
concentrations. HMBA was also found to increase the CKBB levels in 
H69 cells only at noncytostatic concentrations. HMBA significantly 
reduced the level of BLI in H69 cells. Furthermore, HMBA was found to 
have a marked effect on the H69 cellular morphology, a shift from type 
2 towards type 1 cells was noted. Therefore, the H69 cellular 
phenotype represented by DDC activity, CKBB activity, BLI, morphology 
and growth rate, can undergo an alteration in response to HMBA 
treatment. The pattern of HMBA induced phenotypic alteration in H69 
cells was quite different from that observed following exposure of 
H187 cells.
Although dbcAMP was found to be an effective phenotypic inducer in 
H187 cells, when H69 cells were treated with dbcAMP a different 
pattern of phenotypic change was found. In the presence of dbcAMP H69 
cells exhibited a growth delay and on removal of the drug the cells 
entered an exponential phase but did not resume the control growth
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rate even after 7 days in drug free medium. DbcAMP significantly 
reduced the DDC activity in H69 cells in a dose dependent manner, but 
had no effect on the CKBB activity, BLI and morphological 
characteristics. Therefore, although dbcAMP was found to be a useful 
phenotypic inducer agent in H187 cells its action in H69 cells was 
minimal. Moreover, although a significant growth suppression was 
found following dbcAMP exposure corresponding changes in the other 
phenotypic markers were not found, implying again that cytostasis is 
not causative in phenotypic change.
As discussed previously, the butyrate component of dbcAMP is itself a 
potential phenotypic inducer. When H69 cells were exposed to NaBut 
the cells exhibited a pattern of cytostasis similar to that found 
following dbcAMP treatment. On a mole to mole basis NaBut exerted a 
greater cytostatic effect than dbcAMP. NaBut treatment was found to 
significantly reduce the DDC activity in H69 cells. This effect was 
even greater than that found for dbcAMP treatment. H69 cells treated 
with NaBut had similar CKBB and BLI as the untreated controls. NaBut 
treatment did, however, change the H69 cell morphology, a shift 
towards type 1 cells was found, although this effect was not as marked 
as that seen following HMBA treatment. Therefore, on the basis of 
these results, it is possible that the effects seen following dbcAMP 
could be accounted for by the presence of butyrate. However, NaBut 
appeared to have a more potent effect than dbcAMP on a mole to mole 
basis and had an additional effect on the H69 cell morphology.
The effect of dexamethasone on the phenotype of H69
cells was examined. Dexamethasone had no effect on the growth, DDC 
activity or CKBB activity in H69 cells.
The DDC and CKBB activties in H69 cells do not appear to be 
coordinately controlled. There is no direct correlation between
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cytostasis and the other phenotypic changes seen. In summary 
therefore, the phenotype of H69 cells can be altered following 
treatment with selected agents.
(iii) NCI-H128d
Finally, the effect of phenotypic inducer treatment on the phenotype 
of H128d cells was examined. H128d cells expressed the highest DDC 
activity and the highest BLI of the three cell lines examined. The 
CKBB activity of H128d cells was similar to the other two cell lines. 
H128d cells grew as tight aggregates with a spherical shape where 
individual cells could not be distinguished. In the larger H128d 
aggregates an area of central necrosis was not uncommon. H128d cells 
are classed as type 1 cells.
When H128d cells were exposed to HMBA the CKBB activity was 
significantly reduced. Although HMBA was shown to have multiple 
phenotypic effects in the other two cell lines this was the only 
effect seen in H128d. When the effect of dbcAMP on the H128d 
phenotype was examined a significant increase in the DDC activity was 
found. Interestingly, NaBut significantly reduced the DDC activity 
in H128d cells. The changes seen do not follow any particular pattern 
and in fact this is the only instance where the expression of a 
phenotypic marker, DDC, can be either increased or decreased depending 
on the inducer treatment. The general pattern up until now has been 
that if the expression of a phenotypic marker changes in response to a 
particular inducer then that change appears to be in one direction. 
In conclusion therefore, H128d cells do not appear to be significantly 
altered by the phenotypic inducers, since changes in only one marker 
have been found following inducer treatment.
As mentioned earlier, the pattern of phenotypic change within the SCLC 
cell lines following inducer treatment was not consistent. This is
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particularly evident when one considers the biochemical markers. 
However, when one considers morphological changes of the SCLC cell 
lines a consistent pattern of change was found. The SCLC cells 
underwent a morphological change which, if one views the morphological 
classes of SCLC as ranging from type 4 through to type 1, was always 
towards type 1. Therefore the morphological change of the SCLC cell 
lines does not correlate with the biochemical change.
Do These Alterations in the Various SCLC Phenotypic Markers 
Represent an Actual Shift in the SCLC Phenotype ?
A change in more than one marker in response to drug treatment implies 
a phenotypic shift of the cells. As discussed previously, a number of 
changes were found in the levels of the selected phenotypic markers in 
the SCLC cell lines following treatment with a variety of phenotypic 
inducer agents. However, there were some instances when only one or 
two changes in phenotypic marker expression were noted. For example 
H69 cells exposed to dbcAMP had significantly lower levels of DDC but 
alterations in the levels of the other phenotypic markers were not 
seen. It would be difficult to claim, therefore, that this represents 
a shift in the H69 cell phenotype. However, following treatment of 
H69 cells with HMBA and H187 with dbcAMP, a change in the expression 
of all the selected phenotypic markers was found. Therefore it would 
seem that treatment of these cell lines with these drugs does 
represent a shift in the phenotype of the cells.
Cycloheximide, a protein synthesis inhibitor, was able to inhibit the 
changes in DDC and CKBB expression in H69 and H187 cells following 
treatment with HMBA and dbcAMP, respectively. This implies that de 
novo protein synthesis is required for the observed changes in 
phenotypic marker expression in response to drug treatment. The 
increased expression of DDC and CKBB in H187 cells following exposure
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to dbcAMP is blocked by cycloheximide. If the increased expression of 
DDC and CKBB in these cells was due to increased enzyme synthesis, it 
can be visualised how cycloheximide would block the dbcAMP effect. 
However, HMBA was found to reduce the expression of DDC in H69 cells, 
how then does cycloheximide block a reduction in enzyme activity ? It 
may be that DDC is under the control of an inhibitor protein and 
following HMBA treatment the amount of this inhibitor protein is 
increased with the result DDC activity is reduced. Therefore in the 
presence of cycloheximide the increased synthesis of this DDC 
inhibitor is blocked and the DDC activity remains at the control 
level. Such a mechanism for the regulation of an enzyme has been 
described for ornithine decarboxylase (Meilhoc et al, 1986). 
Synthesis of a protein inhibitor of ornithine decarboxylase is 
stimulated by putrescine, spermidine, spermine and synthetic diamines 
(e.g. HMBA).
The Effect of the SCLC Phenotypic Change on Chemosensitivity.
Having established that a phenotypic change in the SCLC phenotype can 
be achieved following exposure of the cells to the appropriate drugs 
the effect of this phenotypic alteration on the chemosensitivity of 
the cells was examined. Initially the effect of phenotypic change on 
the adriamycin chemosensitivity of the cells was examined and it was 
found that phenotypic alteration of the SCLC cell lines had no 
significant effect. Another important drug in the treatment of SCLC, 
vincristine, was also selected to determine whether the phenotypic 
alteration of the SCLC cell lines altered the vincristine 
chemosensivity. Once again no significant differences between the 
vincristine chemosensitivity of the control cells and the phenotypic 
drug treated cells was found. Finally, the effect of the phenotypic 
change on the VP16 chemosensitivity of the cells was examined. Only 
the two combinations where the maximum phenotypic changes were seen
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were examined, namely H187 cells exposed to dbcAMP and H69 cells 
exposed to HMBA. No difference in the VP16 chemosensitivity was found 
in HMBA treated H69 cells, however, dbcAMP treated H187 cells were 
significantly more resistant to VP16 than the untreated controls.
As discussed in the Introduction, VP16 is believed to act as a 
cytotoxic agent via an action on topoisomerase II. Pronounced 
increases in cellular topoisomerase II activity have been associated 
with cell proliferation both in vitro and in vivo, and this
proliferative activity has in turn been associated with increased 
tumour cell sensitivity to topoisomerase-II-interactive drugs 
(Markovits et al, 1987; Sullivan et al 1986). Since dbcAMP causes a 
marked growth suppression in H187 cells the increased resistance to 
VP16 may be a reflection of the decreased cell proliferation. NaBut
also has a marked growth suppressive effect on H187 cells without all
the other phenotypic effects of dbcAMP. It would be of interest to 
examine the effect of NaBut treatment of H187 cells on the VP16 
chemosensitivity to determine whether a similar change in
chemosensitivity was found.
From these results it appears that phenotypic change, as determined by 
the change in the levels of selected SCLC markers, has no effect on 
the chemosensitivity of the SCLC cell lines examined. It is possible 
however that the MIT assay was not sensitive enough to detect subtle 
changes in the chemosensitivity of the cells in response to phenotypic 
change. This possibility seems unlikely however since significant 
differences between the ID^q1 s of the three cell lines could be seen 
using this assay and the ID^ q 1 s differed by less than two fold.
As discussed in the Introduction, an established cell line of human 
small cell lung cancer (OH-1) underwent a subtle morphological change 
which was accompanied by a profound loss of neuroendocrine 
differentiation and the emergence of radiation resistance (Goodwin &
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Baylin 1982). This change in the sensitivity of SCLC cell lines to 
radiation following the loss of APUD cell characteristics has been 
noted elsewhere. In a group of seven SCLC cell lines, two cell lines 
had undergone "transformation” to large cell morphological variants 
with loss of APUD cell characteristics. When the in vitro response of 
the cells lines to radiation and chemotherapeutic drugs was examined 
it was found that the large cell variants were 2- to 5- fold more 
resistant to radiation compared to the classic SCLC cell lines 
(Carney, Mitchell & Kinsella 1983). Therefore, it may be that an 
alteration in the SCLC phenotype could affect the sensitivity of the 
SCLC cell lines to radiation without necessarily altering the cells 
chemosensitivity. This avenue of investigation may well be worth 
pursuing.
The phenotypic change of the SCLC cells following exposure to the 
various drugs may have been insufficient to cause a change in the 
cells’ chemosensitivity. It is apparent from the literature that 
"transformation" of classic SCLC cell lines to large cell variants is 
accompanied by a profound decrease in APUD properties, including DDC 
and the presence of neurosecretory granules, decreased levels of 
bombesin and a change in morphology resembling cell type 3 or 4. 
Although changes in the levels of the SCLC phenotypic markers were 
found in the present study, these changes were modest compared to the 
differences between classic SCLC cell lines and the "transformed" 
large cell variant cell lines. The cells were treated with the 
appropriate phenotypic drugs for 72 hours. This exposure time was 
selected since in other systems 72 hours was shown to be sufficient 
time to allow phenotypic change. It is important to extend this study 
to investigate the effect of longer exposure times of the SCLC cell 
lines to the various inducer agents on the expression of the 
phenotypic markers with a view to maximising the phenotypic change. 
Moreover, combinations of the different phenotypic agents may be more 
effective in inducing a change in the SCLC phenotype than using single
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agents. Agents such as dexamethasone which were shown to have no 
effect when added alone may have a synergistic effect when added in 
combination with other agents.
Are the Observed SCLC Phenotypic Changes Reversible or Stable ?
The cell lines were treated with the various inducer agents at which 
point the levels of the various phenotypic markers were measured. It 
would be of interest to investigate whether the changes in the 
phenotypic markers following a 72 hour exposure to the various agents 
were still evident after a certain period in drug free medium. It is 
possible that a proportion of the cells underwent an irreversible 
phenotypic change in response to drug treatment, however a number of 
other cells in the population may be left unchanged. If the unchanged 
cells were growing at an increased rate the phenotypically altered 
cells would be selected against and eventually disappear from the 
culture and it would appear that a reversible phenotypic change had 
occurred. Cloning of the drug treated cells could perhaps clarify 
this possibility but since the cloning efficiency of SCLC cultures is 
extremely low it is unlikely whether this would give a conclusive 
answer. If indeed only a proportion of the SCLC cells had undergone a 
phenotypic change the levels of phenotypic marker expression found 
would be the net value from a heterogenous population with varying 
response levels. Therefore it is possible that some cells had irr fact 
undergone a greater degree of change than the results would suggest. 
However, this is purely speculation and further investigation would be 
required to substantiate this claim. The problem of reversibility is 
an important one but is not easily resolved.
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SCLC Phenotypic Shift: More Differentiated or Nonspecific ?
The drugs used to induce a phenotypic change in the SCLC cell lines 
have been shown to be able to induce a more differentiated phenotype 
in other in vitro systems. With respect to the SCLC cell lines, do 
these phenotypic inducers shift the SCLC phenotype towards a more 
differentiated phenotype or are the phenotypic changes a nonspecific 
shift in the SCLC phenotype ?
It has been proposed that cancer is a disorder resulting from an 
uncoupling of gene expression that controls cellular proliferation and 
differentiation. Normal cell development is classically depicted as 
proceeding from an immature stem cell, which possesses unlimited self­
renewal to commited progenitors and terminally, lineage-specific, 
differentiated cells with limited, restricted or no self-renewal 
capacity. The multiplication and differentiation of normal cells are 
controlled• by different regulatory molecules. These regulators must 
interact to achieve the correct balance between cell multiplication 
and differentiation during embryogenesis and during the normal 
functioning of the adult individual.
Cell differentiation is the result of precise gene programming. It is 
based on selective activation of only a very small part of the genome 
with the vast majority of genes remaining silent in each cell type. 
From one genotype many different cell phenotypes are thus generated 
giving rise to the structural and functional specialisations that 
constitute differentiated tissues. The origin and further progression 
of malignancy result from genetic changes that uncouple the normal 
balance between multiplication and differentiation so that there are 
too many growing cells. In most cases neoplastic cells are often 
defined by the pattern of molecular gene activation and inactivation, 
so that the observed effect is the loss and/or appearance of certain
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specific gene products, which are not normally found in the particular 
cell type at that point in its differentiation pathway.
The classification of tumours is based on the expression of 
morphological, biochemical and functional properties. Historically, 
the expression of certain specific characteristics by tumour cells has 
been ascribed to the origin of the tumour in question from a specific 
parent cell expressing the same phenotype. For example, in SCLC the 
expression of APUD properties has led to the proposal that SCLC 
originates from the endocrine cell (K cells) of the lung (Pearse, 
1969). However, the expression of these differentiation 
characteristics do not necessarily reflect origin from a particular 
parent cell and there is accumulating evidence that tumours may 
frequently exhibit more than one type of differentiation (Mendelsohn & 
Maksem 1986). SCLC is a good illustration of this point; the presence 
of certain differentiation characteristics could imply the existence 
of neuroendocrine, haemopoietic and nonSCLC differentiation, but is 
more likely to represent the expression of nonspecific markers shared 
by these different cell types.
The criteria for differentiation are the expression of specific 
characteristics by tumour cells which are associated with the mature 
counterparts. In the case of SCLC where the cell of origin is 
unknown, differentiation associated properties cannot be determined. 
While there are readily identifiable markers of APUD or neuroendocrine 
phenotype which can be measured, the relationship of these markers to 
the "normal" counterpart is not understood and there is a possibility 
that a cell may differentiate towards an alternative phenotype showing 
a decrease in neuroendocrine markers in the process. Therefore, 
whether the phenotypic drug treatment causes a shift in the cell*s 
phenotype towards a more differentiated phenotype cannot be determined 
due to the lack of suitable differentiation associated markers.
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It is a premise of histopathology that those tumours which are 
morphologically poorly differentiated tend to be most aggressive. 
This raises the possibility of a modality of cancer therapy involving 
the shift of tumour cells towards a more differentiated phenotype more 
closely resembling normal cells. However, it does not necessarily 
follow that a cell responding to induction of differentiation becomes 
less malignant, although recent reports have shown that following 
induction of differentiation of tumour cells there is a phenotypic 
shift involving a reduction in some malignancy associated properties 
(Freshney 1985; Calabresi et al, 1979; Biedler et al 1983; Speers, 
1982; M°Lean h et al, 1986; Frame, et al 1983). For this
reason a marker of malignancy rather than differentiation which is not 
dependent on knowing the mature phenotype of the cells, were they to 
complete the process of differentiation, is particularly valuable in 
determining a phenotypic shift in response to phenotypic drug 
treatment.
Plasminogen activators (PA) are serine proteases which catalyse the 
cleavage of the inactive plasminogen to the active protease plasmin, 
which digests fibrin. Two main forms of PA have been described, 
tissue-type (t-PA) and urokinase-like (u-PA) PA. PA activity has been 
found to be significantly higher in a number of human neoplastic 
tissues compared to the normal counterparts (Nagy, Ban & Brdar 1977; 
Markus et al 1980; Camiolo & Greco 1986), and a role for PA in tumour 
growth and metastasis has been implicated. The secretion of these 
enzymes by neoplastic tissues and transformed cells may initiate a 
proteolytic cascade which reduces or eliminates the extracellular 
barriers for tumour growth and migration. The relationship between 
the level of PA produced by tumour cells and the degree of 
tumourigenicity and/or the metastatic potential depends greatly upon 
the experimental system. Data both in favour (Ossowski & Reich 1983) 
and against (Barratt et al 1980) a positive correlation have been
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reported. Therefore, although the precise function of PA in the 
invasive and metastatic properties of a tumour is unclear PA does 
appear to be associated with malignancy. In this respect, PA was 
measured in lung carcinomas and anaplastic astrocytomas following 
exposure to various differentiating agents (Freshney 1985). It was 
found that stimulation of differentiation associated properties was 
accompanied by a dramatic decrease in the production of PA by the 
cells. Therefore, induction of differentiation in these tumour cells 
was accompanied by a reduction in this malignancy associated property.
In order to investigate the effect of the phenotypic inducer agents on 
the malignancy associated properties of the SCLC cell lines PA was 
selected as a marker of the malignant phenotype. PA activity was 
determined using a chromogenic substrate assay (Whur et al 1980). 
Using this assay the PA activity, both cellular and secreted, in the 
SCLC cell lines was determined. However, no PA activity could be 
detected in the three SCLC cell lines, H187, H69 and H128d. Therefore 
PA activity could not be used as a marker of malignancy in this 
tumour. It is possible however, that PA does not have an important 
role in the SCLC malignant phenotype, other proteolytic enzymes such 
as collagenase may be involved.
Angiogenesis has long been considered to be essential for tumour 
growth. Tumours can propagate to volumes of approximately lmm^ by 
simple diffusion and exchange of nutrients and metabolites through the 
extracellular fluid, the critical event that converts a self-contained 
pocket of aberrant cells into a rapidly growing malignancy comes when 
the tumour becomes vascularised. The tumour must induce the host to 
provide it with its own network of blood vessels. Ample evidence 
suggests that tumours secrete various factors that promote the 
ingrowth of blood vessels from surrounding tissues. One such factor 
tumour angiogenesis factor (TAF) was recently purified using heparin-
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Sepharose chromatography (Shing et al 1984). The purified factor is a 
cationic polypeptide with an isoelectric point of about 9.8 and a 
molecular weight of approximately 18,000 daltons. It stimulates 
capillary endothelial cell proliferation in vitro half maximally at 
lng/ml and strongly stimulates neovascularisation in the chick embryo. 
Since this, many other endothelial cell growth factors have been 
purified to homogeneity.
The ability to stimulate angiogenesis in vivo or endothelial division 
and motility in vitro are properties which are associated with 
tumours. The tendency of tumours to have a greater angiogenic effect 
than their normal equivalents has been used as a marker of 
transformation. Endothelial stimulation in vitro provides a 
convenient and quantifiable measure of parameters which are believed 
to broadly correlate with the angiogenic response in vivo. The 
ability of the SCLC cell lines to stimulate the growth of an 
endothelial cell line was examined as a measure of transformation. 
Preliminary data suggested that conditioned medium from the SCLC cell 
lines was able to induce a mitogenic effect on a quiescent culture of 
bovine pulmonary artery derived cells, CPAE cells (Beveridge,
personal communication). The degree of mitogenesis was however 
difficult to reproduce on a day to day basis. Therefore this marker 
of malignancy could not be used convincingly to examine the 
phenotypic changes of the SCLC cell lines.
The growth of normal cells is largely controlled by the interplay 
between several polypeptide hormones and hormone-like growth factors 
that are present in tissue fluids. Malignant cells, however, are not 
subject to all the same growth controls as are normal cells. In 
general malignant cells require less of these exogenous growth factors 
than do their normal counterparts for optimal growth and 
multiplication and it has been suggested that transformed or malignant 
cells escape from normal growth controls by requiring less of such
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hormones or growth factors. To explain this phenomenon, it was 
suggested that cells could become malignant by the endogenous 
production of polypeptide growth factors acting on their producer 
cells via functional external receptors, allowing a mitogenic response 
to the peptide by the same cell that produces it. This process has 
been termed autocrine secretion. Moreover, this autocrine hypothesis 
provides an explanation as to how oncogenes make cancer cells 
autonomous of growth factors particularly if the hypothesis is 
broadened to include the importance of receptors and post-receptor 
signal transduction as critical control elements in the normal 
mitogenic pathway.
Bombesin is believed to function as an autocrine growth factor in 
SCLC. The action of bombesin is believed to be mediated via a 
distinct membrane receptor (Moody et al 1985), which presumably 
activates a post-receptor signalling mechanism and leads eventually to 
a mitogenic response. If bombesin is indeed acting as an autocrine 
growth factor in SCLC cells then one should be able to control the 
growth of the cancer cells using a bombesin antagonist. This has been 
accomplished recently using a monoclonal antibody to bombesin 
(Cuttitta et al 1985). The monoclonal antibody was found to bind to 
the C-terminal region of bombesin-like peptides, it blocked the 
binding of the hormone to its cellular receptor, and inhibited clonal 
growth of SCLC in vitro and the growth of SCLC xenografts in vivo. 
More recently, [D-Arg^ , D-Fhe^ , D-Trp^’^ , Leu^] substance P, a potent 
bombesin antagonist in murine Swiss 3T3 cells was found to inhibit the 
growth of human SCLC cells in vitro (Woll & Rozengurt, 1988). 
Autocrine growth control appears to be associated with the transformed 
phenotype, therefore on the basis of this criterion bombesin 
expression could be viewed as a malignancy associated marker.
Following HMBA treatment of the SCLC cell line, H69, a significant 
reduction in the level of BLI was found. Therefore HMBA induced a
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phenotypic shift in the H69 cells which involved a significant 
reduction in a malignancy associated property. However, dbcAMP 
treated H187 cells expressed an increased level of BLI. Therefore 
dbcAMP induced a phenotypic shift in the H187 cellular phenotype which 
involved an increase in the expression of a malignancy associated 
property. On the basis of BLI as a malignancy associated marker, SCLC 
cell lines can be induced to change their phenotypic status in 
opposite directions.
An anomaly to the hypothesis that BLI is a marker of malignancy is the 
apparent distribution of BLI in the three cell lines. Within the 
three SCLC examined BLI expression was found to be the highest in 
H128d cells and undectable in H187 cells. The distribution of BLI 
within the SCLC cell lines paralleled the distribution of DDC. That 
is, H128d cells expressed the highest levels of DDC activity whereas, 
the lowest levels were found in H187 cells. The presence of DDC 
activity has implied a neuroendocrine origin of SCLC and DDC activity 
may be associated with neuroendocrine differentiation. According to 
this hypothesis H128d cells exhibit elevated levels of malignancy and 
differentiation associated properties. Since the origin of SCLC is 
unclear differentiation associated markers cannot be identified
unequivocally, and one cannot conclude that increased expression of 
DDC is associated with neuroendocrine differentiation. However, it is 
possible that the presence of DDC may in fact be associated with the 
malignancy of the cells. DDC is an Enzyme involved in the synthesis 
of the catecholamines, dopamine, adrenaline and noradrenaline. 
Although SCLC may synthesise catecholamines which act as autocrine 
growth factors, SCLC express no clinical manifestations of over­
production of catecholamines. If SCLC cells produce catecholamines 
then they could respond to them by dividing if the necessary receptors 
were present and functional. Three major questions arise from this 
hypothesis: (1) Do SCLC cells produce catecholamines ? (2) Do SCLC
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cells have catecholamine receptors ? (3) Is mitosis induced in SCLC by 
catecholamines ?
In order to investigate whether DDC was involved in an autocrine 
growth system SCLC cells were grown in the presence of either 
noradrenaline, phentolamine and/or propranolol. Noradrenaline is a 
catecholamine which acts as an agonist on c< and receptors, 
phentolamine is an oC receptor antagonist and propranolol is a p  
receptor antagonist. If catecholamines act as autocrine growth 
factors in SCLC via functional and receptors then one could 
hypothesise that a mitogenic response may be elicited by exogenous 
addition of noradrenaline or inhibited by receptor antagonists.
The effect of catecholamine agonists, antagonists and synthesis 
inhibitors on the growth of a SCLC cell line was investigated. 
However, since no change in the growth of the cells was found the data 
is not presented. The implications of the results will be discussed.
The growth of H187 cells, measured by either electronic particle 
counting or thymidine incorporation, was found to be unalterd by 
either noradrenaline, phentolamine and/or propranolol. SCLC cell 
lines have been shown to be able to take up and metabolise L-DOPA to 
dopamine (Pettengill, Bacopoulos & Sorenson 1982), therefore dopamine 
may be an autocrine growth factor in SCLC acting via dopaminergic 
receptors. However, exogenous addition of dopamine was also found to 
have no effect on the growth of H187 cells. It may be however, that 
endogenous production of the putative autocrine growth factor is such 
that the receptors are saturated and so exogenous addition of dopamine 
would not enhance the mitogenic effect. If the synthesis of the 
putative autocrine growth factor could be inhibited could this then 
alter the growth of the SCLC cells ? Tyrosine hydroxylase is the rate 
limiting enzyme in the biosynthesis of catecholamines. oC-Methyl 
tyrosine inhibits the synthesis of catecholamines by competing with
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tyrosine for the active site of tyrosine hydroxylase. When H187 cells 
were grown in the presence ofo<- methyl tyrosine it was found that the 
growth rate of H187 cells was unaffected. In conclusion therefore, it 
is unlikely that a catecholamine autocrine growth system exists in the 
SCLC cell line H187. With hindsight it may have been useful to extend 
these studies to include other SCLC cell lines which expressed higher 
DDC activity to examine whether these findings held true for other 
SCLC cell lines irrespective of the level of DDC activity.
Following phenotypic drug treatment of the SCLC cell lines (H187 and 
H69) various morphological alterations were noticed. H187 cells were 
classed as type 3 cells which are characterised as irregular shaped 
aggregates which resembled a "bunch of grapes'* morphology. Whereas, 
H69 cells were classified as type 2 cells characterised as irregular 
shaped aggregates where individual cells can not be visualised. The 
pattern of morphological change was towards a more spherical aggregate 
shape where individual cells could not be distinguished. These 
morphological changes imply a change in cell-cell adhesiveness.
Development of resistance to actinomycin D, daunomycin or vincristine 
in Chinese hamster cells was accompanied by reduced uptake of 
antibiotic in proportion to the degree of resistance, a reduction in 
tumourigenicity and a change in morphology towards a more normal 
phenotype (Biedler et al 1975). The cells with acquired resistance 
were found to have a greater cell adhesiveness compared to their 
malignant counterparts. In another study, comparison of two SCLC 
xenografts, one sensitive to cyclophosphamide and the other a 
cyclophosphamide induced resistant subline of the first xenograft, 
indicated that induction of cyclophosphamide resistance was 
accompanied by expression of keratin suggesting squamous 
differentiation (Berman, Gusterson & Steel 1985). Moreover, the in 
vitro growth characteristics of the two xenografts differed; the 
sensitive cell line was anchorage independent whereas the induced
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cyclophosphamide resistant counterpart showed flattened angular 
adherent culture characteristics. Therefore an increase in 
adhesiveness appears to be associated with an increase in drug 
resistance in some cell lines and also with expression of a more 
differentiated phenotype. The morphological changes observed with the 
SCLC cell lines following treatment with the appropriate drugs implies 
a change in the cell-cell adhesiveness of the cultures. Although it 
would be premature to conclude that this change in cell-cell 
adhesiveness represents a shift towards a more differentiated state it 
is nevertheless important to consider this aspect when one examines 
the overall SCLC phenotype change. It is perhaps also worth noting at 
this time that the phenotype of H128d cells, including morphological 
characteristics, did not undergo a significant change in response to 
drug treatment. H128d cells are characterised as type 1 cells (Carney 
et al 1985). The cells grow as tightly packed spherical aggregates of 
floating cells, individual H128d cells cannot be seen within an 
aggregate which suggests a high degree of adhesiveness between cells. 
If cell-cell adhesiveness is associated with the degree of 
differentiation of the cells then this would imply that H128d cells 
are the most differentiated of the three cell lines examined. If this 
is the case this may explain why the phenotype of H128d cells could 
not be significantly changed by phenotypic inducer treatment.
The entry into and exit of malignant cells from the circulation is an 
important requirement for the successful establishment of a secondary 
tumour during blood-borne metastasis. The acquisition by neoplastic 
cells of the capacity to invade locally and to metastasise remains the 
aspect of tumour progression that is of greatest clinical 
significance; this is still the fundamental definition of malignancy. 
Measurement of tumour invasiveness is difficult due to the absence of 
good quantifiable assays. One assay that has been used as a measure 
of invasiveness is the chick heart assay (Mareel, Kint & Meyvisch 
1979). Chick heart fragments are co-cultured with tumour cell
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aggregates in organotypic culture. This system is specific in that 
invasion of the chick heart fragment, its destruction and ultimately 
replacement is only carried out by malignant cells. The invasiveness 
of the SCLC cell lines, H187 H69 and H128d, was investigated using 
this assay, in collaboration with De Ridder. The cells were co­
cultured with a fragment of chick heart for periods up to 10 days. At 
various time points during the co-culture the invasiveness of the 
cells was examined. Sections of the chick heart were taken and 
examined for the presence of SCLC cells. Chick heart cells were 
identified using a specific antibody against chick mesoderm, whereas 
SCLC cells were identified using an antibody against NSE. All three 
SCLC cell lines were shown to be invasive as defined by the ability to 
infiltrate the chick heart fragments. H128d cells had the greatest 
capacity to invade then H69 cells and finally H187 cells. Preliminary 
data suggests that phenotypic drug treatment of the cell lines 
decreases invasive ability. H69 cells treated with 5mM HMBA or ImM 
NaBut did not invade the chick heart. Moreover, HMBA treated H128d 
cells did not invade the chick heart. Furthermore when either HMBA or 
NaBut were removed (following a 72 hour drug exposure) 5 days before 
co-culture the cells grew round the chick heart but did not invade, 
then some 7-9 days later the cells started to infiltrate the heart. 
Two things emerge from this 1) the SCLC cells remain viable after the 
phenotypic inducer treatment and 2) the phenotypic change is 
apparently reversible and decays in about 10 days.
Since the tumour cells are required to adhere to the chick heart 
fragment it is possible that changes in the adhesiveness of the tumour 
cells could account for the differences found. Both control and drug 
treated tumour cells were found to adhere to the chick heart fragment 
quite effectively.
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The question originally posed was: Do these phenotypic inducers shift 
the SCLC phenotype towards a more differentiated phenotype or are the 
phenotypic changes nonspecific ? In an attempt to answer the first 
part of the question a number of malignancy associated markers were
measured to investigate whether the cells became less malignant
\
following phenotypic drug treatment, since an inverse relationship has 
been shown to exist in some cases between differentiation and 
malignancy. Preliminary data suggests that the SCLC phenotype becomes j 
less malignant following phenotypic drug treatment with respect to ! 
BLI, invasiveness and cell-cell adhesiveness. However further work is ! 
required support these findings. All of these malignancy associated 
properties are difficult to assay and caution is required when 
interpreting the results. Other markers of malignancy should be 
measured for example tumorigenicity in nude mice or clonogenicity in 
soft agar. Whether the phenotypic shift observed following phenotypic 
inducer treatment is nonspecific cannot be answered at this time. 
Perhaps it would be useful to measure other cellular markers not 
directly associated with the SCLC phenotype for example actin or 
lactate dehydrogenase to see if these markers also changed following 
drug treatment.
Do the Changes in the SCLC Phenotype Following Phenotypic Drug 
Treatment Further our Understanding of the Origin of SCLC in 
Particular the Position of SCLC in the Histogenesis of Lung Cancer ?
In order to be able to answer these questions a more thorough 
investigation into phenotypic alteration in SCLC needs to be carried 
out. As mentioned earlier the use of other phenotypic inducer agents 
as well as combinations of phenotypic agents may improve the degree of
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phenotypic change found. Also more phenotypic markers need to be 
measured to give a more detailed picture of the phenotypic change. At 
present the results do not give many clues to understanding the origin 
of SCLC. What does seem to be apparent is the considerable 
heterogeneity of SCLC, in particular the ability of different cell 
lines to undergo a phenotypic shift in opposite directions. A shift 
towards a more neuroendocrine-like phenotype characterised by 
increases in neuroendocrine associated markers has been found in some 
cases, whereas a loss of neuroendocrine characteristics has been found 
in others. In the case of an induced loss of neuroendocrine features 
it would be of interest to examine whether there is an associated 
increase in any nonSCLC phenotypic characteristics, for example 
keratin expression, mucin production or surfactant secretion. 
Moreover, analysis of cell surface proteins following phenotypic drug 
treatment may aid the definition of SCLC phenotypic change and may 
also aid the understanding of the origin of SCLC since nonSCLC cell 
surface proteins can also be measured. It has been proposed that all 
histological subtypes of lung cancer are linked via progressive 
differentiation, or shift in differentiation characteristics, from 
SCLC to large cell undifferentiated and ultimately to squamous 
carcinoma and adenocarcinoma (Yesner, 1978). Therefore the 
differences in phenotypic shifts between cell lines in response to 
drug treatment may reflect the position of the individual cell lines 
in the differentiation pathway linking the different lung cancer 
histologies.
Conclusions.
The aim of this study was to determine whether the SCLC phenotype 
could be altered and if so did this phenotypic alteration have any 
effect on chemosensitivity. DDC, CKBB, BLI, morphology and growth 
characteristics were selected as representing the SCLC phenotype. On
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the basis of changes in these markers it was concluded that the SCLC 
phenotype could be altered by various phenotypic drugs. When the 
effect of this phenotypic change on the chemosensitivity was examined 
it was found that in general alteration of the SCLC phenotype had no 
effect on the chemosensitivity.
Future Considerations.
Since it has been shown that the SCLC phenotype can change following 
drug treatment it will be of interest to try and maximise this change 
with perhaps longer drug exposure times, new drugs or drug 
combinations. It would also be important to investigate the effect of 
phenotypic drug treatment on other markers associated with SCLC for 
example NSE, the presence of neurosecretory granules or secretion of 
hormones. Moreover, measurement of phenotypic markers not associated 
with the SCLC phenotype will also help determine whether the shift in 
phenotype is nonspecific or perhaps towards nonSCLC phenotype. If a 
greater phenotypic shift could be induced it may then be useful to 
determine whether there was any effect on chemosensitivity or indeed 
radiation sensitivity.
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